Dataset Viewer
image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
8972e89bad9919ad83c32b48e7b9e9cd51e4789b2ccabb477e312941d5761c82.png | simple | <table><tr><td>Parameters</td><td>School A</td><td>School B</td></tr><tr><td><i>q</i><sub><i>c</i></sub>, mean [ 95 <i>%</i> CI]</td><td>1.39×10<sup>−2</sup> [ 8.10×10<sup>−3</sup>−2.03×10<sup>−2</sup>]</td><td>1.96×10<sup>−2</sup> [ 1.11×10<sup>−2</sup>−2.89×10<sup>−2</sup>]</td></tr><tr><td><i>q</i><sub><i>g</i></sub>, mean [ 95 <i>%</i> CI]</td><td>4.36×10<sup>−3</sup> [ 9.61×10<sup>−4</sup>−8.34×10<sup>−3</sup>]</td><td>4.61×10<sup>−3</sup> [ 2.98×10<sup>−4</sup>−1.15×10<sup>−2</sup>]</td></tr><tr><td><i>q</i><sub><i>s</i></sub>, mean [ 95 <i>%</i> CI]</td><td>9.52×10<sup>−4</sup> [ 2.87×10<sup>−4</sup>−1.82×10<sup>−3</sup>]</td><td>2.96×10<sup>−3</sup> [ 1.64×10<sup>−3</sup>−4.45×10<sup>−3</sup>]</td></tr><tr><td><i>ε</i>, mean [ 95 <i>%</i> CI]</td><td>3.70×10<sup>−3</sup> [ 1.95×10<sup>−3</sup>−5.69×10<sup>−3</sup>]</td><td>2.65×10<sup>−3</sup> [ 1.37×10<sup>−3</sup>−4.20×10<sup>−3</sup>]</td></tr></table> |
6c338e811af9402b98f215c9759761bc6c3def789a9ad83789f208d267d0006a.png | complex | <table><tr><td>Dependent variable</td><td colspan="2">ANC4</td><td colspan="2">SBA</td><td colspan="2">IFD</td></tr><tr><td>Density variable</td><td>% "urban"</td><td>score</td><td>% "urban"</td><td>score</td><td>% "urban"</td><td>score</td></tr><tr><td rowspan="2">Density</td><td>0.003***</td><td>0.002**</td><td>0.004***</td><td>0.002**</td><td>0.004***</td><td>0.002*</td></tr><tr><td>(0.001)</td><td>(0.001)</td><td>(0.001)</td><td>(0.001)</td><td>(0.001)</td><td>(0.001)</td></tr><tr><td rowspan="2">ln(health expenditure)</td><td>0.07***</td><td>0.101***</td><td>0.073***</td><td>0.115***</td><td>0.085***</td><td>0.129***</td></tr><tr><td>(0.011)</td><td>(0.008)</td><td>(0.011)</td><td>(0.008)</td><td>(0.011)</td><td>(0.009)</td></tr><tr><td rowspan="2">Hospital beds, per capita</td><td>0.003</td><td>0.000</td><td>0.006</td><td>0.002</td><td>0.006</td><td>0.002</td></tr><tr><td>(0.006)</td><td>(0.006)</td><td>(0.006)</td><td>(0.006)</td><td>(0.006)</td><td>(0.006)</td></tr><tr><td rowspan="2">Total fertility rate</td><td>−0.009</td><td>−0.009</td><td>0.000</td><td>0.002</td><td>0.002</td><td>0.003</td></tr><tr><td>(0.011)</td><td>(0.011)</td><td>(0.010)</td><td>(0.010)</td><td>(0.010)</td><td>(0.011)</td></tr><tr><td rowspan="2"># 4-wheel vehicles, per capita</td><td>0.035</td><td>0.068</td><td>0.014</td><td>0.054</td><td>0.013</td><td>0.054</td></tr><tr><td>(0.057)</td><td>(0.059)</td><td>(0.052)</td><td>(0.055)</td><td>(0.054)</td><td>(0.056)</td></tr><tr><td>Constant</td><td>0.130</td><td>0.039</td><td>0.154**</td><td>0.040</td><td>0.050</td><td>−0.058</td></tr><tr><td> </td><td>(0.066)</td><td>(0.070)</td><td>(0.062)</td><td>(0.068)</td><td>(0.064)</td><td>(0.070)</td></tr></table> |
8be7af498b313fcdc872c170f32425cebc75098e7c2119ea1b47a88c691245eb.png | complex | <table><tr><td></td><td>Weeks</td><td>Daily dose</td><td>Niaspan FCT dosage</td></tr><tr><td rowspan="4">Initial titration schedule</td><td>0 to 4</td><td>500 mg</td><td>One 500 mg tablet at bedtime</td></tr><tr><td>5 to 8</td><td>1,000 mg</td><td>One 1,000 mg tablet or two 500 mg tablets at bedtime</td></tr><tr><td>9 to 12</td><td>1,500 mg</td><td>One 1,000 mg tablet and one 500 mg tablet at bedtime</td></tr><tr><td>13 to 24</td><td>2,000 mg</td><td>Two 1,000 mg tablets at bedtime</td></tr></table> |
60f7079ba6d811dea21e96d519da45548135509ecd489525770ce40514ffb5a0.png | simple | <table><tr><td>Combination</td><td>TP</td><td>FP</td><td>TN</td><td>FN</td><td>sensitivity (HCC = 50)</td><td>specificity (LC = 41)</td><td>TPP</td><td>TPN</td><td>LR</td></tr><tr><td>afp</td><td>28</td><td>0</td><td>41</td><td>22</td><td>56.00%</td><td>100.00%</td><td>100.0%</td><td>65.10%</td><td>-</td></tr><tr><td>afp+piv</td><td>47</td><td>8</td><td>33</td><td>3</td><td>94.00%</td><td>80.50%</td><td>85.50%</td><td>91.70%</td><td>4.82</td></tr><tr><td>piv</td><td>39</td><td>8</td><td>33</td><td>11</td><td>78.00%</td><td>80.50%</td><td>83.00%</td><td>75.00%</td><td>4</td></tr><tr><td>afp+scca</td><td>36</td><td>11</td><td>30</td><td>14</td><td>72.00%</td><td>73.20%</td><td>76.60%</td><td>68.20%</td><td>2.68</td></tr><tr><td>afp+piv+scca</td><td>45</td><td>16</td><td>25</td><td>5</td><td>90.00%</td><td>61.00%</td><td>73.80%</td><td>83.30%</td><td>2.31</td></tr><tr><td>piv+scca</td><td>42</td><td>16</td><td>25</td><td>8</td><td>84.00%</td><td>61.00%</td><td>72.40%</td><td>75.80%</td><td>2.15</td></tr><tr><td>gcp+scca</td><td>36</td><td>16</td><td>25</td><td>14</td><td>72.00%</td><td>61.00%</td><td>69.20%</td><td>64.10%</td><td>1.85</td></tr><tr><td>afp+gcp</td><td>41</td><td>22</td><td>19</td><td>9</td><td>82.00%</td><td>46.30%</td><td>65.10%</td><td>67.90%</td><td>1.53</td></tr><tr><td>afp+piv+gcp</td><td>48</td><td>27</td><td>14</td><td>2</td><td>96.00%</td><td>34.10%</td><td>64.00%</td><td>87.50%</td><td>1.46</td></tr><tr><td>gcp+piv</td><td>46</td><td>27</td><td>14</td><td>4</td><td>92.00%</td><td>34.10%</td><td>63.00%</td><td>77.80%</td><td>1.4</td></tr><tr><td>all</td><td>48</td><td>31</td><td>10</td><td>2</td><td>96.00%</td><td>24.40%</td><td>60.80%</td><td>83.30%</td><td>1.27</td></tr><tr><td>gcp</td><td>34</td><td>22</td><td>19</td><td>16</td><td>68.00%</td><td>46.30%</td><td>60.70%</td><td>54.30%</td><td>1.27</td></tr><tr><td>gcp+piv+scca</td><td>47</td><td>31</td><td>10</td><td>3</td><td>94.00%</td><td>24.40%</td><td>60.30%</td><td>76.90%</td><td>1.24</td></tr><tr><td>afp+gcp+scca</td><td>36</td><td>28</td><td>13</td><td>14</td><td>72.00%</td><td>31.70%</td><td>56.30%</td><td>48.10%</td><td>1.05</td></tr><tr><td>scca</td><td>9</td><td>11</td><td>30</td><td>41</td><td>18.00%</td><td>73.20%</td><td>45.00%</td><td>42.30%</td><td>0.67</td></tr></table> |
da8512c3da0b345d6c822eda63edeec3e5bd7bbf92e06c067178beb54447138f.png | complex | <table><tr><td></td><td>Variable</td><td>OR<sup>a</sup> (IC95%)</td><td><i>p</i><sup>a</sup> value</td><td>OR<sup>B</sup> (IC95%)</td><td><i>p</i><sup>b</sup> value</td></tr><tr><td>PSVI</td><td colspan="5">Part 1</td></tr><tr><td></td><td>Low PSVI</td><td>1</td><td>< 0.01</td><td></td><td></td></tr><tr><td></td><td>Middle PSVI</td><td>1.21 (1.21; 1.21)</td><td>< 0.01</td><td></td><td></td></tr><tr><td></td><td>High PSVI</td><td>2.50 (2.49; 2.51)</td><td>< 0.01</td><td></td><td></td></tr><tr><td></td><td colspan="5">Part 2</td></tr><tr><td>Gender</td><td>Female</td><td>2.05 (2.04, 2.05)</td><td>< 0.01</td><td>1.78 (1.59; 2.00)</td><td>< 0.01</td></tr><tr><td></td><td>Male</td><td>1</td><td>< 0.01</td><td>1</td><td></td></tr><tr><td>Skin Color</td><td>White</td><td>1</td><td>< 0.01</td><td>1</td><td>< 0.01</td></tr><tr><td></td><td>Black</td><td>1.51 (1.51; 1.52)</td><td>< 0.01</td><td>1.56 (1.25; 1.93)</td><td>< 0.01</td></tr><tr><td></td><td>Brown</td><td>1.32 (1.32; 1.32)</td><td>< 0.01</td><td>1.66 (1.47; 1.88)</td><td></td></tr><tr><td>Age group</td><td>15–19</td><td>1.09 (1.09; 109)</td><td>< 0.01</td><td>1.04 (1, 1.08)</td><td></td></tr><tr><td></td><td colspan="5">Part 3</td></tr><tr><td>Family income</td><td colspan="5">Household income (R$)</td></tr><tr><td></td><td>Up to 1.500</td><td>1.28 (1.28; 1.29)</td><td>< 0.001</td><td>1.28 (1.28; 1.29)</td><td>< 0.001</td></tr><tr><td></td><td>Over 1.500</td><td>1</td><td></td><td></td><td>1</td></tr><tr><td></td><td colspan="5">Part 4</td></tr><tr><td>Clinical factors</td><td colspan="5">Untreated caries lesions</td></tr><tr><td></td><td>None</td><td>1</td><td>< 0.01</td><td>1</td><td></td></tr><tr><td></td><td>At least one decayed tooth</td><td>2.11 (1.89; 2.36)</td><td>< 0.01</td><td>1.42 (1.25; 1.61)</td><td>< 0.01</td></tr><tr><td></td><td colspan="5">Tooth loss</td></tr><tr><td></td><td>None</td><td>1</td><td>< 0.01</td><td>1</td><td></td></tr><tr><td></td><td>At least one tooth loss</td><td>1.87 (1.59; 2.19)</td><td>< 0.01</td><td>1.49 (1.25; 1.78)</td><td>< 0.01</td></tr><tr><td></td><td colspan="5">Toothache</td></tr><tr><td></td><td>Yes</td><td>5.47 (4.80; 6.24)</td><td>< 0.01</td><td>4.87 (4.25; 5.59)</td><td>< 0.01</td></tr><tr><td></td><td>No</td><td>1</td><td>< 0.01</td><td>1</td><td></td></tr><tr><td></td><td colspan="5">Maxillary Overjet</td></tr><tr><td></td><td>Normal</td><td>1</td><td></td><td>1</td><td></td></tr><tr><td></td><td>Moderate</td><td>1.25 (1.11; 1.40)</td><td>< 0.01</td><td>1.23 (1.09; 1.40)</td><td>0.01</td></tr><tr><td></td><td>Severe</td><td>1.80 (1.28; 2.54)</td><td>< 0.01</td><td>1.68 (1.15; 2.45)</td><td>0.006</td></tr><tr><td></td><td colspan="5">Cross Bite</td></tr><tr><td></td><td>Absence</td><td>1</td><td>< 0.01</td><td></td><td></td></tr><tr><td></td><td>Presence</td><td>0.94 (0.74; 1.20)</td><td>0.667</td><td></td><td></td></tr><tr><td></td><td colspan="5">Open Bite</td></tr><tr><td></td><td>Mild</td><td>1</td><td></td><td>1</td><td></td></tr><tr><td></td><td>Moderate</td><td>1.34 (1.07; 1.68)</td><td>0.01</td><td>1.14 (0.89; 1.47)</td><td>0.275</td></tr><tr><td></td><td>Severe</td><td>1.28 (0.84; 1.96)</td><td>0.239</td><td>1.27 (0.80; 2.03)</td><td>0.302</td></tr><tr><td></td><td colspan="5">Presence of bleeding</td></tr><tr><td></td><td>Yes</td><td>2.09 (1.86; 2.35)</td><td>< 0.01</td><td>1.45 (1.25; 1.68)</td><td>< 0.01</td></tr><tr><td></td><td>No</td><td>1</td><td></td><td>1</td><td></td></tr><tr><td></td><td colspan="5">Presence of calculus</td></tr><tr><td></td><td>Yes</td><td>2.05 (1.82; 2.31)</td><td>< 0.01</td><td>1.55 (1,34; 1,80)</td><td>< 0.01</td></tr><tr><td></td><td>No</td><td>1</td><td></td><td>1</td><td></td></tr></table> |
c26a54401dc062f7ff2aff801c23eccf6a5c71206acd06bc029182e31ca1f01d.png | simple | <table><tr><td> </td><td>Group I(<i>n</i> = 25)</td><td>Group P(<i>n</i> = 25)</td><td><i>P</i> value</td></tr><tr><td>Desaturation (SpO<sub>2</sub> < 90%)</td><td>3 (12%)</td><td>2 (8%)</td><td>1.000</td></tr><tr><td>Gastric insufflations</td><td>1 (4%)</td><td>0 (0%)</td><td>1.000</td></tr><tr><td>Aspiration</td><td>0 (0%)</td><td>0 (0%)</td><td>—</td></tr><tr><td>Laryngospasm</td><td>1 (4%)</td><td>1 (4%)</td><td>1.000</td></tr><tr><td>Bronchospasm</td><td>0 (0%)</td><td>0 (0%)</td><td>—</td></tr><tr><td>Blood stain</td><td>0 (0%)</td><td>2 (8%)</td><td>0.490</td></tr></table> |
3df4c15b6e133af47b8de862f86279470a08b80f5332c42d7772054da865abf1.png | simple | <table><tr><td>Remaining per-base coverage after B-tail removal</td><td>Number of positions with this coverage in the ZR reference (Bv-95nt data)</td><td>Number of positions with this coverage in the PhiX reference (PhiX-95nt data)</td></tr><tr><td>90 to 100%</td><td>41,130 (40.26%)</td><td>4,016 (91.65%)</td></tr><tr><td>80 to 90%</td><td>4,056 (3.97%)</td><td>266 (6.07%)</td></tr><tr><td>60 to 80%</td><td>1,711 (1.67%)</td><td>100 (2.28%)</td></tr><tr><td>40 to 60%</td><td>310 (0.30%)</td><td>0 (0.00%)</td></tr><tr><td>20 to 40%</td><td>76 (0.07%)</td><td>0 (0.00%)</td></tr><tr><td>0 to 20%</td><td>29 (0.03%)</td><td>0 (0.00%)</td></tr></table> |
f8e5e3067d00554e8de86b5f0fc0fd401ea4aa43d2cafca8f83aeb2b3c94593a.png | complex | <table><tr><td rowspan="3">Parameter</td><td rowspan="3">DF</td><td rowspan="2" colspan="2">TPC</td><td colspan="6">Antioxidant Capacity</td></tr><tr><td colspan="2">ABTS</td><td colspan="2">DPPH</td><td colspan="2">CUPRAC</td></tr><tr><td><i>F</i></td><td><i>p</i> > <i>F</i></td><td><i>F</i></td><td><i>p</i> > <i>F</i></td><td><i>F</i></td><td><i>p</i> > <i>F</i></td><td><i>F</i></td><td><i>p</i> > <i>F</i></td></tr><tr><td><i>β</i><sub>0</sub></td><td>1</td><td>16.90</td><td><0.01 *</td><td>16.85</td><td><0.01 *</td><td>8.91</td><td><0.01 *</td><td>16.34</td><td><0.01 *</td></tr><tr><td><i>β</i><sub>1</sub></td><td>1</td><td>0.45</td><td>0.53</td><td>7.16</td><td>0.04 *</td><td>23.92</td><td>0.00 *</td><td>12.63</td><td>0.02 *</td></tr><tr><td><i>β</i><sub>2</sub></td><td>1</td><td>1.78</td><td>0.24</td><td>0.62</td><td>0.47</td><td>1.46</td><td>0.28</td><td>0.32</td><td>0.59</td></tr><tr><td><i>β</i><sub>3</sub></td><td>1</td><td>6.47</td><td>0.05 *</td><td>1.78</td><td>0.24</td><td>2.22</td><td>0.20</td><td>2.98</td><td>0.15</td></tr><tr><td><i>β</i><sub>12</sub></td><td>1</td><td>7.24</td><td>0.04 *</td><td>0.01</td><td>0.92</td><td>5.96</td><td>0.06</td><td>0.35</td><td>0.58</td></tr><tr><td><i>β</i><sub>13</sub></td><td>1</td><td>0.02</td><td>0.89</td><td>1.07</td><td>0.35</td><td>0.35</td><td>0.58</td><td>0.00</td><td>0.99</td></tr><tr><td><i>β</i><sub>23</sub></td><td>1</td><td>0.02</td><td>0.90</td><td>0.31</td><td>0.60</td><td>0.86</td><td>0.40</td><td>0.26</td><td>0.63</td></tr><tr><td><i>β</i><sub>11</sub></td><td>1</td><td>6.65</td><td>0.05 *</td><td>7.59</td><td>0.04 *</td><td>0.85</td><td>0.40</td><td>7.26</td><td>0.04*</td></tr><tr><td><i>β</i><sub>22</sub></td><td>1</td><td>0.11</td><td>0.75</td><td>0.00</td><td>0.96</td><td>2.17</td><td>0.20</td><td>1.89</td><td>0.23</td></tr><tr><td><i>β</i><sub>33</sub></td><td>1</td><td>2.50</td><td>0.17</td><td>7.75</td><td>0.04 *</td><td>0.10</td><td>0.77</td><td>11.59</td><td>0.02 *</td></tr></table> |
903042a25ca43bbf9921d7abf1757d3c6c75af5fb987812cb41cdb01eb670685.png | simple | <table><tr><td>Medical categories</td><td>Number of species</td><td>Citations</td><td>Fic</td></tr><tr><td>Tonic</td><td>5</td><td>38</td><td>0.89</td></tr><tr><td>Dermatological</td><td>4</td><td>120</td><td>0.97</td></tr><tr><td>Gastrointestinal</td><td>32</td><td>433</td><td>0.92</td></tr><tr><td>Galactagogue</td><td>8</td><td>86</td><td>0.91</td></tr><tr><td>Reproductive</td><td>11</td><td>155</td><td>0.93</td></tr><tr><td>Miscellaneous</td><td>22</td><td>201</td><td>0.89</td></tr><tr><td>Respiratory disorders</td><td>4</td><td>37</td><td>0.91</td></tr><tr><td>Fever</td><td>5</td><td>41</td><td>0.90</td></tr><tr><td>Wound healing</td><td>7</td><td>41</td><td>0.85</td></tr></table> |
70bf8d7bdd26521240c6df2c0310cd7ece22e69d598f725caf8d4247d3790079.png | simple | <table><tr><td>Marker</td><td>Peripheral stroma</td><td>Central stroma</td><td>Anterior stroma</td><td>Posterior stroma</td></tr><tr><td>ABCG2</td><td>−</td><td>−</td><td>−</td><td>−</td></tr><tr><td>ABCG5</td><td>−</td><td>−</td><td>−</td><td>−</td></tr><tr><td>ALDH1A1</td><td>++</td><td>++</td><td>++</td><td>+</td></tr><tr><td><i>α</i>-Actinin</td><td>++</td><td>++</td><td>++</td><td>+</td></tr><tr><td>CD31</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>CD34</td><td>++</td><td>++</td><td>++</td><td>++</td></tr><tr><td>CD73</td><td>−</td><td>−</td><td>−</td><td>−</td></tr><tr><td>CD90</td><td>−</td><td>−</td><td>−</td><td>−</td></tr><tr><td>CD105</td><td>−</td><td>−</td><td>−</td><td>−</td></tr><tr><td>Collagen I</td><td>++</td><td>++</td><td>++</td><td>++</td></tr><tr><td>Collagen IV</td><td>−</td><td>−</td><td>−</td><td>−</td></tr><tr><td>CXCR4</td><td>−</td><td>−</td><td>−</td><td>−</td></tr><tr><td>Fibroblast marker</td><td>−</td><td>−</td><td>−</td><td>−</td></tr><tr><td>Fibronectin</td><td>−</td><td>−</td><td>−</td><td>−</td></tr><tr><td>Ki-67</td><td>−</td><td>−</td><td>−</td><td>−</td></tr><tr><td>Nestin</td><td>−</td><td>−</td><td>−</td><td>−</td></tr><tr><td>VE-Cadherin</td><td>−</td><td>−</td><td>−</td><td>−</td></tr><tr><td>Vimentin</td><td>++</td><td>++</td><td>++</td><td>++</td></tr></table> |
18e1b93b8340cf2b853cddc614226757d23d6bdeeef0a3e94530be06efbe04b2.png | complex | <table><tr><td></td><td colspan="4">Ezetimibe plus Fenofibrate</td><td colspan="4">Atorvastatin Monotherapy</td><td></td><td></td></tr><tr><td></td><td>Baseline</td><td>6 Weeks</td><td>% Change</td><td>p Value</td><td>Baseline</td><td>6 Weeks</td><td>% Change</td><td>p Value</td><td>% Difference</td><td>p Value</td></tr><tr><td>Total Chol (mmol/L)</td><td>5.9</td><td>4.4</td><td>-25.1</td><td>< 0.001</td><td>5.8</td><td>4.4</td><td>-24.6</td><td>< 0.001</td><td>-0.4</td><td>0.806</td></tr><tr><td>LDL-C (mmol/L)</td><td>3.8</td><td>2.4</td><td>-34.6</td><td>< 0.001</td><td>3.7</td><td>2.3</td><td>-36.7</td><td>< 0.001</td><td>2.1</td><td>0.46</td></tr><tr><td>HDL-C (mmol/L)</td><td>1.4</td><td>1.5</td><td>10.0</td><td>0.002</td><td>1.3</td><td>1.5</td><td>8.9</td><td>0.006</td><td>1.1</td><td>0.778</td></tr><tr><td>Triglycerides (mmol/L)</td><td>1.5</td><td>1.0</td><td>-25.4</td><td>< 0.001</td><td>1.6</td><td>1.4</td><td>-14.5</td><td>0.002</td><td>-11.0</td><td>0.079</td></tr><tr><td>TC:HDL Ratio</td><td>4.3</td><td>3.0</td><td>-29.0</td><td>< 0.001</td><td>4.4</td><td>3.1</td><td>-28.7</td><td>< 0.001</td><td>-0.2</td><td>0.904</td></tr><tr><td>Apo A</td><td>1.27</td><td>1.32</td><td>4.5</td><td>0.041</td><td>1.29</td><td>1.30</td><td>1.5</td><td>0.493</td><td>3.04</td><td>0.295</td></tr><tr><td>Apo B</td><td>1.21</td><td>0.82</td><td>-31.8</td><td>< 0.001</td><td>1.19</td><td>0.82</td><td>-29.8</td><td>< 0.001</td><td>-1.99</td><td>0.392</td></tr></table> |
42597d9582fe42683d4bcea786ddf46f1cfbd60f5714f6206a665bd779c02c8f.png | complex | <table><tr><td rowspan="3">Axis</td><td colspan="2">CoG Position</td><td colspan="2">Linear Acceleration</td></tr><tr><td>First Version</td><td>Second Version</td><td>First Version</td><td>Second Version</td></tr><tr><td><i>X</i></td><td>2.4252e−06</td><td>1.0008e−06</td><td>--*</td><td>--*</td></tr><tr><td><i>Y</i></td><td>1.3992e−05</td><td>1.3390e−05</td><td>6.3191e−06</td><td>5.1146e−06</td></tr><tr><td><i>Z</i></td><td>1.5306e−05</td><td>4.4980e−06</td><td>2.7849e−06</td><td>2.3104e−06</td></tr></table> |
834c2f9603f4bacecdf442d509f5486e5987a4f4604b79241771b8f8c29329cd.png | simple | <table><tr><td></td><td>Over-expressed in melan-a v B16</td><td>Under-expressed in melan-a v B16</td><td>Total</td></tr><tr><td>Upregulated by RA treatment</td><td>71</td><td>14</td><td>85</td></tr><tr><td>Downregulated by RA treatment</td><td>16</td><td>132</td><td>151</td></tr><tr><td>Total</td><td>87</td><td>149</td><td>233</td></tr></table> |
af753c587e401fa38d39ab7e2a29990dd85b9cee68ff289a1ee09396b7077482.png | simple | <table><tr><td>Characteristics</td><td><i>n</i> (%)</td></tr><tr><td>Patient factors</td><td></td></tr><tr><td>Age (years)</td><td></td></tr><tr><td> ≥ 50</td><td>68 (30.9)</td></tr><tr><td> < 50</td><td>152 (69.1)</td></tr><tr><td>Gender</td><td></td></tr><tr><td> Male</td><td>167 (75.9)</td></tr><tr><td> Female</td><td>53 (24.1)</td></tr><tr><td>Tumor factors</td><td></td></tr><tr><td>Histology</td><td></td></tr><tr><td> WHO type I</td><td>2 (0.9)</td></tr><tr><td> WHO type II</td><td>15 (6.8)</td></tr><tr><td> WHO type III</td><td>203 (92.3)</td></tr><tr><td>Clinical stage</td><td></td></tr><tr><td> I</td><td>10 (4.5)</td></tr><tr><td> II</td><td>46 (20.9)</td></tr><tr><td> III</td><td>106 (48.2)</td></tr><tr><td> IV</td><td>58 (26.4)</td></tr><tr><td>T category</td><td></td></tr><tr><td> T1</td><td>39 (17.7)</td></tr><tr><td> T2</td><td>33 (15.0)</td></tr><tr><td> T3</td><td>103 (46.8)</td></tr><tr><td> T4</td><td>45 (20.5)</td></tr><tr><td>N category</td><td></td></tr><tr><td> N0</td><td>30 (13.6)</td></tr><tr><td> N1</td><td>132 (60.0)</td></tr><tr><td> N2</td><td>40 (18.2)</td></tr><tr><td> N3</td><td>18 (8.2)</td></tr><tr><td>Treatment factors</td><td></td></tr><tr><td>chemotherapy</td><td></td></tr><tr><td> Yes</td><td>190 (86.4)</td></tr><tr><td> No</td><td>30 (13.6)</td></tr></table> |
1e3d063bd2a22f6d1f3e4a4518b4b8875d54e4ba9ea94bb9cd42726210c2712e.png | simple | <table><tr><td>Group</td><td>Variable</td><td>Lambda</td><td>F</td><td>DF1</td><td>DF2</td><td><i>p</i>-value</td></tr><tr><td>SD-Risk</td><td>IFN</td><td>0.4841</td><td>17.5871</td><td>2</td><td>33</td><td>< 0.0001</td></tr><tr><td>SD-Risk</td><td>IL-2</td><td>0.3719</td><td>27.8637</td><td>2</td><td>33</td><td>< 0.0001</td></tr><tr><td>SD-Risk</td><td>IL-10</td><td>0.6091</td><td>10.5889</td><td>2</td><td>33</td><td>0.0003</td></tr><tr><td>Treatment</td><td>IFN</td><td>0.7142</td><td>5.6031</td><td>2</td><td>28</td><td>0.0090</td></tr><tr><td>Treatment</td><td>IL-2</td><td>0.6751</td><td>6.7385</td><td>2</td><td>28</td><td>0.0041</td></tr></table> |
b8be3d5b9226ae98763531e3cc05f3d194628d6863e351cb90e0558a871369fa.png | simple | <table><tr><td>line</td><td>gene copy number</td></tr><tr><td>WT</td><td>0</td></tr><tr><td>Sox23</td><td>6 (12 homozygous)</td></tr><tr><td>Sox42</td><td>1 (2 homozygous)</td></tr><tr><td>Sox44</td><td>2 (4 homozygous)</td></tr></table> |
3131f597fe5d7c6831f472a1fe5bf587cb8920fc9a4e5c1ef2246381a02416a0.png | simple | <table><tr><td></td><td>Skill 1</td><td>Skill 2</td><td>Skill 3</td><td>Skill 4</td><td>Skill 5</td><td>Total/Avg</td><td>Skill 6</td></tr><tr><td>Pre-workshop (n = 12)</td><td>3.5</td><td>4.3</td><td>3.8</td><td>2.8</td><td>2.3</td><td>16.7/3.3</td><td>3.5</td></tr><tr><td>Post-workshop (n = 7)</td><td>4.6</td><td>5.0</td><td>4.4</td><td>4.7</td><td>2.6</td><td>21.3/4.3</td><td>2.0</td></tr><tr><td>p-value</td><td><0.01</td><td><0.05</td><td>0.18</td><td>0.01</td><td>0.86</td><td>0.01</td><td>0.01</td></tr></table> |
546526ada8af73eb8b1a7608e2cf49686977324b40c7dcd68f7e33b2a3c80b1d.png | simple | <table><tr><td>Index</td><td>Placebo group</td><td>Zaleplon 10 mg group</td><td>Zaleplon 15 mg group</td></tr><tr><td>Scores of SQS</td><td>3.75 ± 1.04</td><td>5.38 ± 0.92<sup>**</sup></td><td>6.00 ± 0.76<sup>**</sup></td></tr><tr><td>Scores of SDS</td><td>3.25 ± 1.04</td><td>4.62 ± 1.41<sup>*</sup></td><td>6.12 ± 0.83<sup>**∆</sup></td></tr><tr><td>Scores of SSS</td><td>2.38 ± 0.92</td><td>2.12 ± 0.64</td><td>2.38 ± 0.92</td></tr></table> |
a97b1dea321e4959385b0c3c7724ccce8bc379b880263c44c67aba9d2e1544af.png | simple | <table><tr><td><i>Characteristic</i></td><td><i>No. of patients</i></td><td><i>%</i></td></tr><tr><td>Patients evaluable</td><td>40</td><td>100</td></tr><tr><td>Age, years</td><td></td><td></td></tr><tr><td> Median</td><td>65</td><td></td></tr><tr><td> Range</td><td>34–75</td><td></td></tr><tr><td>Sex</td><td></td><td></td></tr><tr><td> Male</td><td>24</td><td>60</td></tr><tr><td> Female</td><td>16</td><td>40</td></tr><tr><td>ECOG PS</td><td></td><td></td></tr><tr><td> 0</td><td>6</td><td>15</td></tr><tr><td> 1</td><td>27</td><td>67.5</td></tr><tr><td> 2</td><td>7</td><td>17.5</td></tr><tr><td>Disease location</td><td></td><td></td></tr><tr><td> Gastric</td><td>30</td><td>75</td></tr><tr><td> GEJ</td><td>10</td><td>25</td></tr><tr><td>Histologic type</td><td></td><td></td></tr><tr><td> Diffuse</td><td>19</td><td>47.5</td></tr><tr><td> Intestinal</td><td>15</td><td>37.5</td></tr><tr><td> Unspecified</td><td>6</td><td>15</td></tr><tr><td>Previous adjuvant chemotherapy</td><td>6</td><td>15</td></tr><tr><td>Status of primary tumor</td><td></td><td></td></tr><tr><td> Unresected</td><td>28</td><td>70</td></tr><tr><td> Resected</td><td>12</td><td>30</td></tr><tr><td>Predominant site of disease</td><td></td><td></td></tr><tr><td> Liver</td><td>24</td><td>60</td></tr><tr><td> Peritoneum</td><td>8</td><td>20</td></tr><tr><td> Nodes</td><td>4</td><td>10</td></tr><tr><td> Lung</td><td>2</td><td>5</td></tr><tr><td> Bone</td><td>2</td><td>5</td></tr><tr><td>No. of metastatic sites</td><td></td><td></td></tr><tr><td> 1</td><td>11</td><td>27.5</td></tr><tr><td> 2</td><td>19</td><td>47.5</td></tr><tr><td> ≥ 3</td><td>10</td><td>25</td></tr></table> |
465f25e16086d4dac57994d374e6e51ddac600e80d821e1de256610b56e32983.png | simple | <table><tr><td>Patient</td><td>Karyotype/Molecular lesion(s)</td><td>FAB subgroup</td><td>Age at diagnosis</td><td>IDO1 status</td><td>CR</td><td>Relapse</td><td>Alive</td></tr><tr><td>UPN #1</td><td>Normal</td><td>M2</td><td>13.0</td><td>Negative</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>UPN #2</td><td>t(8;21) (q22;q22)</td><td>M2</td><td>13.0</td><td>Negative</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>UPN #3</td><td>Normal</td><td>M1</td><td>10.0</td><td>Negative</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>UPN #4</td><td>Normal</td><td>M2</td><td>4.9</td><td>Negative</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>UPN #5</td><td>Normal</td><td>M5</td><td>12.0</td><td>Negative</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>UPN #6</td><td>Normal</td><td>M1</td><td>3.0</td><td>Negative</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>UPN #7</td><td>t(8;21) (q22;q22)</td><td>M2</td><td>9.0</td><td>Negative</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>UPN #8</td><td>Normal</td><td>M1/M2</td><td>1.0</td><td>Negative</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>UPN #9</td><td>Normal</td><td>M2</td><td>15.0</td><td>Negative</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>UPN #10</td><td>N.A.</td><td>M1</td><td>15.4</td><td>Negative</td><td>No</td><td>Yes</td><td>No</td></tr><tr><td>UPN #11</td><td>Normal</td><td>N.A.</td><td>N.A.</td><td>Negative</td><td>No</td><td>Yes</td><td>No</td></tr><tr><td>UPN #12</td><td>FLT3-ITD</td><td>U</td><td>6.0</td><td>Negative</td><td>No</td><td>Yes</td><td>Yes</td></tr><tr><td>UPN #13</td><td>Normal</td><td>M2</td><td>3.4</td><td>Negative</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td>UPN #14</td><td>t(6;9) - FLT3-ITD</td><td>M4</td><td>23.0</td><td>Negative</td><td>Yes</td><td>Yes</td><td>No</td></tr><tr><td>UPN #15</td><td>Normal</td><td>M5</td><td>15.5</td><td>Negative</td><td>Yes</td><td>Yes</td><td>No</td></tr><tr><td>UPN #16</td><td>t(8;21) (q22;q22)</td><td>M2</td><td>11.3</td><td>Negative</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td>UPN #17</td><td>t(8;21) (q22;q22)</td><td>M2</td><td>9.0</td><td>Negative</td><td>Yes</td><td>Yes</td><td>No</td></tr><tr><td>UPN #18</td><td>FLT3-ITD</td><td>N.A.</td><td>14.0</td><td>Negative</td><td>N.A.</td><td>Yes</td><td>No</td></tr><tr><td>UPN #19</td><td>t(9;11)(p22;q23) - MLL-AF9</td><td>M5</td><td>1.0</td><td>Positive</td><td>No</td><td>No</td><td>No</td></tr><tr><td>UPN #20</td><td>t(10;11) - MLL-AF10</td><td>M5</td><td>6.0</td><td>Positive</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>UPN #21</td><td>inv(16)(p13q22)</td><td>M4</td><td>16.0</td><td>Positive</td><td>Yes</td><td>No</td><td>No</td></tr><tr><td>UPN #22</td><td>t(8;21) (q22;q22)</td><td>M4</td><td>16.0</td><td>Positive</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>UPN #23</td><td>t(10;11) - MLL-AF10</td><td>M4/M5</td><td>4.0</td><td>Positive</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>UPN #24</td><td>FLT3-ITD</td><td>M4</td><td>12.3</td><td>Positive</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>UPN #25</td><td>inv(16) (p13q22)</td><td>M4</td><td>17.2</td><td>Positive</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>UPN #26</td><td>t(1;11) - MLL-AF1</td><td>M5</td><td>0.2</td><td>Positive</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>UPN #27</td><td>inv(16)(p13q22)</td><td>M5</td><td>9.0</td><td>Positive</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>UPN #28</td><td>Normal</td><td>M5</td><td>16.5</td><td>Positive</td><td>N.A.</td><td>No</td><td>No</td></tr><tr><td>UPN #29</td><td>FLT3-ITD</td><td>M5</td><td>7.0</td><td>Positive</td><td>No</td><td>Yes</td><td>No</td></tr><tr><td>UPN #30</td><td>Normal</td><td>M5</td><td>14.1</td><td>Positive</td><td>Yes</td><td>Yes</td><td>No</td></tr><tr><td>UPN #31</td><td>FLT3-ITD</td><td>M5</td><td>15.0</td><td>Positive</td><td>Yes</td><td>Yes</td><td>No</td></tr><tr><td>UPN #32</td><td>Normal</td><td>M5</td><td>0.4</td><td>Positive</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td>UPN #33</td><td>FLT3-ITD</td><td>M5</td><td>12.3</td><td>Positive</td><td>Yes</td><td>Yes</td><td>No</td></tr><tr><td>UPN #34</td><td>inv(16) (p13q22)</td><td>M4</td><td>13.0</td><td>Positive</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td>UPN #35</td><td>t(10;11) - MLL-AF10</td><td>M5</td><td>4.0</td><td>Positive</td><td>Yes</td><td>Yes</td><td>No</td></tr><tr><td>UPN #36</td><td>inv(16) (p13q22)</td><td>M4</td><td>0.8</td><td>Positive</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td>UPN #37</td><td>FLT3-ITD</td><td>M4</td><td>15.7</td><td>Positive</td><td>N.A.</td><td>Yes</td><td>No</td></tr></table> |
108caffb46f5d2d3b9e391f68e12c6627a9f1696d012fc7506f47a279b244189.png | complex | <table><tr><td></td><td colspan="2">Sock-only</td><td colspan="2">Shod</td></tr><tr><td>Subject</td><td>r</td><td>nMAD</td><td>r</td><td>nMAD</td></tr><tr><td>1</td><td>0.91</td><td>0.09</td><td>0.59</td><td>0.23</td></tr><tr><td>2</td><td>0.77</td><td>0.16</td><td>0.56</td><td>0.22</td></tr><tr><td>3</td><td>0.84</td><td>0.13</td><td>0.7</td><td>0.18</td></tr><tr><td>4</td><td>0.91</td><td>0.1</td><td>0.84</td><td>0.12</td></tr><tr><td>5</td><td>0.79</td><td>0.16</td><td>0.39</td><td>0.27</td></tr><tr><td>6</td><td>0.92</td><td>0.1</td><td>0.87</td><td>0.12</td></tr><tr><td>7</td><td>0.85</td><td>0.14</td><td>0.83</td><td>0.13</td></tr><tr><td>8</td><td>0.92</td><td>0.09</td><td>0.8</td><td>0.15</td></tr><tr><td>9</td><td>0.65</td><td>0.16</td><td>0.05</td><td>0.29</td></tr><tr><td>10</td><td>0.83</td><td>0.14</td><td>0.7</td><td>0.17</td></tr><tr><td>11</td><td>0.75</td><td>0.17</td><td>0.4</td><td>0.26</td></tr><tr><td>12</td><td>0.74</td><td>0.17</td><td>0.5</td><td>0.25</td></tr><tr><td>13</td><td>0.91</td><td>0.1</td><td>0.71</td><td>0.19</td></tr><tr><td>14</td><td>0.8</td><td>0.16</td><td>0.56</td><td>0.23</td></tr><tr><td>15</td><td>0.76</td><td>0.16</td><td>0.82</td><td>0.13</td></tr><tr><td>16</td><td>0.86</td><td>0.13</td><td>0.5</td><td>0.23</td></tr><tr><td>17</td><td>0.66</td><td>0.2</td><td>0.53</td><td>0.23</td></tr><tr><td>18</td><td>0.71</td><td>0.19</td><td>0.18</td><td>0.28</td></tr><tr><td>19</td><td>0.76</td><td>0.16</td><td>0.46</td><td>0.23</td></tr><tr><td>20</td><td>0.28</td><td>0.26</td><td>0.22</td><td>0.26</td></tr><tr><td>Mean</td><td>0.78</td><td>0.15</td><td>0.56</td><td>0.21</td></tr></table> |
1bb88fd1455395a16cff183d37599c390cee3b1b0af5930f889f36b37f061cb2.png | complex | <table><tr><td rowspan="2">Patient</td><td colspan="2">Before</td><td colspan="2">2 months</td><td colspan="2">6 months</td><td colspan="2">1 year</td></tr><tr><td>Right<sup>a</sup></td><td>Left<sup>b</sup></td><td>Right</td><td>Left</td><td>Right</td><td>Left</td><td>Right</td><td>Left</td></tr><tr><td> </td><td colspan="8">Biceps brachii muscle (latency)</td></tr><tr><td> 6</td><td>0.00<sup>c</sup></td><td>0.00</td><td> 0.00</td><td> 0.00</td><td>14.49</td><td>14.31</td><td>15.99</td><td>17.37</td></tr><tr><td> 9</td><td>0.00</td><td>0.00</td><td>13.01</td><td>13.27</td><td>14.57</td><td>14.40</td><td>14.50</td><td>14.60</td></tr><tr><td>10</td><td>0.00</td><td>0.00</td><td> 0.00</td><td> 0.00</td><td>12.39</td><td> 0.00</td><td>12.16</td><td> 0.00</td></tr><tr><td> </td><td colspan="8">Biceps brachii muscle (amplitude)</td></tr><tr><td>1</td><td>0.00<sup>d</sup></td><td>0.00</td><td>0.00</td><td>0.00</td><td>0.79</td><td>0.87</td><td>0.69</td><td>0.61</td></tr><tr><td> 2</td><td>0.00</td><td>0.00</td><td>0.00</td><td>0.00</td><td>0.22</td><td>0.00</td><td>0.62</td><td>0.00</td></tr><tr><td> 6</td><td>0.00</td><td>0.00</td><td>0.00</td><td>0.00</td><td>0.75</td><td>1.25</td><td>0.88</td><td>0.53</td></tr><tr><td> 9</td><td>0.00</td><td>0.00</td><td>0.36</td><td>0.20</td><td>0.65</td><td>0.40</td><td>0.84</td><td>0.54</td></tr><tr><td>10</td><td>0.00</td><td>0.00</td><td>0.00</td><td>0.00</td><td>1.37</td><td>0.00</td><td>1.66</td><td>0.00</td></tr><tr><td>12</td><td>0.00</td><td>0.00</td><td>0.00</td><td>0.00</td><td>0.00</td><td>0.00</td><td>0.51</td><td>0.42</td></tr><tr><td>14</td><td>0.55</td><td>0.00</td><td>0.62</td><td>0.38</td><td>2.14</td><td>1.39</td><td>1.07</td><td>0.66</td></tr><tr><td>16</td><td>0.00</td><td>0.00</td><td>0.85</td><td>0.76</td><td>0.91</td><td>2.49</td><td>1.57</td><td>1.00</td></tr><tr><td>17</td><td>0.00</td><td>0.00</td><td>0.82</td><td>0.84</td><td>0.93</td><td>1.24</td><td>1.21</td><td>1.58</td></tr><tr><td> </td><td colspan="8">Abductor pollicis brevis muscle (latency)</td></tr><tr><td> 3</td><td>0.00</td><td>0.00</td><td>24.85</td><td>0.00</td><td>25.95</td><td> 0.00</td><td>28.59</td><td>0.00</td></tr><tr><td>11<sup>e</sup></td><td>0.00</td><td>0.00</td><td> 0.00</td><td>0.00</td><td> 0.00</td><td>30.06</td><td> 0.00</td><td>0.00</td></tr><tr><td> </td><td colspan="8">Abductor pollicis brevis muscle (amplitude)</td></tr><tr><td> 3</td><td>0.00</td><td>0.00</td><td>0.39</td><td>0.00</td><td>0.07</td><td>0.00</td><td>0.18</td><td>0.00</td></tr><tr><td>11<sup>e</sup></td><td>0.00</td><td>0.00</td><td>0.00</td><td>1.06</td><td>0.00</td><td>0.00</td><td>0.00</td><td>0.00</td></tr></table> |
1add04ad3d4466031d7bdd5af31027c428a1c6f028242e592dba1e3960a1317a.png | complex | <table><tr><td>Age range</td><td>Count<sup>a</sup></td><td>ERP<sup>b</sup></td><td>Rate<sup>c</sup></td><td>Ratio<sup>d</sup></td><td colspan="2">95 % CI</td></tr><tr><td>4</td><td>7,594</td><td>72,820</td><td>10.4</td><td>0.26</td><td>0.26</td><td>0.26</td></tr><tr><td>5–9</td><td>100,787</td><td>340,503</td><td>29.6</td><td>0.74</td><td>0.74</td><td>0.74</td></tr><tr><td>10–14</td><td>132,965</td><td>330,448</td><td>40.2</td><td>1</td><td>1</td><td>1</td></tr><tr><td>15–19</td><td>81,910</td><td>355,117</td><td>23.1</td><td>0.57</td><td>0.57</td><td>0.57</td></tr><tr><td>20–24</td><td>47,831</td><td>412,009</td><td>11.6</td><td>0.29</td><td>0.29</td><td>0.29</td></tr><tr><td>25–29</td><td>31,965</td><td>433,533</td><td>7.4</td><td>0.18</td><td>0.18</td><td>0.18</td></tr><tr><td>30–34</td><td>20,529</td><td>406,284</td><td>5.1</td><td>0.13</td><td>0.13</td><td>0.13</td></tr><tr><td>35–39</td><td>13,952</td><td>391,179</td><td>3.6</td><td>0.09</td><td>0.09</td><td>0.09</td></tr><tr><td>40–44</td><td>12,831</td><td>411,667</td><td>3.1</td><td>0.08</td><td>0.08</td><td>0.08</td></tr><tr><td>45–49</td><td>7,824</td><td>378,012</td><td>2.1</td><td>0.05</td><td>0.05</td><td>0.05</td></tr><tr><td>50–54</td><td>4,357</td><td>371,333</td><td>1.2</td><td>0.03</td><td>0.03</td><td>0.03</td></tr><tr><td>55–59</td><td>1,570</td><td>333,160</td><td>0.5</td><td>0.01</td><td>0.01</td><td>0.01</td></tr><tr><td>60–64</td><td>789</td><td>296,984</td><td>0.3</td><td>0.01</td><td>0.01</td><td>0.01</td></tr><tr><td>65–69</td><td>288</td><td>249,830</td><td>0.1</td><td><0.01</td><td><0.01</td><td><0.01</td></tr><tr><td>70–74</td><td>144</td><td>188,531</td><td>0.1</td><td><0.01</td><td><0.01</td><td><0.01</td></tr><tr><td>75–79</td><td>33</td><td>146,349</td><td><0.1</td><td><0.01</td><td><0.01</td><td><0.01</td></tr><tr><td>80–84</td><td>12</td><td>114,990</td><td><0.1</td><td><0.01</td><td><0.01</td><td><0.01</td></tr><tr><td>85–100</td><td>22</td><td>110,096</td><td><0.1</td><td><0.01</td><td><0.01</td><td><0.01</td></tr><tr><td>All</td><td>465,403</td><td>5,629,122</td><td>8.3</td><td>0.21</td><td>0.21</td><td>0.21</td></tr></table> |
31779a6c73bacce3fe6e376a74314056faa235bb6555c4b932c17ea33e7da319.png | complex | <table><tr><td rowspan="2"> </td><td colspan="2">Patients withAlzheimer's disease (n=21)</td><td rowspan="2"> </td><td colspan="2">Patients withfrontotemporal dementia (n=23)</td><td rowspan="2">U</td><td rowspan="2">Z</td><td rowspan="2">p*</td></tr><tr><td>M±SD</td><td>CI 95%</td><td>M±SD</td><td>CI 95%</td></tr><tr><td>Age, y</td><td>73.52±7.94</td><td>69.90|-|77.14</td><td> </td><td>63.95±13.47</td><td>58.12|-|69.78</td><td>598</td><td>-1.136</td><td>0.310<sup>†</sup></td></tr><tr><td>Dementia duration,y</td><td>2.84±2.21</td><td>1.83|-|3.85</td><td> </td><td>4.41±4.18</td><td>2.60|-|6.22</td><td>697</td><td>-0.245</td><td>0.376<sup>†</sup></td></tr><tr><td>MMSE score</td><td>13.19±7.41</td><td>9.81|-|16.56</td><td> </td><td>13.82±9.39</td><td>9.76|-|17.88</td><td>576</td><td>-1.178</td><td>0.298<sup>†</sup></td></tr><tr><td>FAQ</td><td>22.00±10.34</td><td>17.28|-|26.71</td><td> </td><td>20.04±10.45</td><td>15.52|-|24.56</td><td>818</td><td>-0.034</td><td>0.816<sup>†</sup></td></tr><tr><td>Education, y</td><td>7.00±5.71</td><td>4.40|-|9.59</td><td> </td><td>7.67±5.48</td><td>5.30|-|10.04</td><td>688</td><td>-1.29</td><td>0.358<sup>†</sup></td></tr><tr><td>BFI</td><td>35.05±5.01</td><td>32.76 |-| 37.33</td><td> </td><td>34.90±5.33</td><td>32.6 |-|37.21</td><td>556</td><td>-0.394</td><td>0.742<sup>†</sup></td></tr></table> |
61015fa3438e3f6f3d7105aace6b5df60ab2f5d3acb3e7632bfe8dd12c07e5c0.png | complex | <table><tr><td rowspan="2">Concentration range (pg/g lipid)</td><td colspan="2">Second-order (equivalent to minus change in apparent elimination rate in 2006)</td><td colspan="2">First-order (equivalent to minus apparent elimination rate)</td></tr><tr><td>coefficient</td><td><i>p</i>-value</td><td>coefficient</td><td><i>p</i>-value</td></tr><tr><td>0–10</td><td>−0.000596</td><td>0.599665</td><td>−0.004032</td><td>0.165814</td></tr><tr><td>10–20</td><td>0.000464</td><td>0.463854</td><td>−0.000462</td><td>0.786707</td></tr><tr><td>20–50</td><td>0.000643</td><td>0.182574</td><td>0.001669</td><td>0.229181</td></tr><tr><td>50–100</td><td>0.002124</td><td>7.99 × 10<sup>−5</sup></td><td>−0.005452</td><td>0.000216</td></tr><tr><td>>100</td><td>0.001436</td><td>9.68 × 10<sup>−7</sup></td><td>−0.008294</td><td><2 × 10<sup>−16</sup></td></tr></table> |
b82b74ede38db7487e6946fe4c11597b8ba733ef06042b74b49534376e8bcebe.png | complex | <table><tr><td><i>N</i> = 1352</td><td>Non-responders <i>n</i> = 909</td><td>Responders <i>n</i> = 443</td><td><i>p</i> value</td></tr><tr><td>Women, <i>n</i> (%)</td><td>520 (57)</td><td>273 (62)</td><td>0.12 A</td></tr><tr><td>Age, average years (SD)</td><td>41.3 (11.8)</td><td>44.4 (10.8)</td><td>0.05 B</td></tr><tr><td>Work <i>n</i> (%)</td><td></td><td></td><td>0.15 A</td></tr><tr><td>Farming, fishery, industry</td><td>150 (17)</td><td>65 (15)</td><td></td></tr><tr><td>Construction, trading and transport</td><td>231 (25)</td><td>109 (25)</td><td></td></tr><tr><td>Communication, information, finance, insurance, real estate and consultancy</td><td>103 (11)</td><td>49 (11)</td><td></td></tr><tr><td>Public administration, teaching, health, culture and leisure</td><td>329 (36)</td><td>189 (43)</td><td></td></tr><tr><td>Other</td><td>36 (4)</td><td>11 (2)</td><td></td></tr><tr><td>Missing</td><td>60 (7)</td><td>20 (5)</td><td></td></tr><tr><td>Self-reported reason for sickness absence <i>n</i> (%)</td><td></td><td></td><td><0.001 A</td></tr><tr><td>Musculoskeletal disorder (MSD)</td><td>387 (43)</td><td>244 (55)</td><td></td></tr><tr><td>Common mental disorder (CMD)</td><td>294 (32)</td><td>94 (21)</td><td></td></tr><tr><td>Stress</td><td>95 (19)</td><td>52 (12)</td><td></td></tr><tr><td>Functional somatic syndrome/unknown</td><td>19 (2)</td><td>10 (2)</td><td></td></tr><tr><td>Heart disorder, lung disorder, cancer</td><td>36 (4)</td><td>12 (3)</td><td></td></tr><tr><td>Other</td><td>78 (9)</td><td>31 (7)</td><td></td></tr><tr><td colspan="4"><i>Previous year before inclusion</i> median (iqr)</td></tr><tr><td>Employment or unemployment, weeks</td><td>42 (26-46)</td><td>42 (33-45)</td><td>0.35 C</td></tr><tr><td>Duration of sickness absence, weeks</td><td>7 (5-12)</td><td>7 (6-11)</td><td>0.43 C</td></tr><tr><td colspan="4">Health care utilization</td></tr><tr><td>Visits in general practice</td><td>11 (7-18)</td><td>12 (7-18)</td><td>0.30 C</td></tr><tr><td>Visits in physiotherapist clinics</td><td>0 (0-0)</td><td>0 (0-1)</td><td>0.30 C</td></tr><tr><td>Visits in out-patient clinics</td><td>2 (1-6)</td><td>3 (1-6)</td><td>0.58 C</td></tr><tr><td>Visits in psychiatric out-patient clinics</td><td>0 (0-0)</td><td>0 (0-0)</td><td>0.19 C</td></tr><tr><td>Admissions in hospitals</td><td>0 (0-0)</td><td>0 (0-0)</td><td>0.45 C</td></tr><tr><td>Admissions in psychiatric hospitals</td><td>0 (0-0)</td><td>0 (0-0)</td><td>0.02 C</td></tr><tr><td colspan="4"><i>One year after inclusion</i></td></tr><tr><td>Labour market participation <i>n</i> (%)</td><td></td><td></td><td>0.92 A</td></tr><tr><td>Non-RTW</td><td>309 (34)</td><td>146 (33)</td><td></td></tr><tr><td>RTW</td><td>548 (60)</td><td>273 (62)</td><td></td></tr><tr><td>Old age and disability pension</td><td>50 (6)</td><td>22 (5)</td><td></td></tr><tr><td>Died</td><td>2 (0)</td><td>2 (0)</td><td></td></tr></table> |
aa44cf6c3f9a961ef2307e446b7253cab3fc474c2e7a9ad91b1d682d92c8efb9.png | complex | <table><tr><td></td><td colspan="2">Perianal disease prior to pregnancy n = 27</td><td colspan="2">No perianal disease prior to pregnancy n = 87</td></tr><tr><td>Mode of childbirth</td><td>Vaginal delivery n (%)</td><td>Caesarean section n (%)</td><td>Vaginal delivery n (%)</td><td>Caesarean section n (%)</td></tr><tr><td></td><td>11 (41)</td><td>16 (59)</td><td>66 (76)</td><td>21 (24)</td></tr><tr><td>Progression perianal disease ≤ 2 years post partum:</td><td>2 (18)</td><td>5 (31)</td><td>3 (5)</td><td>3 (14)</td></tr><tr><td> - Yes</td><td>9 (82)</td><td>9 (56)</td><td>58(94)</td><td>18 (86)</td></tr><tr><td> - No</td><td>0 (0)</td><td>2 (13)</td><td>5 (1)</td><td>0 (0)</td></tr><tr><td> - Not applicable<sup>†</sup></td><td></td><td></td><td></td><td></td></tr></table> |
21d214ad1e4e3238c3aa6ad4b4b716adae35e514a724e799de69cc970660cfc4.png | simple | <table><tr><td>Peptide</td><td>Sequence</td><td>Mw</td><td>pI<sup>1</sup></td><td>Net charge</td><td>Mean hydrophobicity<sup>2</sup></td></tr><tr><td>KHN20</td><td>KHNLGHGHKHERDQGHGHQR</td><td>2365.5</td><td>9.99</td><td>+2</td><td>−4.91</td></tr><tr><td>GHG20</td><td>GHGLGHGHEQQHGLGHGHKF</td><td>2127.2</td><td>7.21</td><td>0</td><td>−2.01</td></tr><tr><td>GHG21</td><td>GHGHKFKLDDDLEHQGGHVLD</td><td>2354.5</td><td>5.63</td><td>−3</td><td>−2.32</td></tr><tr><td>GGH20</td><td>GGHVLDHGHKHKHGHGHGKH</td><td>2169.3</td><td>9.70</td><td>+2</td><td>−3.44</td></tr><tr><td>HKH20</td><td>HKHGHGHGKHKNKGKKNGKH</td><td>2151.5</td><td>10.78</td><td>+7</td><td>−5.91</td></tr><tr><td>GKH17</td><td>GKHKNKGKKNGKHNGWK</td><td>1946</td><td>10.78</td><td>+7</td><td>−5.77</td></tr><tr><td>GKH17WWW</td><td>GKHKNKGKKNGKHNGWKWWW</td><td>2505</td><td>10.78</td><td>+7</td><td>−3.45</td></tr><tr><td>GKH17WWWWW</td><td>GKHKNKGKKNGKHNGWKWWWWW</td><td>2287</td><td>10.78</td><td>+7</td><td>−2.25</td></tr><tr><td>LL-37</td><td>LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES</td><td>4492</td><td>10.61</td><td>+6</td><td>−1.84</td></tr><tr><td>Histatin-5</td><td>DSHAKRHHGYKRKFHEKHHSHRGY</td><td>3036</td><td>10.28</td><td>+5</td><td>−4.67</td></tr></table> |
483d9bc63d82a56209d473d293ba38f1616315880c3d6c1e42c576e119a41735.png | simple | <table><tr><td>Matching phase</td><td>Type of match</td><td>Number linked</td><td>%</td></tr><tr><td>1</td><td>Child’s first, middle, and last name & dob and mother’s dob</td><td>5282</td><td>2.6 %</td></tr><tr><td>2</td><td>Child’s first, middle initial, and last name & dob and mother’s dob</td><td>32094</td><td>16.0 %</td></tr><tr><td>3</td><td>Child’s first, middle, and last name & dob</td><td>3035</td><td>1.5 %</td></tr><tr><td>4</td><td>Child’s first, middle initial, and last name & dob</td><td>66730</td><td>33.3 %</td></tr><tr><td>5</td><td>Child’s first and last name & dob</td><td>90506</td><td>45.2 %</td></tr><tr><td>6</td><td>Child’s first 3 letters of first name and last name & dob</td><td>2696</td><td>1.3 %</td></tr></table> |
1c8c786e697d73021eaa53b2981f842209367d6595154fc3c3110bd98e9f27e0.png | simple | <table><tr><td>Number</td><td>Authors, year</td><td>c</td><td>Age, sex</td><td>Period (years)</td><td>symptoms</td><td>Preoperative lab</td><td>Treatment</td><td>Histological diagnosis</td><td>Outcomes</td></tr><tr><td>1</td><td>Boriani et al, 1978 [8]</td><td>S1-3</td><td>18, M</td><td>DNMI</td><td>Bone pain, weakness</td><td>Hypophosphatemia, elevated ALP</td><td>Complete resection, radiotherapy</td><td>Osteosarcoma</td><td>NOLF</td></tr><tr><td>2</td><td>Stone et al, 1992 [9]</td><td>T3-4</td><td>33, F</td><td>DNMI</td><td>Bone pain, weakness, fractures</td><td>Hypophosphatemia</td><td>Complete resection, supplementation of vitamin D, phosphate, and calcium</td><td>Neuroendocrine tumor</td><td>NOLF</td></tr><tr><td>3</td><td>Yu et al, 1995 [10]</td><td>C2</td><td>58, F</td><td>DNMI</td><td>Musculoskeletal pain, weakness</td><td>Hypophosphatemia, elevated ALP and PTH</td><td>Partial resection, supplementation of vitamin D and phosphate</td><td>PMT</td><td>PSA</td></tr><tr><td>4</td><td>Terek et al, 2001 [11]</td><td>S1-2</td><td>14, M</td><td>1+</td><td>Bone pain, skeletal abnormalities</td><td>Hypophosphatemia, hypocalcemia, low level of vitamin D<sub>3</sub>, elevated ALP</td><td>Partial resection, chemotherapy (doxorubicin)</td><td>Osteosarcoma</td><td>PSA, ALL</td></tr><tr><td>5</td><td>Dissanayake et al, 2003 [37]</td><td>L2</td><td>58, M</td><td>3+</td><td>Musculoskeletal pains, fractures</td><td>Hypophosphatemia, low level of vit D<sub>3</sub>, elevated ALP</td><td>Complete resection</td><td>Haemangiopericytoma</td><td>NOLF</td></tr><tr><td>6</td><td>Folpe et al, 2004 [5]</td><td>C1</td><td>32, F</td><td>4</td><td>DNMI</td><td>DNMI</td><td>Partial resection, radiotherapy</td><td>Malignant PMTMCT</td><td>PSA recurrence</td></tr><tr><td>7</td><td>Chua et al, 2008 [12]</td><td>T3</td><td>34, F</td><td>1</td><td>Musculoskeletal pain, fatigue</td><td>Hypophosphatemia, hypocalcemia, elevated ALP and PTH</td><td>Partial resection, supplementation of phosphate and calcitriol</td><td>Plasmacytoma</td><td>DNMI</td></tr><tr><td>8</td><td>Sciubba et al, 2009 [13]</td><td>T8</td><td>56, F</td><td>5</td><td>Bone pain, weakness, fractures</td><td>Hypophosphatemia, low level of vitamin D<sub>3</sub>, elevated ALP and PTH</td><td>Complete resection</td><td>PMT</td><td>NOLF</td></tr><tr><td>9</td><td>Pirola et al, 2009 [14]</td><td>T4</td><td>57, M</td><td>DNMI</td><td>Fractures, paresthesias</td><td>Hypophosphatemia, low level of vitamin D<sub>3</sub>, elevated ALP and PTH</td><td>Complete resection, supplementation of vitamin D and phosphate</td><td>PMT</td><td>NOLF</td></tr><tr><td>10</td><td>Mavrogenis et al, 2010 [15]</td><td>S1</td><td>42, F</td><td>2</td><td>Bone pain, paresthesias</td><td>Normal</td><td>Complete resection</td><td>PMTMCT</td><td>NOLF</td></tr><tr><td>11</td><td>Marshall et al, 2010 [16]</td><td>T12</td><td>55, F</td><td>6+</td><td>Bone pain; fractures</td><td>Hypophosphatemia</td><td>Complete resection</td><td>PMTMCT</td><td>DNMI</td></tr><tr><td>12</td><td>Akhter et al, 2011 [17]</td><td>C5</td><td>52, M</td><td>1</td><td>Fracture</td><td>Hypophosphatemia</td><td>Complete resection, supplementation of vitamin D, and phosphate</td><td>PMTMCT</td><td>NOLF</td></tr><tr><td>13</td><td>Gandhi et al, 2012 [18]</td><td>L4</td><td>66, F</td><td>2,</td><td>Bone pain, weakness</td><td>Hypophosphatemia, hypocalcemia, low level of vit D<sub>3</sub>, elevated ALP and PTH</td><td>Complete resection</td><td>PMTMCT</td><td>NOLF</td></tr><tr><td>14</td><td>Nakamura et al, 2014 [19]</td><td>C5</td><td>72, M</td><td>2.5</td><td>Weakness</td><td>Hypophosphatemia, elevated ALP and PTH</td><td>Complete resection, supplementation of phosphate and calcitriol.</td><td>PMTMCT</td><td>NOLF</td></tr><tr><td>15</td><td>Puthenveetil et al [38]</td><td>T12</td><td>61, F</td><td>7</td><td>Musculoskeletal pain, weakness, fractures</td><td>Hypophosphatemia, increased ALP</td><td>Complete resection, supplementation of calcium and phosphate</td><td>PMTMCT</td><td>NOLF</td></tr><tr><td>16</td><td>Present case</td><td>T1</td><td>60, M</td><td>6</td><td>Bone pain, weakness, paresthesia</td><td>Hypophosphatemia, hypocalcemia, elevated PTH</td><td>Complete resection, supplementation of calcitriol</td><td>PMT</td><td>NOLF</td></tr></table> |
1d6c6d54bc931bbc726f4d9068f717a7b7a9bc930cefed5207aa0fa6357472e4.png | complex | <table><tr><td rowspan="3">Antibiotics<sup>a</sup></td><td rowspan="3">Extracts concentration<sup>b</sup></td><td colspan="9">Bacteria, MIC (μg/mL) and modulating factors (in bracket)</td><td rowspan="3">Modulating effect (%)<sup>b</sup></td></tr><tr><td colspan="3"><i>E. coli</i></td><td colspan="3"><i>E. aerogenes</i></td><td><i>K. pneumoniae</i></td><td><i>P. stuartuii</i></td><td><i>P. aeruginosa</i></td></tr><tr><td>AG100</td><td>AG102</td><td>AG100<sub>Tet</sub></td><td>CM64</td><td>EA289</td><td>EA298</td><td>K24</td><td>NEA16</td><td>PA124</td></tr><tr><td rowspan="3">AMP</td><td>0</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td></td></tr><tr><td>MIC/2</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>0</td></tr><tr><td>MIC/4</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>0</td></tr><tr><td rowspan="3">CHL</td><td>0</td><td>8</td><td>32</td><td>64</td><td>256</td><td>128</td><td>64</td><td>64</td><td>64</td><td>64</td><td></td></tr><tr><td>MIC/2</td><td>8 (1)</td><td>16 (2)</td><td>32 (2)</td><td>256 (1)</td><td>128 (1)</td><td>32 (2)</td><td>32 (2)</td><td>32 (2)</td><td>32 (2)</td><td>66.67</td></tr><tr><td>MIC/4</td><td>8 (1)</td><td>16 (2)</td><td>64 (1)</td><td>256 (1)</td><td>256 (0.5)</td><td>64 (1)</td><td>64 (1)</td><td>32 (2)</td><td>32 (2)</td><td>33.33</td></tr><tr><td rowspan="3">CIP</td><td>0</td><td>≤0.5</td><td>≤0.5</td><td>128</td><td>64</td><td>128</td><td>1</td><td>128</td><td>1</td><td>32</td><td></td></tr><tr><td>MIC/2</td><td>≤0.5 (na)</td><td>≤0.5 (na)</td><td>64(2)</td><td>32 (2)</td><td>128 (1)</td><td>1 (1)</td><td>64 (2)</td><td>1 (1)</td><td>32 (1)</td><td>33.33</td></tr><tr><td>MIC/4</td><td>≤0.5 (na)</td><td>≤0.5 (na)</td><td>128(1)</td><td>64 (1)</td><td>128 (1)</td><td>1 (1)</td><td>64 (2)</td><td>1 (1)</td><td>32 (1)</td><td>11.11</td></tr><tr><td rowspan="3">KAN</td><td>0</td><td>64</td><td>4</td><td>8</td><td>2</td><td>16</td><td>32</td><td>4</td><td>16</td><td>128</td><td></td></tr><tr><td>MIC/2</td><td>4 (16)</td><td>1 (4)</td><td>2 (4)</td><td>1 (2)</td><td>4 (4)</td><td>32 (1)</td><td>2 (2)</td><td>8 (2)</td><td>64 (2)</td><td>88.89</td></tr><tr><td>MIC/4</td><td>16 (4)</td><td>4 (1)</td><td>2 (4)</td><td>2 (1)</td><td>8 (2)</td><td>32 (1)</td><td>2 (2)</td><td>8 (2)</td><td>64 (2)</td><td>66.67</td></tr><tr><td rowspan="3">ERY</td><td>0</td><td>32</td><td>64</td><td>-</td><td>-</td><td>64</td><td>16</td><td>128</td><td>16</td><td>128</td><td></td></tr><tr><td>MIC/2</td><td>32 (1)</td><td>64 (1)</td><td>-</td><td>-</td><td>64 (1)</td><td>16 (1)</td><td>128 (1)</td><td>8 (2)</td><td>64 (2)</td><td>22.22</td></tr><tr><td>MIC/4</td><td>32 (1)</td><td>64 (1)</td><td>-</td><td>-</td><td>64 (1)</td><td>16 (1)</td><td>128 (1)</td><td>8 (2)</td><td>128 (1)</td><td>11.11</td></tr><tr><td rowspan="3">TET</td><td>0</td><td>2</td><td>8</td><td>32</td><td>16</td><td>32</td><td>4</td><td>16</td><td>4</td><td>16</td><td></td></tr><tr><td>MIC/2</td><td>≤0.5 (≥4)</td><td>4 (2)</td><td>4 (8)</td><td>4 (4)</td><td>4 (8)</td><td>2 (2)</td><td>8 (2)</td><td>2 (2)</td><td>16 (1)</td><td>88.89</td></tr><tr><td>MIC/4</td><td>≤0.5 (≥4)</td><td>4 (2)</td><td>8 (4)</td><td>16 (1)</td><td>8 (4)</td><td>2 (2)</td><td>8 (2)</td><td>2 (2)</td><td>16 (1)</td><td>77.78</td></tr></table> |
8d262637ec2bd2cf4019abcbcb92951ebf038969a6655cc8d7cabf530861342b.png | simple | <table><tr><td>Period</td><td>No. of regions</td><td>STR-realigner</td><td>ReviSTER</td><td>IndelRealigner</td><td>--realign option</td><td>Original BAM</td></tr><tr><td>1</td><td>5345</td><td><underline>2.477</underline></td><td>2.695</td><td>6.017</td><td>6.009</td><td>6.009</td></tr><tr><td>2</td><td>1160</td><td><underline>3.545</underline></td><td>3.740</td><td>6.948</td><td>6.885</td><td>6.899</td></tr><tr><td>3</td><td>517</td><td><underline>3.566</underline></td><td>3.728</td><td>6.898</td><td>6.843</td><td>6.843</td></tr><tr><td>4</td><td>1433</td><td><underline>3.754</underline></td><td>3.818</td><td>7.476</td><td>7.417</td><td>7.431</td></tr><tr><td>5</td><td>668</td><td><underline>3.910</underline></td><td>4.469</td><td>8.760</td><td>8.762</td><td>8.762</td></tr><tr><td>6</td><td>472</td><td>4.319</td><td><underline>4.265</underline></td><td>8.232</td><td>8.217</td><td>8.233</td></tr><tr><td>Total</td><td>9595</td><td><underline>3.116</underline></td><td>3.309</td><td>6.752</td><td>6.727</td><td>6.732</td></tr></table> |
2314ae9f3cbe088777a86993d3c7863ec9dae7b4e78a27677351688d054de18a.png | simple | <table><tr><td>Variables</td><td><i>β</i></td><td><i>P </i>value</td><td>OR (95% CI)</td></tr><tr><td>Age</td><td>0.428</td><td><0.001</td><td>1.53 (1.35–1.75)</td></tr><tr><td>HR</td><td>0.859</td><td><0.001</td><td>2.36 (2.09–2.67)</td></tr><tr><td>BMI</td><td>0.273</td><td>0.001</td><td>1.31 (1.13–1.53)</td></tr><tr><td>WC</td><td>0.510</td><td><0.001</td><td>1.67 (1.3–2.14)</td></tr><tr><td>SBP</td><td>0.018</td><td><0.001</td><td>1.02 (1.01–1.02)</td></tr><tr><td>DBP</td><td>0.019</td><td>0.001</td><td>1.02 (1.01–1.03)</td></tr><tr><td>FPG</td><td>0.450</td><td><0.001</td><td>1.57 (1.39–1.78)</td></tr><tr><td>PBG</td><td>0.475</td><td><0.001</td><td>1.61 (1.41–1.83)</td></tr><tr><td>IR</td><td>0.279</td><td><0.001</td><td>1.32 (1.20–1.46)</td></tr><tr><td>TG</td><td>0.336</td><td>0.003</td><td>1.40 (1.12–1.75)</td></tr><tr><td>DM</td><td>0.936</td><td><0.001</td><td>2.55 (2.00–3.25)</td></tr><tr><td>DM duration</td><td>0.412</td><td><0.001</td><td>1.51 (1.30–1.76)</td></tr><tr><td>PH</td><td>0.779</td><td><0.001</td><td>2.18 (1.74–2.73)</td></tr><tr><td>PH duration</td><td>0.356</td><td><0.001</td><td>1.43 (1.28–1.59)</td></tr></table> |
c2f55c30d3aa8f10229f888d93310dd098f4d07dc90803f295703f636a2c0e04.png | complex | <table><tr><td></td><td colspan="6">Year</td><td></td><td></td></tr><tr><td></td><td colspan="2">1992 (<i>n = </i>321)</td><td colspan="2">2000 (<i>n = </i>433)</td><td colspan="2">2008 (<i>n = </i>607)</td><td colspan="2">Trend</td></tr><tr><td></td><td>%</td><td><i>n</i></td><td>%</td><td><i>n</i></td><td>%</td><td><i>n</i></td><td>χ<sup>2 </sup>(d.f. = 1)</td><td><i>P</i></td></tr><tr><td>No diagnosis specified</td><td>39</td><td>124</td><td>24</td><td>102</td><td>31</td><td>189</td><td></td><td></td></tr><tr><td> Bad news</td><td>76</td><td>94</td><td>73</td><td>74</td><td>48</td><td>91</td><td>26.653</td><td>< 0.001</td></tr><tr><td> Understanding mental illness</td><td>6</td><td>8</td><td>14</td><td>14</td><td>24</td><td>45</td><td>17.096</td><td>< 0.001</td></tr><tr><td> Services and advocacy</td><td>18</td><td>22</td><td>14</td><td>14</td><td>28</td><td>53</td><td>5.692</td><td>0.017</td></tr><tr><td>Depression</td><td>28</td><td>91</td><td>34</td><td>149</td><td>37</td><td>226</td><td></td><td></td></tr><tr><td> Bad news</td><td>38</td><td>35</td><td>32</td><td>47</td><td>28</td><td>63</td><td>3.287</td><td>0.070</td></tr><tr><td> Understanding mental illness</td><td>46</td><td>42</td><td>59</td><td>88</td><td>63</td><td>142</td><td>6.643</td><td>0.010</td></tr><tr><td> Services and advocacy</td><td>15</td><td>14</td><td>9</td><td>14</td><td>9</td><td>21</td><td>1.976</td><td>0.160</td></tr><tr><td>Eating disorders</td><td>14</td><td>45</td><td>13</td><td>58</td><td>14</td><td>82</td><td></td><td></td></tr><tr><td> Bad news</td><td>58</td><td>26</td><td>16</td><td>9</td><td>17</td><td>14</td><td>20.297</td><td>< 0.001</td></tr><tr><td> Understanding mental illness</td><td>42</td><td>19</td><td>78</td><td>45</td><td>78</td><td>64</td><td>14.682</td><td>< 0.001</td></tr><tr><td> Services and advocacy</td><td>0</td><td>0</td><td>7</td><td>4</td><td>5</td><td>4</td><td>-</td><td>-</td></tr><tr><td>Anxiety disorders</td><td>10</td><td>32</td><td>14</td><td>62</td><td>11</td><td>67</td><td></td><td></td></tr><tr><td> Bad news</td><td>19</td><td>6</td><td>21</td><td>13</td><td>18</td><td>12</td><td>0.38</td><td>0.845</td></tr><tr><td> Understanding mental illness</td><td>63</td><td>20</td><td>69</td><td>43</td><td>72</td><td>48</td><td>0.760</td><td>0.383</td></tr><tr><td> Services and advocacy</td><td>19</td><td>6</td><td>10</td><td>6</td><td>10</td><td>7</td><td>-</td><td>-</td></tr><tr><td>Schizophrenia</td><td>12</td><td>38</td><td>14</td><td>59</td><td>9</td><td>57</td><td></td><td></td></tr><tr><td> Bad news</td><td>58</td><td>22</td><td>49</td><td>29</td><td>68</td><td>39</td><td>1.535</td><td>0.215</td></tr><tr><td> Understanding mental illness</td><td>16</td><td>6</td><td>27</td><td>16</td><td>25</td><td>14</td><td>0.758</td><td>0.384</td></tr><tr><td> Services and advocacy</td><td>26</td><td>10</td><td>24</td><td>14</td><td>7</td><td>4</td><td>6.443</td><td>0.011</td></tr><tr><td>Bipolar disorder</td><td>4</td><td>12</td><td>3</td><td>11</td><td>3</td><td>19</td><td></td><td></td></tr><tr><td> Bad news</td><td>50</td><td>6</td><td>64</td><td>7</td><td>21</td><td>4</td><td>-</td><td>-</td></tr><tr><td> Understanding mental illness</td><td>33</td><td>4</td><td>9</td><td>1</td><td>53</td><td>10</td><td>-</td><td>-</td></tr><tr><td> Services and advocacy</td><td>17</td><td>2</td><td>27</td><td>3</td><td>26</td><td>5</td><td>-</td><td>-</td></tr><tr><td>Personality disorders</td><td>2</td><td>7</td><td>6</td><td>26</td><td>1</td><td>9</td><td></td><td></td></tr><tr><td> Bad news</td><td>86</td><td>6</td><td>85</td><td>22</td><td>56</td><td>5</td><td>-</td><td>-</td></tr><tr><td> Understanding mental illness</td><td>0</td><td>0</td><td>8</td><td>2</td><td>33</td><td>3</td><td>-</td><td>-</td></tr><tr><td> Services and advocacy</td><td>14</td><td>1</td><td>8</td><td>2</td><td>11</td><td>1</td><td>-</td><td>-</td></tr><tr><td>ADHD</td><td>0</td><td>0</td><td>4</td><td>18</td><td>4</td><td>24</td><td></td><td></td></tr><tr><td> Bad news</td><td>0</td><td>0</td><td>22</td><td>4</td><td>8</td><td>2</td><td>-</td><td>-</td></tr><tr><td> Understanding mental illness</td><td>0</td><td>0</td><td>72</td><td>13</td><td>88</td><td>21</td><td>-</td><td>-</td></tr><tr><td> Services and advocacy</td><td>0</td><td>0</td><td>6</td><td>1</td><td>4</td><td>1</td><td>-</td><td>-</td></tr><tr><td>Other disorders</td><td>1</td><td>2</td><td>1</td><td>5</td><td>1</td><td>7</td><td></td><td></td></tr><tr><td> Bad news</td><td>50</td><td>1</td><td>40</td><td>2</td><td>14</td><td>1</td><td>-</td><td>-</td></tr><tr><td> Understanding mental illness</td><td>0</td><td>0</td><td>60</td><td>3</td><td>71</td><td>5</td><td>-</td><td>-</td></tr><tr><td> Services and advocacy</td><td>50</td><td>1</td><td>0</td><td>0</td><td>14</td><td>1</td><td>-</td><td>-</td></tr></table> |
cb17a289922844333b0e6ca44260abc1cb959f2d067264fa51a35124da008bba.png | complex | <table><tr><td rowspan="2">Trait (nm)</td><td colspan="2">Standard diet</td><td colspan="2">Standard diet + ATRA</td></tr><tr><td>SHR</td><td>SHR-<i>Lx</i></td><td>SHR</td><td>SHR-<i>Lx</i></td></tr><tr><td></td><td>(n = 7)</td><td>(n = 7)</td><td>(n = 7)</td><td>(n = 8)</td></tr><tr><td>VLDL-TG</td><td>49.51 ± 0.45</td><td>48.24 ± 0.49</td><td>48.48 ± 0.68</td><td>50.27 ± 0.41*<sup>,a</sup></td></tr><tr><td>LDL-C</td><td>21.45 ± 0.25</td><td>21.54 ± 0.11</td><td>21.77 ± 0.12</td><td>22.52 ± 0.18‡<sup>,b</sup></td></tr><tr><td>HDL-C</td><td>12.20 ± 0.04</td><td>12.10 ± 0.03</td><td>12.18 ± 0.03</td><td>11.93 ± 0.05‡<sup>,c</sup></td></tr></table> |
8de1285b04d9bbcdbe6075904c78dbbf8d7e09f8685023507e48bd9e45cc227a.png | complex | <table><tr><td>Method of risk assessment</td><td>Definition</td><td>Advantages</td><td>Limitations</td></tr><tr><td>Clinical prediction rules</td><td>The use of a scoring system based on patient- or procedure-related risk factors to quantify risk</td><td>Often cost-neutral</td><td>Estimates population risk for patient rather than providing an individualized risk assessment</td></tr><tr><td> </td><td> </td><td>Requires no specialist knowledge[34]</td><td> </td></tr><tr><td>ASA-PS</td><td>Six-point scale used to grade patient according to comorbidities[35]</td><td>Validated in a number of settings[36-38]</td><td>Inter-observer variability[39]</td></tr><tr><td> </td><td> </td><td> </td><td>Poor sensitivity and specificity for prediction of morbidity and mortality on an individual patient basis[33,40]</td></tr><tr><td>Lee Revised Cardiac Risk Index (RCRI)</td><td>Scores patients according to six variables, including whether the surgery is high risk</td><td>Discriminates moderately well between patients at low versus high risk for cardiac events after mixed noncardiac surgery[42]</td><td>Designed to identify patients at risk of cardiac complications so may miss patients at risk of other complications who may benefit from PACU care</td></tr><tr><td> </td><td>Assesses cardiac risk[41]</td><td>Well validated</td><td> </td></tr><tr><td>POSSUM</td><td>A more detailed scoring system with 18 components, 6 operative variables and 12 physiological variables[46]</td><td>A revision of POSSUM, the Portsmouth POSSUM[43] has been shown to be a better predictor of outcome in certain surgical settings[33,44,45]</td><td>Some variables cannot be ascertained until after surgery, making it of limited use for preoperative identification of patients who may benefit from PACU care</td></tr><tr><td> </td><td> </td><td>Variations in the model have been devised for specific patient groups, such as the Cr-POSSUM (colorectal), which has been shown to be a better predictor of outcome in this type of surgery[47]</td><td> </td></tr><tr><td rowspan="2">Cardiopulmonary exercise testing</td><td>CPET is an integrative and quantitative measure of a patient’s cardiopulmonary reserve</td><td>Good evidence that CPET is useful to help predict perioperative morbidity and mortality and may aid triage to an appropriate level of postoperative care[48-50]</td><td rowspan="2">In 2008, 17% of Hospital Trusts in England had a CPET service, and a further 7% were in the process of setting one up[52]</td></tr><tr><td>The assessment requires the patient to exercise (usually on a cycle ergometer) while oxygen consumption, carbon dioxide production, and other cardiorespiratory variables are measured</td><td>RCT in progress to further evaluate its use to stratify to appropriate level of postoperative care[51]</td></tr></table> |
7dbae20bf417d120566efbf5e1069658b3102a91265d7544a4148bd8ea269ba7.png | simple | <table><tr><td>Polymorphism</td><td>Reference allele homozygote</td><td>Heterozygote</td><td>Variant allele homozygote</td></tr><tr><td>PAI-2 (<i>SERPINB</i>, rs6095)</td><td></td><td></td><td></td></tr><tr><td>Event Rate (%)</td><td>34.7</td><td>14.6</td><td>6.7</td></tr><tr><td>Number of patients</td><td>72</td><td>48</td><td>15</td></tr><tr><td>Number of patients (%)</td><td>53.3</td><td>35.6</td><td>11.1</td></tr><tr><td>LRP-1 (LRP1, rs1800156)</td><td></td><td></td><td></td></tr><tr><td>Event Rate (%)</td><td>21.1</td><td>24.5</td><td>33.3</td></tr><tr><td>Number of patients</td><td>57</td><td>53</td><td>18</td></tr><tr><td>Number of patients (%)</td><td>44.5</td><td>41.4</td><td>14.1</td></tr><tr><td>p22phox (<i>CYBA</i>, rs4673)*</td><td></td><td></td><td></td></tr><tr><td>Event Rate (%)</td><td>36.9</td><td>15.1</td><td>8.0</td></tr><tr><td>Number of patients</td><td>65</td><td>53</td><td>25</td></tr><tr><td>Number of patients (%)</td><td>45.5</td><td>37.1</td><td>17.5</td></tr><tr><td>TSP-4 (<i>THBS4</i>, rs1866389)*</td><td></td><td></td><td></td></tr><tr><td>Event Rate (%)</td><td>17.9</td><td>36.6</td><td>50.0</td></tr><tr><td>Number of patients</td><td>95</td><td>41</td><td>4</td></tr><tr><td>Number of patients (%)</td><td>67.9</td><td>29.3</td><td>2.9</td></tr><tr><td>CETP (CETP, rs708272)*</td><td></td><td></td><td></td></tr><tr><td>Event Rate (%)</td><td>14.9</td><td>26.4</td><td>33.3</td></tr><tr><td>Number of patients</td><td>47</td><td>72</td><td>24</td></tr><tr><td>Number of patients (%)</td><td>32.9</td><td>50.4</td><td>16.8</td></tr></table> |
c790e2463e5e7b3dfcb06fd98a5c88fd693e3ca1e91ce2133f2d1e9ba2d18483.png | simple | <table><tr><td>Group</td><td>Location</td><td>Gender</td><td>Age range (years)</td><td>Number of participants</td></tr><tr><td>One</td><td>ROI</td><td>Female</td><td>20-29</td><td>8</td></tr><tr><td>Two</td><td>ROI</td><td>Female</td><td>30-40</td><td>9</td></tr><tr><td>Three</td><td>ROI</td><td>Male</td><td>29-39</td><td>8</td></tr><tr><td>Four</td><td>NI</td><td>Male</td><td>29-59</td><td>6</td></tr><tr><td>Five*</td><td>NI</td><td>Male</td><td>20-25</td><td>7</td></tr><tr><td>Six</td><td>NI</td><td>Female</td><td>21-59</td><td>4</td></tr><tr><td>Seven</td><td>NI</td><td>Male</td><td>19-24</td><td>8</td></tr><tr><td>Eight†</td><td>NI</td><td>Female</td><td>39-45</td><td>4</td></tr><tr><td>Nine</td><td>NI</td><td>Female</td><td>22-63</td><td>5</td></tr><tr><td>Ten‡</td><td>NI</td><td>Female</td><td>35-64</td><td>7</td></tr></table> |
9719396d944e667711b48e627cccebac09e62229ec8e1450c5732639d36c45bf.png | complex | <table><tr><td>Gene/Gene Cluster Name</td><td>Localization within the POC9 Draft Genome Sequence(GenBank acc. no.)</td><td>Protein</td><td>Best BLAST Hits:[% Identity] Organism(GeneBank acc. no.)</td><td>Predicted Antimicrobial Resistance Profile</td><td>Tested Antibiotics</td><td>Profile</td></tr><tr><td rowspan="2"><i>gcvA-</i><i>bla<sub>OCH</sub></i></td><td rowspan="2">contig00009 (QGST01000009.1)coordinates: 164,062–165,431</td><td>class Cbeta-lactamase</td><td>[98%] <i>Ochrobactrum tritici</i> C8846-N36 (SME85995)</td><td rowspan="2">penams, penems,cephalosporins, cephamycins, monobactams</td><td rowspan="2">AMPCFMCTXCRO</td><td rowspan="2">RRRR</td></tr><tr><td>transcriptional regulator GcvA</td><td>[98%] <i>Ochrobactrum anthropi</i> (WP_061347328)</td></tr><tr><td rowspan="3"><i>acrAB-</i><i>TolC</i></td><td rowspan="3">contig00001 (QGST01000001.1)coordinates: 191,438-196,605</td><td>transcriptional regulator TetR</td><td>[93%] <i>Ochrobactrum oryzae</i> (WP_104756164)</td><td rowspan="5">tetracyclines, cephalosporins penams, phenicols, ryfamycins, fluoroquinolones</td><td rowspan="5">AMPCIPCFMCTXCROTEMXFRIF</td><td rowspan="5">RSRRRSSR</td></tr><tr><td>efflux RND transporter periplasmic adaptor subunit</td><td>[98%] <i>Ochrobactrum anthropi</i> (WP_061344971)</td></tr><tr><td>efflux RND transporter permease subunit</td><td>[99%] <i>Ochrobactrum anthropi</i> (WP_061344972)</td></tr><tr><td rowspan="2"><i>acrAB-</i><i>TolC</i></td><td rowspan="2">contig00010 (QGST01000010.1)coordinates: 49,666–54,163</td><td>efflux RND transporter periplasmic adaptor unit</td><td>[98%] <i>Ochrobactrum</i> sp. (WP_024900215)</td></tr><tr><td>efflux RND transporter permease subunit</td><td>[99%] <i>Ochrobactrum oryzae</i> (WP_104755654)</td></tr><tr><td><i>qacH</i></td><td>contig00007 (QGST01000007.1)coordinates: 192,104–191,772</td><td>efflux SMR transporter</td><td>[100%] <i>Ochrobactrum</i> sp. (WP_010661279)</td><td>fluoroquinolones</td><td>CIPMXF</td><td>SS</td></tr><tr><td><i>cmlA/floR</i></td><td>contig00016 (QGST01000016.1)coordinates: 56,907–55,714</td><td>CmlA/floR chloramphenicol efflux MFS transporter</td><td>[94%] <i>Ochrobactrum anthropi</i>(WP_061345584)</td><td>chloramphenicol</td><td>C</td><td>R</td></tr><tr><td><i>acc (6’)</i></td><td>contig00016 (QGST01000016.1)coordinates: 92,931–92,485</td><td>aminoglycoside 6’-acetyl-transferase</td><td>[93%] <i>Ochrobactrum anthropi</i> FRAF13(KXO77791)</td><td>aminoglycosides</td><td>CN</td><td>S</td></tr><tr><td rowspan="2"><i>tetG-</i><i>tetR</i></td><td rowspan="2">contig00014 (QGST01000014.1)coordinates: 7148–9063</td><td>Tet(A/B/C) family MFS transporter</td><td>[87%] <i>Ochrobactrum oryzae</i>(WP_104755825)</td><td rowspan="2">tetracyclines</td><td rowspan="2">TE</td><td rowspan="2">S</td></tr><tr><td>transcriptional regulator tetR</td><td>[89%] <i>Ochrobactrum oryzae</i>(WP_104755986)</td></tr></table> |
6aa169f9d5fbada5f015c1d047606c96fbc7b18a28eeeefc48feb4f09b4b2aa7.png | complex | <table><tr><td></td><td>Fixed effects model</td><td>Growth curve model 1</td><td>Growth curve model 2</td></tr><tr><td>Fixed part</td><td></td><td></td><td></td></tr><tr><td> <i>Intercept</i></td><td>0.820 (0.756 to 0.884)</td><td>0.823 (0.779 to 0.866)</td><td>0.830 (0.791 to 0.87)</td></tr><tr><td> <i>Age-centred (linear term)</i></td><td>−0.008 (−0.01 to –0.007)</td><td>−0.007 (−0.008 to –0.006)</td><td>−0.006 (−0.007 to –0.004)</td></tr><tr><td> <i>Age (quadratic term)</i></td><td>−0.0003 (−0.0004 to –0.0003)</td><td>−0.0002 (−0.0002 to –0.0001)</td><td>−0.0002 (−0.0002 to –0.0002)</td></tr><tr><td> <i>p, 2df</i></td><td><i><0.001</i></td><td><i><0.001</i></td><td><i><0.001</i></td></tr><tr><td colspan="3"> Frequency of public transport use(ref: every day or nearly every day)</td><td></td></tr><tr><td> Two or three times a week</td><td>−0.012 (−0.024 to 0.0001)</td><td>−0.006 (−0.016 to 0.003)</td><td>−0.005 (−0.018 to 0.008)</td></tr><tr><td> Once a week</td><td>−0.020 (−0.034 to –0.005)</td><td>−0.011 (−0.022 to –0.0002)</td><td>−0.006 (−0.019 to 0.008)</td></tr><tr><td> No use: no need</td><td>−0.018 (−0.032 to –0.003)</td><td>−0.011 (−0.022 to –0.001)</td><td>−0.005 (−0.018 to 0.008)</td></tr><tr><td> No use: health problems</td><td>−0.058 (−0.075 to –0.040)</td><td>−0.090 (−0.104 to –0.077)</td><td>−0.115 (−0.135 to –0.095)</td></tr><tr><td> No use: structural reasons</td><td>−0.020 (−0.035 to –0.006)</td><td>−0.009 (−0.019 to 0.002)</td><td>−0.002 (−0.014 to 0.011)</td></tr><tr><td> <i>p, 5df</i></td><td></td><td><i><0.001</i></td><td><i><0.001</i></td></tr><tr><td colspan="3"> Interaction between age (linear term) and frequency of public transport use</td><td></td></tr><tr><td> Age* two or three times a week</td><td></td><td></td><td>−0.0003 (−0.002 to 0.001)</td></tr><tr><td> Age* once a week</td><td></td><td></td><td>−0.001 (−0.002 to 0.0004)</td></tr><tr><td> Age* no use: no need</td><td></td><td></td><td>−0.001 (−0.002 to –0.00002)</td></tr><tr><td> Age* no use: health problems</td><td></td><td></td><td>0.002 (0.0001 to 0.003)</td></tr><tr><td> Age* no use: structural reasons</td><td></td><td></td><td>−0.001 (−0.003 to –0.0002)</td></tr><tr><td> <i>p, 5df</i></td><td></td><td></td><td><i><0.001</i></td></tr><tr><td>Random part</td><td></td><td></td><td></td></tr><tr><td> <i>Level 2 (individual)</i></td><td></td><td></td><td></td></tr><tr><td> Intercept variance</td><td></td><td>0.0238</td><td>0.0238</td></tr><tr><td colspan="2"> Age-centred (linear term) variance</td><td>0.00002</td><td>0.00002</td></tr><tr><td colspan="2"> Covariance of intercept and age centred</td><td>−0.0004</td><td>−0.0004</td></tr><tr><td> <i>Level 1 (wave)</i></td><td></td><td></td><td></td></tr><tr><td> Intercept</td><td></td><td>0.020</td><td>0.020</td></tr><tr><td> N observations (level 1)</td><td>27 509</td><td>27 509</td><td>27 509</td></tr><tr><td> N clusters (level 2)</td><td>9656</td><td>9656</td><td>9656</td></tr><tr><td> Goodness of fit</td><td>Adj R-sq: 0.7273</td><td>Deviance: −13 719.59</td><td>Deviance: −13 746.54</td></tr></table> |
ccaa30b2b79fc120081d5d0f41702613b88cac6b56335baac2ee9126bd902fbb.png | simple | <table><tr><td>Characteristic</td><td>N</td><td>%</td></tr><tr><td>Age</td><td> </td><td> </td></tr><tr><td>< = 50</td><td>22</td><td>13.3</td></tr><tr><td>51-60</td><td>42</td><td>25.3</td></tr><tr><td>61-70</td><td>57</td><td>34.3</td></tr><tr><td>> 70</td><td>45</td><td>27.1</td></tr><tr><td>Tumor (T)</td><td> </td><td> </td></tr><tr><td>T1</td><td>68</td><td>41</td></tr><tr><td>T2</td><td>40</td><td>24.1</td></tr><tr><td>T3</td><td>34</td><td>20.5</td></tr><tr><td>T4</td><td>24</td><td>14.4</td></tr><tr><td>Lymph nodes (N)</td><td> </td><td> </td></tr><tr><td>N0</td><td>59</td><td>35.5</td></tr><tr><td>N1</td><td>107</td><td>64.5</td></tr><tr><td>Metastasis (M)</td><td> </td><td> </td></tr><tr><td>M0</td><td>124</td><td>74.7</td></tr><tr><td>M1</td><td>42</td><td>25.3</td></tr><tr><td>Grade (G)</td><td> </td><td> </td></tr><tr><td>G1</td><td>57</td><td>34.4</td></tr><tr><td>G2</td><td>54</td><td>32.5</td></tr><tr><td>G3</td><td>55</td><td>33.1</td></tr></table> |
79e181aa93eba88ac222ea123cb792b90ecdc7862e5cfb598ead0256edc4904b.png | simple | <table><tr><td></td><td>Month 1</td><td>Month 16</td><td>Month 21</td><td>Total sample<i>n</i> = 72</td></tr><tr><td>Decisions to be made, <i>n</i> (%)</td><td></td><td></td><td></td><td></td></tr><tr><td>Medical admission or treatment</td><td>17 (81)<sup>a</sup></td><td>12 (44)<sup>a</sup></td><td>8 (33)<sup>a</sup></td><td>37 (51)</td></tr><tr><td>Psychiatric admission or treatment</td><td>5 (24)</td><td>13 (48)</td><td>13 (54)</td><td>31 (43)</td></tr><tr><td>Agreement status, <i>n</i> (%)</td><td></td><td></td><td></td><td></td></tr><tr><td>Agreeing</td><td>5 (24)</td><td>15 (56)</td><td>12 (50)</td><td>32 (44)</td></tr><tr><td>Not agreeing(or unable to express a choice/not documented)</td><td>16 (76)</td><td>12 (44)</td><td>12 (50)</td><td>40 (56)</td></tr></table> |
81ee06e3d49c6d5e79b5b0194793bb6f3dff718b95f0d6bd127275843a7cac92.png | complex | <table><tr><td colspan="5">Food composition of major foods in Uganda (per 100 g of edible portion)</td></tr><tr><td>Food</td><td>Calories</td><td>Protein (g)</td><td colspan="2">Iron (Mg)</td></tr><tr><td>Finger millet</td><td>346</td><td>8.7</td><td colspan="2">4.0</td></tr><tr><td>Sorghum</td><td>354</td><td>10.2</td><td colspan="2">4.1</td></tr><tr><td>Ground nuts</td><td>577</td><td>27.1</td><td colspan="2">2.5</td></tr><tr><td>Cowpeas</td><td>330</td><td>22.4</td><td colspan="2">5.0</td></tr><tr><td>Bananas</td><td>100</td><td>1.5</td><td colspan="2">0.4</td></tr><tr><td>Cassava</td><td>350</td><td>1.8</td><td colspan="2">2.0</td></tr><tr><td>Maize</td><td>354</td><td>9.0</td><td colspan="2">2.5</td></tr><tr><td>Beans</td><td>330</td><td>19.5</td><td colspan="2">8.0</td></tr><tr><td>Simsim</td><td>593</td><td>20.1</td><td colspan="2">9.8</td></tr><tr><td>Sweet Potato</td><td>166</td><td>1.3</td><td colspan="2">1.2</td></tr><tr><td colspan="5">Per capita of protein and calories derived from the major foods</td></tr><tr><td>Food</td><td colspan="2">Protein</td><td colspan="2">Calories</td></tr><tr><td></td><td>Teso</td><td>Uganda</td><td>Teso</td><td>Uganda</td></tr><tr><td>Finger millet</td><td>53.40</td><td>8.46</td><td>2292</td><td>497</td></tr><tr><td>Sorghum</td><td>22.0</td><td>5.13</td><td>704</td><td>164</td></tr><tr><td>Ground nuts</td><td>27.20</td><td>6.03</td><td>571</td><td>126</td></tr><tr><td>Cowpeas</td><td>38.00</td><td>3.51</td><td>570</td><td>53</td></tr><tr><td>Bananas</td><td>0.30</td><td>3.24</td><td>26</td><td>324</td></tr><tr><td>Cassava</td><td>3.70</td><td>3.96</td><td>814</td><td>854</td></tr><tr><td>Maize</td><td>7.10</td><td>7.21</td><td>258</td><td>261</td></tr><tr><td>Beans</td><td>3.90</td><td>12.25</td><td>55</td><td>172</td></tr><tr><td>Simsim</td><td>3.30</td><td>1.53</td><td>99</td><td>46</td></tr><tr><td>Sweet Potato</td><td>4.80</td><td>2.70</td><td>365</td><td>205</td></tr><tr><td>Others</td><td>0</td><td>1.83</td><td>708</td><td>123</td></tr><tr><td>Total</td><td>163.70</td><td>55.85</td><td>6462</td><td>2825</td></tr></table> |
e671671fe066e5733268260f13cb36a8277c039eaccccd5b61f626a78359a3a7.png | complex | <table><tr><td rowspan="2">Cluster #</td><td colspan="5">Expression level</td></tr><tr><td>High</td><td>Medium high</td><td>Medium</td><td>Medium low</td><td>Low</td></tr><tr><td>1</td><td>Ribosome</td><td>Lumen</td><td>Lumen</td><td>Lumen</td><td>DNA repair/Stress response</td></tr><tr><td>2</td><td>Oxidative Phosphorylation</td><td>Cytoskeleton</td><td>Chromosome structure</td><td>Zinc finger PHD</td><td>Zinc/ion binding</td></tr><tr><td>3</td><td>Ubiquitination</td><td>Protein catabolism</td><td>Protein complexes</td><td>Transcriptional regulation</td><td>Protein catabolism</td></tr><tr><td>4</td><td>Spliceosome</td><td>Chromosome structure</td><td>Mitochondrial subunits</td><td>Mitochondrial matrix</td><td>Protein transport</td></tr><tr><td>5</td><td>RNA binding</td><td>Nucleic acid binding</td><td>Nucleic acid binding/Phospho-rylation</td><td>Ankyrin repeats</td><td>tRNA aminoacylation</td></tr><tr><td>6</td><td>Electron transport</td><td>Ubiquitination</td><td>Endoplasmic reticulum</td><td>Protein/nucleotide interactions</td><td>Zinc finger CH2</td></tr><tr><td>7</td><td>Protein localization</td><td>Protein complex synthesis</td><td>Cell cycle</td><td>Microtubules</td><td>Cell death</td></tr><tr><td>8</td><td>Protein biosynthesis</td><td>Cell cycle</td><td>Cellular membranes</td><td>Mitochondrial membranes</td><td>DNA repair/Polymerase</td></tr><tr><td>9</td><td>Ribosomal subunits</td><td>Mitochondrial components</td><td>Ankyrin repeats</td><td>Phosphorylation</td><td>Suppression of differentiation</td></tr><tr><td>10</td><td>Protein folding</td><td>RNA splicing</td><td>tRNA</td><td>Zinc finger CH2</td><td>Nucleic acid binding</td></tr></table> |
1760b2a9a980613cd0d31f0518c69959cd5abeae1a41b7c004ec897f66ae1127.png | complex | <table><tr><td>Primary reference, Study, Country (secondary references)</td><td>Objectives</td><td>Design</td><td>Sample size</td><td>Patient population</td><td>Follow-up</td></tr><tr><td colspan="6">Treatment-related observational studies</td></tr><tr><td>Driessen 2008[68], Radboud University Registry, The Netherlands (Driessen 2009[69])</td><td>Efficacy and tolerability of etenercept and efalizumab</td><td>Registry</td><td>118</td><td>Psoriasis</td><td>24 weeks</td></tr><tr><td>Fortune 2003[6], PUVA Study, UK and Ireland</td><td>Role of psychological distress on PUVA treatment outcomes</td><td>Cohort</td><td>112</td><td>Plaque psoriasis (chronic)</td><td>2 years</td></tr><tr><td>Lecha 2005[70], Spanish tacalcitol ointment study</td><td>Efficacy and tolerability of tacalcitol</td><td>Cohort</td><td>556</td><td>Psoriasis (moderate)</td><td>2 months</td></tr><tr><td>Naldi 2008[71], Psocare, Italy</td><td>Effect of BMI on clinical response to systemic treatment</td><td>Cohort</td><td>2368</td><td>Plaque psoriasis</td><td>3 years</td></tr><tr><td>Paul 2003[72] Cyclosporine study, Europe and Canada</td><td>Incidence of malignancies in cyclosporine treated patients</td><td>Cohort</td><td>1252</td><td>psoriasis - severe</td><td>5 years</td></tr><tr><td>Wahl 2005[73], Climate therapy study, Norway</td><td>Effectiveness of climate therapy</td><td>Cohort</td><td>286</td><td>Psoriasis</td><td>8 months</td></tr><tr><td>Heiberg 2008[74], Norwegian register of disease modifying anti-rheumatic drugs, (Heiberg 2007[75])</td><td>Comparative effectiveness of TNF inhibitors vs. methotrexate monotherapy</td><td>Registry</td><td>526</td><td>Psoriatic arthritis</td><td>1 year</td></tr><tr><td>Kristensen 2008[76], South Swedish Arthritis Treatment Group register, (Gulfe 2009[77], Geborek 2002[78], Kristensen 2006[79])</td><td>Efficacy, utility and tolerability of TNF-inhibitors (etanercept, infliximab, adalimumab)</td><td>Registry</td><td>261</td><td>Psoriatic arthritis</td><td>7 years</td></tr><tr><td>Sparado 1997[80], Cyclosporin Study, Italy</td><td>Probability of continuing to take cyclosporine vs. other DMARDS</td><td>Cohort</td><td>172</td><td>Psoriatic arthritis</td><td>10 years</td></tr><tr><td>Saad 2009[81], British Society for Rheumatology Biologics Register, (Harrison 2009[82], Silman 2003[83])</td><td>Effectiveness and tolerability of TNF-inhibitors (etanercept, infliximab, adalimumab)</td><td>Registry</td><td>566</td><td>RA, psoriasis, psoriatic arthritis</td><td>1 year</td></tr><tr><td colspan="6">Non-treatment related observational studies</td></tr><tr><td>Carrascosa 2006[84], EPIDERMA cost of illness, Spain</td><td>Direct and indirect cost; relationship between cost and severity</td><td>Cohort</td><td>797</td><td>Psoriasis</td><td>1 year</td></tr><tr><td>Colombo 2008[11], Cost of illness, Italy</td><td>Direct and indirect cost; HRQOL; relationship between cost, HRQOL and severity</td><td>Cohort</td><td>150</td><td>Moderate to severe plaque psoriasis</td><td>3 months</td></tr><tr><td>Schmid-ott 2005[85], Bad Bentheim Rehabilitation Hospital, Germany</td><td>Relationship between the degree of stigmatisation and gender, skin symptoms, PASI and SPASI</td><td>Cohort</td><td>166</td><td>Psoriasis</td><td>1 year</td></tr><tr><td>Ali 2007[86], Husted 2007[2], Gladman 2009[16], Rohekar 2008[87], Toronto PsA clinic, Canada, (Chandran 2007[88], Gladman 1995[89], Gladman 1998[90], Gladman 1999 [91], Gladman 2001[92], Husted 2005[93], Wong 1997[94])</td><td>(1) Mortality associated with PsA; (2) relationship between physical functioning, disease activity and joint damage; (3) CVD associated with PsA; (4) malignancies associated with PsA</td><td>Cohort</td><td>382 to 680</td><td>Psoriatic arthritis</td><td>26 years</td></tr><tr><td>Kane 2003[95], St. Vincent's University study, Ireland, (Kane 2003a[96])</td><td>Clinical presentation, outcome and prognosis of early PsA</td><td>Cohort</td><td>129</td><td>Early psoriatic arthritis</td><td>2 years</td></tr><tr><td>Lindqvist 2008[97], SwePsA registry, Sweden, (Svensson 2002[98])</td><td>Factors associated with disease progression; outcome of treated and non-treated groups, comparison of outcomes with RA patients</td><td>Registry</td><td>135</td><td>Early psoriatic arthritis</td><td>2 years</td></tr></table> |
e9b63f146dc955559d16fe04f4b008cc06ff86cee61a0a6a21294f06ccd8332c.png | complex | <table><tr><td rowspan="2">Characteristics</td><td>No OSA</td><td>Mild-Moderate OSA</td><td>Severe OSA</td><td rowspan="2"><i>p</i> value</td></tr><tr><td><i>n</i> = 10</td><td><i>n</i> = 33</td><td><i>n</i> = 34</td></tr><tr><td>Total sleep time (minutes)</td><td>288.2 ± 88.2</td><td>268.3 ± 80.7</td><td>253.8 ± 74.6</td><td>0.207</td></tr><tr><td>Sleep efficiency (%)</td><td>76.1 ± 22.9</td><td>75.8 ± 16.1</td><td>72.1 ± 18.0</td><td>0.506</td></tr><tr><td>AHI event. h<sup>−1</sup></td><td>2.4 ± 1.5</td><td>16.2 ± 6.6</td><td>61.4 ± 20.0</td><td>0.001</td></tr><tr><td>ODI event. h<sup>−1</sup></td><td>1.7 ± 1.7</td><td>14.5 ± 6.1</td><td>52.1 ± 22.8</td><td>0.001</td></tr><tr><td>Average SaO<sub>2</sub> (%)</td><td>95.0 ± 1.3</td><td>93.1 ± 3.0</td><td>91.4 ± 3.3</td><td>0.001</td></tr><tr><td>Lowest SaO<sub>2</sub> (%)</td><td>88.2 ± 6.0</td><td>82.2 ± 5.5</td><td>74.7 ± 9.7</td><td>0.001</td></tr><tr><td>SaO2 < 90% (%)</td><td>0 ± 0</td><td>9.1 ± 18.2</td><td>20.5 ± 25.9</td><td>0.001</td></tr><tr><td>SaO2 < 80% (%)</td><td>0 ± 0</td><td>0.2 ± 0.4</td><td>3.3 ± 5.2</td><td>0.021</td></tr><tr><td>Wake %</td><td>13.9 ± 8.1</td><td>22.4 ± 13.7</td><td>22.7 ± 17.8</td><td>0.226</td></tr><tr><td>N1 %</td><td>20.8 ± 11.0</td><td>16.5 ± 11.0</td><td>22.3 ± 10.7</td><td>0.423</td></tr><tr><td>N2 %</td><td>27.6 ± 11.5</td><td>28.8 ± 11.2</td><td>34.1 ± 14.1</td><td>0.125</td></tr><tr><td>N3 %</td><td>23.6 ± 8.4</td><td>22.1 ± 10.8</td><td>13.4 ± 9.8</td><td>0.001</td></tr><tr><td>REM %</td><td>14.1 ± 3.4</td><td>10.3 ± 8.5</td><td>7.4 ± 5.9</td><td>0.013</td></tr></table> |
ecaa3f8b2afd8c6029196955bef614115131d03d423e995bc8434738abd43359.png | complex | <table><tr><td rowspan="2">Animal group</td><td colspan="2">Body weight (g)</td><td colspan="2">Blood glucose (mg/dL)</td></tr><tr><td>Before STZ injection</td><td>End experiment</td><td>Before drug injection</td><td>End experiment</td></tr><tr><td>Control (8)</td><td>270 ± 13.9 </td><td>276.25 ± 13.29</td><td>133 ± 33.41</td><td>132.87 ± 35.62</td></tr><tr><td>Vehicle (8)</td><td>260 ± 21.60</td><td>237.14 ± 24.97<sup>*</sup></td><td>423.71 ± 108.85</td><td>491.42 ± 87.83</td></tr><tr><td>Angipars 5 (8)</td><td>257.1 ± 21.38</td><td>210 ± 45.82<sup>*</sup></td><td>457.1 ± 115.71</td><td> 492.85 ± 137.44</td></tr><tr><td>Angipars 10 (8)</td><td>275.5 ± 14.24</td><td>272.22 ± 22.79</td><td>391.33 ± 66.64</td><td>459.22 ± 94.98</td></tr><tr><td>Angipars 20 (8)</td><td>266.25 ± 14.07</td><td>251.87 ± 17.30</td><td>359.87 ± 65.21</td><td>471.25 ± 58.66</td></tr></table> |
0f11f0c50f89213400914c7a505147442058b668589b9430ede7aef5c13d8c07.png | simple | <table><tr><td>Symbol</td><td>Name</td><td>Function</td><td>Reference</td></tr><tr><td>PLK1</td><td>polo-like kinase 1</td><td>cell cycle regulation</td><td>[13-19]</td></tr><tr><td>CDK16</td><td>cyclin-dependent kinase 16</td><td>cell cycle regulation</td><td>[20]</td></tr><tr><td>RYK</td><td>receptor-like tyrosine kinase</td><td>cellular growth and differentiation Regulation</td><td>[21]</td></tr><tr><td>MTOR</td><td>mechanistic target of rapamycin (serine/threonine kinase)</td><td>cellular metabolism, growth, and proliferation Regulation</td><td>[22-24]</td></tr><tr><td>STK17B</td><td>serine/threonine kinase 17b</td><td>positive regulation of apoptosis</td><td>[25]</td></tr><tr><td>PLK4</td><td>polo-like kinase 4</td><td>cell cycle regulation</td><td>[17,26]</td></tr><tr><td>MAST2</td><td>microtubule associated serine/threonine kinase 2</td><td>cellular growth and differentiation Regulation</td><td>[27]</td></tr><tr><td>MAP3K4</td><td>mitogen-activated protein kinase kinase kinase 4</td><td>role in signal transduction cascades</td><td>[28]</td></tr><tr><td>MARK2</td><td>MAP/microtubule affinity-regulating kinase 2</td><td>cell polarity and microtubule dynamics regulation</td><td>[29]</td></tr><tr><td>CDK1</td><td>cyclin-dependent kinase 1</td><td>cell cycle regulation</td><td>[13,15-17,30,31]</td></tr><tr><td>NEK2</td><td>NIMA (never in mitosis gene a)-related kinase 2</td><td>cell cycle regulation</td><td>[14-16,30]</td></tr><tr><td>PRKCSH</td><td>protein kinase C substrate 80K-H</td><td>roles in inflammation, cell growth, signaling and death</td><td>[32]</td></tr><tr><td>AURKA</td><td>aurora kinase A</td><td>cell cycle regulation</td><td>[33,34]</td></tr><tr><td>BUB1</td><td>mitotic checkpoint serine/threonine kinase</td><td>cell cycle regulation</td><td>[35]</td></tr><tr><td>CDC7</td><td>cell division cycle 7 homolog (S. cerevisiae)</td><td>cell cycle regulation</td><td>[30]</td></tr><tr><td>SRPK1</td><td>SRSF protein kinase 1</td><td>cellular growth and differentiation Regulation</td><td>[36]</td></tr><tr><td>TTK</td><td>TTK protein kinase</td><td>cell cycle regulation</td><td>[14-16,37,38]</td></tr><tr><td>VRK1</td><td>vaccinia related kinase 1</td><td>cell cycle regulation</td><td>[39,40]</td></tr></table> |
8a938dcf98995c1cad36b196933af6ea2d61f6576d11c00cb0996bf830a2545c.png | complex | <table><tr><td> </td><td> </td><td colspan="3">Dietary supplementation<sup>a</sup></td><td colspan="3">Statistical significance of variance ratio (P)<sup>b</sup>, effects of</td></tr><tr><td> </td><td>Control</td><td>TTA</td><td>FO</td><td>TTA + FO</td><td>TTA</td><td>FO</td><td>TTA*FO</td></tr><tr><td>CPT-I</td><td>2.79 ± 0.26<sup>c</sup></td><td>1.69 ± 0.38</td><td>2.54 ± 0.12</td><td>1.75 ± 0.14</td><td><0.001</td><td>0.22</td><td>0.06</td></tr><tr><td>CPT-I (with malonyl-CoA)</td><td>1.89 ± 0.21</td><td>1.23 ± 0.28</td><td>1.77 ± 0.14</td><td>1.31 ± 0.13</td><td><0.001</td><td>0.73</td><td>0.14</td></tr><tr><td>CPT-II</td><td>10.79 ± 1.03</td><td>23.55 ± 3.15</td><td>12.40 ± 2.33</td><td>22.39 ± 4.32</td><td><0.001</td><td>0.82</td><td>0.15</td></tr><tr><td>ACOX</td><td>1.65 ± 0.31</td><td>4.53 ± 1.16</td><td>4.61 ± 1.41</td><td>8.47 ± 1.37</td><td><0.001</td><td><0.001</td><td>0.19</td></tr><tr><td>GPAT</td><td>0.25 ± 0.06</td><td>0.43 ± 0.09</td><td>0.39 ± 0.09</td><td>0.64 ± 0.14</td><td><0.001</td><td><0.001</td><td>0.37</td></tr><tr><td>FAS</td><td>0.04 ± 0.01</td><td>0.09 ± 0.01</td><td>0.06 ± 0.02</td><td>0.10 ± 0.02</td><td><0.001</td><td>0.01</td><td>0.34</td></tr></table> |
85dbd38e4c22fe34329f26898b167873c62a81dece6b75b27f9de01171c94c2d.png | complex | <table><tr><td> </td><td colspan="2">D-dimer ≥10 <i>μ</i>g/mL after treatment</td><td> </td></tr><tr><td> </td><td>No</td><td>Yes</td><td><i>p</i><sup>∗</sup></td></tr><tr><td> </td><td>(<i>n</i> = 31)</td><td>(<i>n</i> = 21)</td><td> </td></tr><tr><td>Male sex</td><td>18 (58.1%)</td><td>10 (47.6%)</td><td>0.458</td></tr><tr><td>Age, years</td><td>63 (55–71)</td><td>63 (55–70)</td><td>0.970</td></tr><tr><td>DWI patterns</td><td> </td><td> </td><td>0.724</td></tr><tr><td> Single vascular territory</td><td>6 (19.4%)</td><td>3 (14.3%)</td><td> </td></tr><tr><td>Single lesion</td><td>3</td><td>2</td><td> </td></tr><tr><td>Multiple lesions</td><td>3</td><td>1</td><td> </td></tr><tr><td> Multiple vascular territories</td><td>25 (80.6%)</td><td>18 (85.7%)</td><td> </td></tr><tr><td>Treatment</td><td> </td><td> </td><td>0.002</td></tr><tr><td> Enoxaparin</td><td>21 (67.7%)</td><td>5 (23.8%)</td><td> </td></tr><tr><td> Warfarin</td><td>10 (32.3%)</td><td>16 (72.6%)</td><td> </td></tr><tr><td>Cancer profiles</td><td> </td><td> </td><td> </td></tr><tr><td> Primary cancer type</td><td> </td><td> </td><td>0.586</td></tr><tr><td>Lung</td><td>15 (48.4%)</td><td>12 (57.1%)</td><td> </td></tr><tr><td>Gastrointestinal</td><td>4 (12.9%)</td><td>3 (14.3%)</td><td> </td></tr><tr><td>Hepatobiliary</td><td>5 (16.1%)</td><td>5 (23.8%)</td><td> </td></tr><tr><td>Breast-gynecologic</td><td>4 (12.9%)</td><td>1 (4.8%)</td><td> </td></tr><tr><td>Other</td><td>3 (9.7%)</td><td>0 (0%)</td><td> </td></tr><tr><td> Systemic metastasis</td><td>23 (74.2%)</td><td>20 (95.2%)</td><td>0.067</td></tr><tr><td> Adenocarcinoma</td><td>19 (61.3%)</td><td>17 (85.0%)</td><td>0.070</td></tr></table> |
2e223de9d2a4188ea3d600f4da5d81bb8f015ad92f14d270ecae7d7ae159a10a.png | simple | <table><tr><td>Generic name</td><td>Study drug name (Brand name)</td><td>Active ingredient content</td><td>Manufacturers/distributors</td></tr><tr><td>amlodipine besilate</td><td>Amlodin<sup>® </sup>tablets 2.5</td><td>containing 2.5 mg of amlodipine</td><td>Sumitomo Pharmaceuticals Co., Ltd.</td></tr><tr><td></td><td>Amlodin<sup>® </sup>tablets 5</td><td>containing 5 mg of amlodipine</td><td></td></tr><tr><td></td><td>Norvasc<sup>® </sup>tablets 2.5 mg</td><td>containing 2.5 mg of amlodipine</td><td>Pfizer Japan Inc.</td></tr><tr><td></td><td>Norvasc<sup>® </sup>tablets 5 mg</td><td>containing 5 mg of amlodipine</td><td></td></tr></table> |
0a9d75ddd91445ba6a219610e77e40ee6bf6ebcc81a85cc7e82d45983f98cc04.png | simple | <table><tr><td>BPG</td><td>Patient Eligibility Criteria </td><td>Participating Program Units</td></tr><tr><td>Asthma</td><td>Patients who present to the participating units with a primary or secondary diagnosis of asthma</td><td>Emergency, in-patient and medical units</td></tr><tr><td>Breastfeeding</td><td>Postpartum women and their infants with a singleton birth, gestational age of 37 or more weeks, hospital length of stay for mother and infant 24 hours or more after birth, infant not delivered by a midwife. Additional infant criteria included: no major congenital anomalies, no galactasemia. Additional postpartum women criteria included: no documented use of street drugs, no major psychiatric illness, baby not up for adoption.</td><td>Labour and delivery, postpartum, neonatal intensive care, and public health unit</td></tr><tr><td>Delirium-Dementia-Depression</td><td>Clients admitted to participating units, age 65 years and older.</td><td>Surgical, medical and rehabilitation units</td></tr><tr><td>Smoking Cessation</td><td>Clients age 18 years and older admitted to participating unit. For outpatients, admission to out-patient services within the past month and currently attending the clinic.</td><td>In-patient and out-patient long-term mental health, in-patient unit for drug and alcohol addition, in-patient unit for acute psychiatric disorders, resource unit for nicotine dependency</td></tr><tr><td>Venous Leg Ulcers</td><td>All clients with new and recurrent venous leg ulcers. Patients with primary lymphedema, vasculitis, and under diabetic management excluded.</td><td>Chronic care unit, wound care clinic, and community care agency</td></tr><tr><td>Diabetes</td><td>Adults age 18 and over with a diagnosis of diabetes admitted to one of the participating units. Women with gestational diabetes excluded.</td><td>Oncology, medical and diabetes care and education centre and community care agency</td></tr></table> |
912b9b91fdaca3c74a75ca6d1cb893ea7d8a60f1059bd1b71d4691632ce9fa0d.png | simple | <table><tr><td>Organism</td><td>Precision</td><td>Recall</td><td>F-score</td></tr><tr><td>Mouse</td><td>0.77</td><td>0.81</td><td>0.79</td></tr><tr><td>Yeast</td><td>0.97</td><td>0.84</td><td>0.90</td></tr><tr><td>Fly</td><td>0.83</td><td>0.80</td><td>0.82</td></tr><tr><td>FlyAccept matches of synonyms associated to up to 3 different Entrez Gene entries</td><td>0.74</td><td>0.83</td><td>0.79</td></tr><tr><td>Human</td><td>0.86</td><td>0.81</td><td>0.84</td></tr></table> |
e65e582dc802d0364c209deb4409969b2d88f0a20ace377494eb5d13d4fcd674.png | simple | <table><tr><td>Command</td><td>Value</td><td>Description</td></tr><tr><td>ACK</td><td>0×06</td><td>It is sent when a frame has been received and decoded correctly.</td></tr><tr><td>NACK</td><td>0×15</td><td>It is sent when a frame has not been decoded correctly.</td></tr><tr><td>RESET</td><td>0×08</td><td>It forces the node to be reset. After this command, the node sends an ACK and resets itself. For the next 2 seconds the node enters a programing mode which allows the central computer to reprogram the device.</td></tr><tr><td>ALIFE</td><td>0×0C</td><td>This command is sent to a specific node to check if it is in working mode. If the board is correctly working, it answers with an ACK command.</td></tr></table> |
f004dd934af35ecfb12802de9b2f588aa0c04d668fb47d61fd9ad800a4cba792.png | simple | <table><tr><td></td><td>N</td><td>%</td><td>% susceptible TMP/SMX</td><td>Ciprofloxacin</td><td>Nitrofurantoin</td></tr><tr><td><i>E. coli</i></td><td>73</td><td>82</td><td>93</td><td>100</td><td>95</td></tr><tr><td><i>P. mirabillis</i></td><td>5</td><td>5.6</td><td>100</td><td>100</td><td>na</td></tr><tr><td><i>K. pneumonia</i></td><td>4</td><td>4.4</td><td>100</td><td>100</td><td>50</td></tr><tr><td><i>S. aureus</i></td><td>3</td><td>3.3</td><td>100</td><td>0</td><td>100</td></tr><tr><td><i>C. koseri</i></td><td>2</td><td>2.2</td><td>100</td><td>100</td><td>100</td></tr><tr><td><i>B-hemolytic Strep</i></td><td>1</td><td>1.1</td><td>na</td><td>na</td><td>na</td></tr><tr><td><i>S. saphophyticus</i></td><td>1</td><td>1.1</td><td>0</td><td>100</td><td>100</td></tr><tr><td>Total</td><td>89</td><td>100</td><td></td><td></td><td></td></tr></table> |
228a830e40b5d378aff210113a9bb0879ffd29faf1451bf619922c3ee1867680.png | complex | <table><tr><td>Dimension</td><td>Categories</td></tr><tr><td rowspan="3">Primary diagnosis</td><td>Organic mental health problem (most commonly dementia)</td></tr><tr><td>Depression or anxiety</td></tr><tr><td>Other mental health problem e.g., schizophrenia</td></tr><tr><td rowspan="4">Main reason for admission</td><td>Risk of deliberate self-harm</td></tr><tr><td>Other risks i.e., self-neglect, accidental self-harm, abuse/exploitation or falls, or carer stress</td></tr><tr><td>Behaviour management related i.e., need for behaviour management, risk of harming others or care breakdown</td></tr><tr><td>Need for diagnostic assessment, medication review or treatment</td></tr><tr><td rowspan="3">Challenging behaviour</td><td>Low (behaviour score 0 or 1)</td></tr><tr><td>Medium (behaviour score 2–7, typically including agitation, wandering and/or disturbed sleep)</td></tr><tr><td>High (behaviour score 8–14, typically including resistance to care and/or aggression)</td></tr><tr><td rowspan="2">Living situation</td><td>Resident primary carer (including care home residents)</td></tr><tr><td>No resident carer</td></tr></table> |
94720a5bd9803f7796b257557a55129f6d1e532f5ea6187324b92c47c0f7abc2.png | simple | <table><tr><td>Adsorbent</td><td><i>q<sub>m</sub></i> (mg/g)</td><td>Ref.</td></tr><tr><td>GO sponge</td><td>446</td><td>[38]</td></tr><tr><td>GO-CS sponge</td><td>468</td><td>[39]</td></tr><tr><td>GO-Fe<sub>3</sub>O<sub>4</sub> sponge</td><td>526</td><td>[40]</td></tr><tr><td>RGO sponge</td><td>27</td><td>[38]</td></tr><tr><td>RGO-MFe<sub>2</sub>O<sub>4</sub></td><td>34.72</td><td>[41]</td></tr><tr><td>RL-GO</td><td>529.10</td><td>[42]</td></tr><tr><td>MCGO</td><td>95.16</td><td>[43]</td></tr><tr><td>GO-biopolymer gel</td><td>701.78</td><td>[44]</td></tr><tr><td>GO-COOH sponge</td><td>780 ± 47</td><td>This study</td></tr></table> |
4b7d56d9312dd7ef7b823170a551366c4684c18a6dac097d4267e147362e6230.png | complex | <table><tr><td rowspan="3">Line</td><td rowspan="3">Duration in 2013DS</td><td rowspan="3"><i>qDTY</i><sub><i>12.1</i></sub></td><td rowspan="3"><i>qDTY</i><sub><i>3.1</i></sub></td><td rowspan="3"><i>qDTY</i><sub><i>2.2</i></sub></td><td colspan="4">GY (kg ha<sup>−1</sup>)</td></tr><tr><td colspan="2">DS2013</td><td colspan="2">DS2014</td></tr><tr><td>RS</td><td>NS</td><td>RS</td><td>NS</td></tr><tr><td>IR 99784-156-137-1-1</td><td>Medium</td><td>-</td><td>√</td><td>-</td><td>1362</td><td>6200</td><td>2523</td><td>10713</td></tr><tr><td>IR 99784-255-7-2-5</td><td>Medium</td><td>√</td><td>√</td><td>-</td><td>1346</td><td>7783</td><td>1591</td><td>8383</td></tr><tr><td>IR 99784-188-202-1-2</td><td>Medium</td><td>-</td><td>√</td><td>√</td><td>939</td><td>9431</td><td>1562</td><td>8369</td></tr><tr><td>IR 99784-188-202-1-1</td><td>Medium</td><td>-</td><td>√</td><td>√</td><td>939</td><td>9431</td><td>1478</td><td>7937</td></tr><tr><td>IR 99784-255-68-1-5</td><td>Medium</td><td>√</td><td>√</td><td>√</td><td>1611</td><td>6905</td><td>1183</td><td>7782</td></tr><tr><td>IR 99784-188-202-1-3</td><td>Medium</td><td>-</td><td>√</td><td>√</td><td>939</td><td>9431</td><td>1058</td><td>6947</td></tr><tr><td>IR 99784-255-55-2-5</td><td>Medium</td><td>√</td><td>-</td><td>√</td><td>2073</td><td>8525</td><td>1049</td><td>7858</td></tr><tr><td>IR 99784-188-201-B-1</td><td>Medium</td><td>√</td><td>-</td><td>√</td><td>977</td><td>8610</td><td>1042</td><td>9975</td></tr><tr><td>IR 99784-255-7-2-2</td><td>Medium</td><td>√</td><td>√</td><td>-</td><td>1346</td><td>7783</td><td>983</td><td>9438</td></tr><tr><td>IR 99784-40-1-B-6</td><td>Medium</td><td>-</td><td>-</td><td>√</td><td>1164</td><td>8168</td><td>942</td><td>8254</td></tr><tr><td>IR 99784-11-35-2-2</td><td>Short</td><td>-</td><td>√</td><td>√</td><td>1300</td><td>8633</td><td>-</td><td>-</td></tr><tr><td>IR 99784-255-9-1-3</td><td>Medium</td><td>√</td><td>√</td><td>-</td><td>888</td><td>8174</td><td>936</td><td>9014</td></tr><tr><td>IR 99784-156-87-1-9</td><td>Medium</td><td>√</td><td>√</td><td>√</td><td>923</td><td>5808</td><td>930</td><td>11672</td></tr><tr><td>IR 99784-188-179-1-2</td><td>Medium</td><td>√</td><td>√</td><td>-</td><td>1459</td><td>9107</td><td>927</td><td>7419</td></tr><tr><td>IR 99784-11-8-1-5</td><td>Short</td><td>-</td><td>-</td><td>√</td><td>756</td><td>9573</td><td>-</td><td>-</td></tr><tr><td>IR 99784-255-49-1-1</td><td>Medium</td><td>√</td><td>√</td><td>-</td><td>2521</td><td>5832</td><td>903</td><td>8152</td></tr><tr><td>MR 219</td><td></td><td>-</td><td>-</td><td>-</td><td>13</td><td>5917</td><td>0</td><td>8322</td></tr></table> |
5b0df7bf5cadd1e77981f776572d701e0b5cfaecbf907b0937892321923e4bce.png | complex | <table><tr><td rowspan="2">Pathogen</td><td>CSF</td><td>Blood</td><td>Urine</td><td>Aspirates</td><td>Pus swabs</td><td>Sputum</td><td>Stool</td><td>Total</td></tr><tr><td><i>n</i> = 303 (%)</td><td><i>n</i> = 2238(%)</td><td><i>n</i> = 307(%)</td><td><i>n</i> = 148 (%)</td><td><i>n</i> = 206(%)</td><td><i>n</i> = 86(%)</td><td><i>n</i> = 42(%)</td><td><i>n</i> = 3330(%)</td></tr><tr><td><i>Candida</i> species.</td><td>0 (0)</td><td>0 (0)</td><td>1 (0.33)</td><td>0 (0)</td><td>12 (5.8)</td><td>0 (0)</td><td>0 (0)</td><td>13</td></tr><tr><td><i>Citrobacter</i> species.</td><td>0 (0)</td><td>11 (0.5)</td><td>4 (1.3)</td><td>0 (0)</td><td>9 (4.4)</td><td>3 (3.48)</td><td>0 (0)</td><td>27</td></tr><tr><td><i>Escherichia coli</i></td><td>1 (0.33)</td><td>9 (0.4)</td><td>22 (7.2)</td><td>0 (0)</td><td>8 (3.9)</td><td>1 (1.16)</td><td>0 (0)</td><td>41</td></tr><tr><td><i>Klebsiella pneumoniae</i></td><td>1 (0.33)</td><td>42 (1.9)</td><td>15 (4.9)</td><td>0 (0)</td><td>3 (1.45)</td><td>4 (4.65)</td><td>0 (0)</td><td>65</td></tr><tr><td>Other gram-positive<sup>a</sup></td><td>0 (0)</td><td>4 (0.2)</td><td>3 (0.9)</td><td>0 (0)</td><td>1 (0.5)</td><td>0 (0)</td><td>0 (0)</td><td>8</td></tr><tr><td>Other gram-negative<sup>b</sup></td><td>1 (0.33)</td><td>54 (2.4)</td><td>35 (11.4)</td><td>1 (0.67)</td><td>24 (11.65)</td><td>14 (16.3)</td><td>3 (7.14)</td><td>132</td></tr><tr><td><i>Pseudomonas aeruginosa</i></td><td>0 (0)</td><td>5 (0.22)</td><td>2 (0.7)</td><td>0 (0)</td><td>14 (6.8)</td><td>3 (3.48)</td><td>0 (0)</td><td>24</td></tr><tr><td><i>Staphylococcus aureus</i></td><td>0 (0)</td><td>80 (3.6)</td><td>1 (0.33)</td><td>0 (0)</td><td>18 (8.7)</td><td>1 (1.16)</td><td>0 (0)</td><td>100</td></tr><tr><td><i>Salmonella</i> species.</td><td>0 (0)</td><td>22 (0.9)</td><td>0 (0)</td><td>0 (0)</td><td>1 (0.48)</td><td>0 (0)</td><td>0 (0)</td><td>23</td></tr><tr><td><i>Streptococcus</i> species.</td><td>1 (0.33)</td><td>4 (0.2)</td><td>1 (0.33)</td><td>0 (0)</td><td>0 (0)</td><td>0 (0)</td><td>0 (0)</td><td>6</td></tr><tr><td>Total</td><td>4 (1.32)</td><td>231 (10.32)</td><td>84 (27.39)</td><td>1 (0.67)</td><td>90 (43.68)</td><td>26 (30.23)</td><td>3 (7.14)</td><td>439 (13.2)</td></tr></table> |
ca4082856163ee1c244dda9e1aeebf1e996a17fd444199d8cfca416328d8c12a.png | complex | <table><tr><td>Characteristic, N (%)</td><td>Arm AN = 22</td><td>Arm BN = 14</td><td>Arm CN = 14</td><td><i>P</i> value</td></tr><tr><td colspan="5">Age at randomization</td></tr><tr><td> 18–39 years</td><td>2 (9)</td><td>5 (36)</td><td>1 (7)</td><td></td></tr><tr><td> 40–49 years</td><td>8 (36)</td><td>0</td><td>5 (36)</td><td></td></tr><tr><td> 50–59 years</td><td>5 (23)</td><td>4 (29)</td><td>7 (50)</td><td></td></tr><tr><td> ≥ 60 years</td><td>7 (32)</td><td>5 (36)</td><td>1 (7)</td><td>0.02</td></tr><tr><td colspan="5">Extent of surgery</td></tr><tr><td> Breast sparing</td><td>9 (41)</td><td>6 (43)</td><td>6 (43)</td><td></td></tr><tr><td> Mastectomy</td><td>13 (59)</td><td>8 (57)</td><td>8 (57)</td><td>0.99</td></tr><tr><td colspan="5">Tumor size</td></tr><tr><td> ≤ 2.0 cm</td><td>9 (41)</td><td>6 (43)</td><td>9 (64)</td><td></td></tr><tr><td> 2.1–4.9 cm</td><td>13 (59)</td><td>7 (50)</td><td>5 (36)</td><td></td></tr><tr><td> ≥ 5.0 cm</td><td>0</td><td>1 (7%)</td><td>0</td><td>0.33</td></tr><tr><td colspan="5">Axillary lymph node dissection</td></tr><tr><td> Yes</td><td>20 (91)</td><td>14 (100)</td><td>14 (100)</td><td></td></tr><tr><td> No</td><td>2 (9)</td><td>0</td><td>0</td><td>0.27</td></tr><tr><td colspan="5">Sentinel node biopsy</td></tr><tr><td> Yes</td><td>8 (36)</td><td>8 (57)</td><td>6 (43)</td><td></td></tr><tr><td> No</td><td>14 (64)</td><td>6 (43)</td><td>8 (57)</td><td>0.47</td></tr><tr><td colspan="5">Tumor grade</td></tr><tr><td> Low/Intermediate</td><td>4 (18)</td><td>4 (29)</td><td>6 (43)</td><td></td></tr><tr><td> High</td><td>18 (82)</td><td>10 (71)</td><td>8 (57)</td><td>0.28</td></tr><tr><td colspan="5">T stage</td></tr><tr><td> 1</td><td>9 (41)</td><td>6 (43)</td><td>9 (64)</td><td></td></tr><tr><td> 2</td><td>13 (59)</td><td>7 (50)</td><td>5 (36)</td><td></td></tr><tr><td> 3</td><td>0</td><td>1 (7)</td><td>0</td><td>0.33</td></tr><tr><td colspan="5">N stage</td></tr><tr><td> 1</td><td>21 (95)</td><td>13 (93)</td><td>14 (100)</td><td></td></tr><tr><td> 2</td><td>1 (5)</td><td>1 (7)</td><td>0</td><td>0.62</td></tr></table> |
ac4f223389eda33f56522c945ff7c16055ce0faf510da9f6180f3d4b9c062273.png | simple | <table><tr><td>Dataset</td><td>Note</td><td>Reference</td></tr><tr><td>Global</td><td>289 isolates; Human and environmental isolates, from six countries (Australia, Indonesia, Laos, Singapore, Vietnam, USA), sampled to maximize diversity and exclude members of a clonal outbreak, metadata includes invasiveness, acquisition type and sample site. Invasiveness status of human isolates consists of three types: carriage (isolates not considered to be the cause of an infection), non-invasive (pneumonia, urinary tract infection, wound infection; with no recorded bacteraemia) and invasive (isolated from normally sterile sites: blood, CSF, intra-ocular, pleural, pericardial, joint fluids, deep-seated tissue abscesses). Acquisition type is either community acquisition (isolated within 48 hours of admission to hospital) or hospital acquisition (isolated after 48 hours after admission)</td><td>(Holt <i>et al.</i> 2015)</td></tr><tr><td>UK Hospital</td><td>162 isolates; Collection from Cambridge University Hospitals NHS Foundation Trust in the UK over a period of seven years, invasive isolates isolated from normally sterile sites. Biased selection for antimicrobial resistance to three or more of six antimicrobial classes (penicillins, amoxacillin-clavulanate, aminoglycosides, fluoroquinolones, trimethoprim and third-generation cephalosporins), metadata includes sample site</td><td>(Ellington 2016)</td></tr><tr><td>Nepal Hospital</td><td>88 isolates; Nepalese hospital outbreak from May to December 2012, consisting mainly of two clonal lineages; randomly selected blood cultures.</td><td>(Chung The <i>et al.</i> 2015)</td></tr><tr><td>Preantibiotic</td><td>34 isolates; Collection of isolates isolated before the widespread use of antibiotics (pre 1949). No additional metadata available.</td><td>(Wand <i>et al.</i> 2015)</td></tr></table> |
c8e4d2ab91529d9ca86d740c0c27aa18e23abfefff0bc7ea7968ad80f8905381.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">FHS</td><td colspan="2">HRS</td></tr><tr><td>(1)</td><td>(2)</td><td>(3)</td><td>(4)</td></tr><tr><td>Female sex</td><td>0.55† (0.14)</td><td>0.53† (0.14)</td><td>−0.33† (0.06)</td><td>−0.31† (0.06)</td></tr><tr><td>Age</td><td>0.01 (0.01)</td><td>0.01 (0.01)</td><td>0.00 (0.00)</td><td>0.00 (0.00)</td></tr><tr><td>Survey year</td><td></td><td></td><td>0.02 (0.01)</td><td>0.02 (0.01)</td></tr><tr><td>Mother’s highest grade completed</td><td>0.25† (0.04)</td><td>0.24† (0.04)</td><td>0.17† (0.01)</td><td>0.17† (0.01)</td></tr><tr><td>Respondent’s educational genetic score, standardized</td><td></td><td>0.24* (0.11)</td><td></td><td>0.32† (0.03)</td></tr><tr><td>Mother’s educational genetic score, standardized</td><td></td><td>−0.14 (0.11)</td><td></td><td></td></tr><tr><td>Father’s highest grade completed</td><td>0.13† (0.04)</td><td>0.13† (0.04)</td><td>0.17† (0.01)</td><td>0.17† (0.01)</td></tr><tr><td>Father’s educational genetic score, standardized</td><td></td><td>0.00 (0.09)</td><td></td><td></td></tr><tr><td>Constant</td><td>8.45 (0.74)†</td><td>8.65† (0.90)</td><td>−26.95 (26.80)</td><td>−35.35 (26.54)</td></tr><tr><td><i>R</i><sup>2</sup></td><td>0.16</td><td>0.17</td><td>0.18</td><td>0.20</td></tr></table> |
370e92f7bca3152f064bd9c1251fc23921d7ecc930bbd16f4dba83ef7b0af5f3.png | simple | <table><tr><td></td><td>All (n = 713)</td><td>Anterolateral (n = 463)</td><td>Posterolateral (n = 250)</td><td>p-value</td></tr><tr><td>Age, mean (SD)</td><td>76.8 (9.0)</td><td>77.2 (8.4)</td><td>76.1 (10.1)</td><td>0.1</td></tr><tr><td>Sex <sup>a</sup></td><td></td><td></td><td></td><td></td></tr><tr><td>Female</td><td>573 (80)</td><td>374 (81)</td><td>199 (80)</td><td>0.8</td></tr><tr><td>Male</td><td>140 (20)</td><td>89 (19)</td><td>51 (20)</td><td></td></tr><tr><td>Indication <sup>a</sup></td><td></td><td></td><td></td><td></td></tr><tr><td>Primary</td><td>311 (44)</td><td>251 (54)</td><td>60 (24)</td><td>< 0.001</td></tr><tr><td>Secondary</td><td>402 (56)</td><td>212 (46)</td><td>190 (76)</td><td></td></tr><tr><td>Surgeons’ experience <sup>a</sup></td><td></td><td></td><td></td><td></td></tr><tr><td>Registrar</td><td>77 (11)</td><td>64 (14)</td><td>13 (5)</td><td>< 0.001</td></tr><tr><td>Post-registrar</td><td>636 (89)</td><td>399 (86)</td><td>237 (95)</td><td></td></tr><tr><td>Femoral head size <sup>a</sup></td><td></td><td></td><td></td><td></td></tr><tr><td>22-mm</td><td>171 (24)</td><td>14 (3)</td><td>157 (63)</td><td>< 0.001</td></tr><tr><td>28-mm</td><td>542 (76)</td><td>449 (97)</td><td>93 (37)</td><td></td></tr></table> |
c296e3717dafebe791e5be8a9420288d9592195a53d15d1c73efbb20fef885d2.png | complex | <table><tr><td colspan="4">Cell growth inhibition ratios (%)</td></tr><tr><td>Cell groups</td><td colspan="3">time</td></tr><tr><td></td><td>24 h</td><td>48 h</td><td>72 h</td></tr><tr><td>HepG2</td><td>55.45 ± 1.4</td><td>68.91 ± 1.8</td><td>78.83 ± 3.9</td></tr><tr><td>DMSO</td><td>1.00 ± 0.9</td><td>1.53 ± 1.6</td><td>1.72 ± 0.7</td></tr><tr><td>CAV1</td><td>68.32 ± 2.0*</td><td>80.12 ± 1.7*</td><td>90.02 ± 4.0*</td></tr><tr><td>CAVM1</td><td>55.78 ± 1.0</td><td>74.83 ± 2.8</td><td>82.46 ± 1.6</td></tr><tr><td>CAVM2</td><td>57.27 ± 1.2</td><td>76.79 ± 1.6</td><td>84.35 ± 2.6</td></tr><tr><td>CAVRNAi</td><td>41.23 ± 1.5*</td><td>55.39 ± 1.2*</td><td>68.27 ± 1.9*</td></tr><tr><td>GFP</td><td>54.04 ± 1.6</td><td>70.06 ± 1.1</td><td>76.27 ± 1.7</td></tr></table> |
ffb7ac157ef7e9287c20476cc3d4a487093a1b8f324c1fafe46461979df9c8d4.png | simple | <table><tr><td>Standard sections</td><td>Keywords</td></tr><tr><td>Introduction</td><td>Introduction, Background, Review, Context, Literature</td></tr><tr><td>Materials and Methods</td><td>Methods, Materials, Implementation, Experimental</td></tr><tr><td>Results</td><td>Results, Findings</td></tr><tr><td>Discussion</td><td>Discussion</td></tr><tr><td>Conclusion</td><td>Conclusion(s)</td></tr></table> |
c9bc2682cbb0d84512354b0cc48ee6c279d73a491f9914465aeff66d0958bf72.png | complex | <table><tr><td></td><td colspan="2">Patients</td></tr><tr><td>Characteristic</td><td>No.</td><td>%</td></tr><tr><td>Median age at onset (yr)</td><td colspan="2">4 (0.1-15.7)</td></tr><tr><td>Gender</td><td></td><td></td></tr><tr><td> Female</td><td>74</td><td>81</td></tr><tr><td> Male</td><td>17</td><td>19</td></tr><tr><td>JIA onset subtype</td><td></td><td></td></tr><tr><td> Oligoarticular</td><td>62</td><td>68</td></tr><tr><td> Polyarticular</td><td>29</td><td>32</td></tr><tr><td>NSAID*</td><td></td><td></td></tr><tr><td> Naproxen</td><td>87</td><td>95</td></tr><tr><td> Meloxicam</td><td>4</td><td>4</td></tr><tr><td> Tolmetin</td><td>11</td><td>12</td></tr><tr><td> Ibuprofen</td><td>16</td><td>18</td></tr><tr><td> Rofecoxib</td><td>6</td><td>7</td></tr><tr><td> Diclofenac</td><td>8</td><td>9</td></tr><tr><td> Celecoxib</td><td>3</td><td>3</td></tr><tr><td> Nabumetone</td><td>2</td><td>2</td></tr><tr><td>Other Medications†</td><td>6</td><td>7</td></tr><tr><td>Median duration of treatment (yr)</td><td></td><td></td></tr><tr><td> Oligoarticular</td><td colspan="2">1.5 (0.14-17.7)</td></tr><tr><td> Polyarticular</td><td colspan="2">0.58 (0.11-9.8)</td></tr></table> |
5cc12d969c1fc4544020067482df25001e699da04cc4f228466f88cf73d1ab54.png | complex | <table><tr><td rowspan="3"></td><td colspan="6">Models</td></tr><tr><td colspan="3">WAG</td><td colspan="3">GTR</td></tr><tr><td>Observed</td><td>Predicted</td><td>P</td><td>Observed</td><td>Predicted</td><td>P</td></tr><tr><td>Substitutions</td><td>65.4727 ± 1.1915</td><td>63.8521 ± 1.5705</td><td>0.04</td><td>71.4523 ± 1.41065</td><td>71.5064 ± 1.73156</td><td>0.51</td></tr><tr><td>Homoplasy</td><td>52.4011 ± 1.13881</td><td>49.5447 ± 1.52248</td><td>0</td><td>58.443 ± 1.37283</td><td>57.4735 ± 1.7008</td><td>0.15</td></tr></table> |
d8fb48adb3b9420a1520fcbb3eee3ede8a66cb1566c4f7c549e49add36dbf8c3.png | complex | <table><tr><td>Characteristic</td><td>OCP Users (<i>n</i> = 449)</td><td>DMPA Users (<i>n</i> = 181)</td><td><i>P</i> value</td></tr><tr><td>Age in years, mean [range]</td><td>23 [21, 26]</td><td>24 [22, 27]</td><td>0.04</td></tr><tr><td colspan="3">Race</td><td rowspan="5"><0.01</td></tr><tr><td> White/European American</td><td>347 (77.3)</td><td>103 (56.9)</td></tr><tr><td> Black/African American</td><td>19 (4.2)</td><td>38 (21.0)</td></tr><tr><td> Latina</td><td>23 (5.1)</td><td>24 (13.3)</td></tr><tr><td> Other</td><td>60 (13.4)</td><td>16 (8.8)</td></tr><tr><td colspan="3">Marital Status</td><td rowspan="5"><0.01</td></tr><tr><td> Single</td><td>201 (44.8)</td><td>59 (32.6)</td></tr><tr><td> Married</td><td>15 (3.3)</td><td>15 (8.3)</td></tr><tr><td> Divorced</td><td>2 (0.5)</td><td>3 (1.7)</td></tr><tr><td> In a relationship</td><td>231 (51.5)</td><td>104 (57.5)</td></tr><tr><td colspan="3">Education</td><td rowspan="5"><0.01</td></tr><tr><td> High school or less</td><td>24 (5.4)</td><td>29 (16.0)</td></tr><tr><td> Some college</td><td>133 (29.6)</td><td>72 (39.8)</td></tr><tr><td> College graduate</td><td>206 (46.0)</td><td>54 (29.8)</td></tr><tr><td> Graduate or professional school</td><td>86 (19.2)</td><td>26 (14.4)</td></tr><tr><td colspan="3">Income (personal, annual)</td><td rowspan="4"><0.01</td></tr><tr><td> $9,999 or less</td><td>187 (41.8)</td><td>50 (27.8)</td></tr><tr><td> $10,000–34,999</td><td>162 (36.2)</td><td>80 (44.4)</td></tr><tr><td> $35,000 or more</td><td>98 (21.9)</td><td>50 (27.8)</td></tr><tr><td>Number of Prior PregnanciesMean [range]</td><td>0 [0, 0]</td><td>1 [0, 2]</td><td><0.01</td></tr><tr><td>Any prior Pregnancy</td><td>89 (19.9)</td><td>92 (50.8)</td><td><0.01</td></tr></table> |
65c8b553a565de305801a414ac7e117431db39d87cccfa41145b74090dd5e25d.png | simple | <table><tr><td>No</td><td>Pathotype</td><td>AGE</td><td>N 9-p</td><td>N 10-p</td><td>N 14-p</td><td>Micro</td><td>Sexta</td></tr><tr><td> 1</td><td>EAggEC</td><td>P</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 2</td><td>EAggEC</td><td>P</td><td></td><td></td><td>L</td><td>L</td><td></td></tr><tr><td> 3</td><td>EAggEC</td><td>P</td><td></td><td></td><td></td><td>L</td><td></td></tr><tr><td> 4</td><td>EAggEC</td><td>P</td><td>L</td><td>L</td><td>L</td><td>L</td><td>L</td></tr><tr><td> 5</td><td>EAggEC</td><td>P</td><td></td><td></td><td>L</td><td></td><td>L</td></tr><tr><td> 6</td><td>EAggEC</td><td></td><td>L</td><td>L</td><td>L</td><td>L</td><td></td></tr><tr><td> 7</td><td>EAggEC</td><td>P</td><td></td><td>L</td><td>L</td><td>L</td><td>L</td></tr><tr><td> 8</td><td>EAggEC</td><td>P</td><td></td><td></td><td>L</td><td>L</td><td></td></tr><tr><td> 9</td><td>EAggEC</td><td>P</td><td></td><td>L</td><td>L</td><td>L</td><td></td></tr><tr><td>10</td><td>EAggEC</td><td>P</td><td></td><td>L</td><td>L</td><td>L</td><td>L</td></tr><tr><td>11</td><td>EIEC</td><td></td><td>L</td><td>L</td><td>L</td><td>L</td><td>L</td></tr><tr><td>12</td><td>EIEC</td><td></td><td>L</td><td>L</td><td>L</td><td>L</td><td>L</td></tr><tr><td>13</td><td>EIEC</td><td></td><td>L</td><td>L</td><td>L</td><td>L</td><td>L</td></tr><tr><td>14</td><td>EPEC</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>15</td><td>EPEC</td><td></td><td></td><td>L</td><td>L</td><td></td><td></td></tr><tr><td>16</td><td>EPEC</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>17</td><td>EPEC</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>18</td><td>EPEC</td><td></td><td>L</td><td>L</td><td>L</td><td></td><td></td></tr><tr><td>19</td><td>EPEC</td><td>P</td><td></td><td>L</td><td>L</td><td>L</td><td>L</td></tr><tr><td>20</td><td>EPEC</td><td>P</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>21</td><td>EPEC</td><td>P</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>22</td><td>EPEC</td><td>P</td><td>L</td><td>L</td><td>L</td><td></td><td></td></tr><tr><td>23</td><td>EPEC</td><td>P</td><td></td><td></td><td></td><td>L</td><td></td></tr><tr><td>24</td><td>EPEC</td><td></td><td></td><td></td><td></td><td>L</td><td>L</td></tr><tr><td>25</td><td>EPEC</td><td></td><td></td><td>L</td><td>L</td><td></td><td></td></tr><tr><td>26</td><td>EPEC</td><td></td><td></td><td></td><td>L</td><td></td><td>L</td></tr><tr><td>27</td><td>EPEC</td><td>P</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>28</td><td>EPEC</td><td>P</td><td></td><td>L</td><td>L</td><td></td><td>L</td></tr><tr><td>29</td><td>VTEC</td><td></td><td>L</td><td>L</td><td>L</td><td>L</td><td>L</td></tr><tr><td>30</td><td>VTEC</td><td></td><td>L</td><td>L</td><td>L</td><td>L</td><td>L</td></tr><tr><td>31</td><td>VTEC</td><td></td><td>L</td><td>L</td><td>L</td><td>L</td><td></td></tr><tr><td>32</td><td>ETEC O114</td><td>P</td><td></td><td>L</td><td>L</td><td>L</td><td></td></tr><tr><td>33</td><td>ETEC O167</td><td>P</td><td></td><td></td><td></td><td>L</td><td>L</td></tr><tr><td>34</td><td>ETEC O6</td><td>P</td><td></td><td></td><td>L</td><td></td><td></td></tr><tr><td>35</td><td>ETEC O25</td><td>P</td><td></td><td>L</td><td>L</td><td></td><td></td></tr><tr><td>36</td><td>ETEC O25</td><td>P</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>37</td><td>ETEC O78</td><td>P</td><td></td><td>L</td><td>L</td><td>L</td><td>L</td></tr><tr><td>38</td><td>ETEC O115</td><td>P</td><td></td><td>L</td><td>L</td><td></td><td></td></tr><tr><td>39</td><td>ETEC O114</td><td>P</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>40</td><td>ETEC O115</td><td>P</td><td></td><td></td><td></td><td>L</td><td>L</td></tr><tr><td>41</td><td>ETEC O25</td><td>P</td><td></td><td></td><td></td><td>L</td><td></td></tr><tr><td>42</td><td>ETEC O115</td><td>P</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>43</td><td>ETEC O6</td><td>P</td><td>L</td><td>L</td><td>L</td><td></td><td></td></tr><tr><td>44</td><td>ETEC O167</td><td>P</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>45</td><td>ETEC O114</td><td>P</td><td></td><td>L</td><td>L</td><td>L</td><td></td></tr><tr><td>46</td><td>ETEC O8</td><td>P</td><td></td><td></td><td></td><td></td><td></td></tr></table> |
e112e07153a6b935483197aa72bfeebcf259538216e4842ebd613147154bc1fd.png | complex | <table><tr><td colspan="4">Cox proportional hazard model for independent risk factors of survival</td></tr><tr><td></td><td>Hazard ratio</td><td>95% Confidence interval</td><td><i>P</i>‐value</td></tr><tr><td colspan="4">Age groups</td></tr><tr><td>0–5</td><td>Ref</td><td>–</td><td></td></tr><tr><td>6–10</td><td>1.41</td><td>1.069–1.854</td><td>0.015</td></tr><tr><td>11–19</td><td>1.41</td><td>1.094–1.806</td><td>0.008</td></tr><tr><td colspan="4">Race</td></tr><tr><td>White</td><td>Ref</td><td>–</td><td></td></tr><tr><td>Black</td><td>1.29</td><td>1.017–1.656</td><td>0.036</td></tr><tr><td>Other</td><td>1.04</td><td>0.718–1.521</td><td>0.8181</td></tr><tr><td colspan="4">Income</td></tr><tr><td><$30,000</td><td>1.173</td><td>0.895–1.536</td><td>0.2471</td></tr><tr><td>$30,000–$34,999</td><td>1.492</td><td>1.171–1.9</td><td>0.0012</td></tr><tr><td>$35,000–$45,999</td><td>1.198</td><td>0.966–1.487</td><td>0.0996</td></tr><tr><td>>$46,000</td><td>Ref</td><td>–</td><td>–</td></tr><tr><td colspan="4">Primary Site</td></tr><tr><td>Hemispheric</td><td>Ref</td><td>–</td><td></td></tr><tr><td>Central location</td><td>1.467</td><td>1.153–1.868</td><td>0.0018</td></tr><tr><td>Others</td><td>0.986</td><td>0.793–1.227</td><td>0.9022</td></tr><tr><td colspan="4">Treatment combination</td></tr><tr><td>None</td><td>Ref</td><td>–</td><td>–</td></tr><tr><td>RT+CT+Surgery</td><td>0.53</td><td>0.341–0.824</td><td>0.0048</td></tr><tr><td>RT+CT</td><td>0.883</td><td>0.537–1.454</td><td>0.6257</td></tr><tr><td>RT+Surgery</td><td>0.727</td><td>0.435–1.215</td><td>0.2232</td></tr><tr><td>Surgery alone</td><td>0.905</td><td>0.564–1.451</td><td>0.6773</td></tr><tr><td>Other</td><td>0.62</td><td>0.387–0.995</td><td>0.0476</td></tr></table> |
c3398943a2eccb04dcd1c25b6222f00ce76f8ec35f439a4bde372adc097fc23f.png | simple | <table><tr><td>Level</td><td>Vision</td><td>Hearing</td><td>Speech</td><td>Ambulation</td><td>Dexterity</td><td>Emotion</td><td>Cognition</td><td>Pain</td></tr><tr><td>1</td><td>126(100)</td><td>122(97)</td><td>105(83.3)</td><td>126 (100)</td><td>126 (100)</td><td>6(4.8)</td><td>16(12.7)</td><td>125(99)</td></tr><tr><td>2</td><td>0(0.0)</td><td>3(2.4)</td><td>5(4.0)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>16(12.7)</td><td>24(19.0)</td><td>1 (0.8)</td></tr><tr><td>3</td><td>0(0.0)</td><td>0(0.0)</td><td>7(5.6)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>49(38.9)</td><td>24(19.0)</td><td>0 (0.0)</td></tr><tr><td>4</td><td>0(0.0)</td><td>0(0.0)</td><td>6(4.8)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>39(31.0)</td><td>34(27.0)</td><td>0 (0.0)</td></tr><tr><td>5</td><td>0(0.0)</td><td>0(0.0)</td><td>3(2.4)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>16(12.7)</td><td>18(14.3)</td><td>0 (0.0)</td></tr><tr><td>6</td><td>0(0.0)</td><td>1(0.8)</td><td>n/a</td><td>0 (0.0)</td><td>0 (0.0)</td><td>n/a</td><td>10(7.9)</td><td>n/a</td></tr><tr><td>Total</td><td>126</td><td>126</td><td>126</td><td>126</td><td>126</td><td>126</td><td>126</td><td>126</td></tr></table> |
deb00918c1c5250bc3f75c665e9b28e952faea01fb2c15dbe7830f47321af565.png | simple | <table><tr><td></td><td>9%</td><td>3%</td><td>1%</td><td>Control</td></tr><tr><td>Proximates</td><td></td><td></td><td></td><td></td></tr><tr><td> Moisture (g/100 g)</td><td>8.395</td><td>8.625</td><td>8.57</td><td>8.27</td></tr><tr><td> Ash (g/100 g)</td><td>7.14</td><td>6.835</td><td>6.66</td><td>6.63</td></tr><tr><td> Protein (g/100 g)</td><td>28.155</td><td>23.545</td><td>22.185</td><td>21.21</td></tr><tr><td> Fat (g/100 g)</td><td>3.94</td><td>3.61</td><td>4.26</td><td>3.77</td></tr><tr><td> Fiber (g/100 g)</td><td>3.16</td><td>3.14</td><td>3.39</td><td>3.43</td></tr><tr><td> Carbohydrate (g/100 g)</td><td>52.37</td><td>57.385</td><td>58.325</td><td>60.13</td></tr><tr><td> Energy (Kcal/100 g)</td><td>362.02</td><td>360.75</td><td>364.79</td><td>363.81</td></tr><tr><td>Amino acids(mg/g)</td><td></td><td></td><td></td><td></td></tr><tr><td> Asp</td><td>15.91</td><td>14.20</td><td>13.39</td><td>12.43</td></tr><tr><td> Thr</td><td>6.73</td><td>6.12</td><td>5.71</td><td>5.32</td></tr><tr><td> Ser</td><td>8.75</td><td>8.26</td><td>7.95</td><td>7.11</td></tr><tr><td> Glu</td><td>39.61</td><td>36.72</td><td>35.09</td><td>32.39</td></tr><tr><td> Gly</td><td>15.13</td><td>10.22</td><td>7.93</td><td>6.52</td></tr><tr><td> Ala</td><td>10.94</td><td>9.21</td><td>7.73</td><td>7.21</td></tr><tr><td> Cys</td><td>2.46</td><td>3.22</td><td>2.69</td><td>2.72</td></tr><tr><td> Val</td><td>7.46</td><td>7.49</td><td>6.86</td><td>6.71</td></tr><tr><td> Met</td><td>2.64</td><td>2.66</td><td>2.31</td><td>1.79</td></tr><tr><td> Ile</td><td>6.24</td><td>5.74</td><td>5.49</td><td>5.21</td></tr><tr><td> Leu</td><td>12.98</td><td>12.29</td><td>11.45</td><td>11.11</td></tr><tr><td> Tyr</td><td>4.00</td><td>3.80</td><td>3.60</td><td>3.54</td></tr><tr><td> Phe</td><td>8.31</td><td>7.63</td><td>7.33</td><td>6.94</td></tr><tr><td> Lys</td><td>9.31</td><td>7.90</td><td>7.11</td><td>6.99</td></tr><tr><td> His</td><td>4.12</td><td>3.83</td><td>3.57</td><td>3.36</td></tr><tr><td> Arg</td><td>11.61</td><td>9.92</td><td>9.18</td><td>8.20</td></tr><tr><td> Pro</td><td>14.61</td><td>12.22</td><td>10.32</td><td>9.91</td></tr><tr><td>Total amino acids(mg/g)</td><td>180.81</td><td>161.42</td><td>147.71</td><td>137.46</td></tr><tr><td>Minerals</td><td></td><td></td><td></td><td></td></tr><tr><td> Calcium (g/100 g)</td><td>1.03</td><td>1.12</td><td>1.29</td><td>1.21</td></tr><tr><td> Phosphorus (g/100 g)</td><td>0.79</td><td>0.98</td><td>0.315</td><td>0.65</td></tr></table> |
e499f41a571f179cf48b8391075732b7a426d59be9f5c5cbe69381ba85b91372.png | simple | <table><tr><td>Gene</td><td>TGCT Probands (<i>n</i>=150)</td><td>Controls (<i>n</i>=1,609)</td><td>OR</td><td><i>P</i>-value</td><td>Total no. affected familial cases (<i>n</i>=306)</td><td>Rank</td></tr><tr><td><i>DNAAF1</i></td><td>2</td><td>1</td><td>21.3</td><td>9.9 × 10<sup>−3</sup></td><td>4</td><td>1</td></tr><tr><td><i>ACSM1</i></td><td>2</td><td>6</td><td>3.6</td><td>6.4 × 10<sup>−2</sup></td><td>4</td><td>2</td></tr><tr><td><i>TSNAXIP1</i></td><td>3</td><td>11</td><td>2.9</td><td>6.9 × 10<sup>−2</sup></td><td>6</td><td>3</td></tr><tr><td><i>C1orf186</i></td><td>2</td><td>8</td><td>2.7</td><td>1.3 × 10<sup>−1</sup></td><td>4</td><td>4</td></tr><tr><td><i>KIAA1586</i></td><td>2</td><td>8</td><td>2.7</td><td>1.3 × 10<sup>−1</sup></td><td>4</td><td>5</td></tr><tr><td><i>ABCA10</i></td><td>2</td><td>8</td><td>2.7</td><td>1.6 × 10<sup>−1</sup></td><td>4</td><td>6</td></tr><tr><td><i>PIK3C2G</i></td><td>3</td><td>13</td><td>2.5</td><td>2.4 × 10<sup>−1</sup></td><td>6</td><td>7</td></tr><tr><td><i>C1orf168</i></td><td>2</td><td>9</td><td>2.4</td><td>2.5 × 10<sup>−1</sup></td><td>5</td><td>8</td></tr><tr><td><i>RRP15</i></td><td>3</td><td>18</td><td>1.8</td><td>2.8 × 10<sup>−1</sup></td><td>6</td><td>9</td></tr><tr><td><i>MUC4</i></td><td>3</td><td>22</td><td>1.5</td><td>2.9 × 10<sup>−1</sup></td><td>7</td><td>10</td></tr><tr><td><i>OR6K2</i></td><td>2</td><td>15</td><td>1.4</td><td>3.0 × 10<sup>−1</sup></td><td>5</td><td>11</td></tr><tr><td><i>KRTAP1-1</i></td><td>2</td><td>15</td><td>1.4</td><td>3.0 × 10<sup>−1</sup></td><td>4</td><td>12</td></tr><tr><td><i>ABCC12</i></td><td>3</td><td>23</td><td>1.4</td><td>3.3 × 10<sup>−1</sup></td><td>7</td><td>13</td></tr><tr><td><i>CALML4</i></td><td>2</td><td>16</td><td>1.3</td><td>3.4 × 10<sup>−1</sup></td><td>5</td><td>14</td></tr></table> |
527bc8b76fca92605fd72bea78d932d0ffee0d1d633893de3a2b23adb80ec3da.png | complex | <table><tr><td>Factor</td><td>Level</td><td>n</td><td>Test +ve</td><td>%</td><td>OR</td><td>95 % CI</td><td>χ<sup>2</sup></td><td>P value</td></tr><tr><td rowspan="2">Farm type</td><td>Extensive</td><td>33</td><td>14</td><td>42.4</td><td></td><td></td><td></td><td></td></tr><tr><td>Intensive</td><td>4</td><td>3</td><td>75</td><td>4.07</td><td>0.38–43.38</td><td>1.52</td><td>0.22</td></tr></table> |
bc68751c62cfa52d47470206eceb4a0de450aaa15ff500dd645f102b481e075a.png | simple | <table><tr><td>Line</td><td>Patients by gender identity</td><td>Number (a)</td></tr><tr><td>20</td><td>Male</td><td> </td></tr><tr><td>21</td><td>Female</td><td> </td></tr><tr><td>22</td><td>Transgender male/female-to-male</td><td> </td></tr><tr><td>23</td><td>Transgender female/male-to-female</td><td> </td></tr><tr><td>24</td><td>Other</td><td> </td></tr><tr><td>25</td><td>Choose not to disclose</td><td> </td></tr><tr><td>26</td><td>Total patients (sum lines 20 to 25)</td><td> </td></tr></table> |
8dbc191acdfa8ff4786d438129b23d7032429e5e71b8151e8b2adaedbc7ec114.png | complex | <table><tr><td></td><td>Bird ID</td><td>Paired-End Reads</td><td>Reads Mapped (%)</td><td>Reads Unmapped (%)</td><td>Genes (FPKM > 0.5)</td></tr><tr><td rowspan="4">HG</td><td>1536</td><td>64,372,528</td><td>58,450,255 (91%)</td><td>5,922,272 (9%)</td><td>14,171</td></tr><tr><td>1572</td><td>72,993,942</td><td>54,526,474 (75%)</td><td>18,467,467 (25%)</td><td>14,086</td></tr><tr><td>1759</td><td>72,258,015</td><td>54,988,349 (76%)</td><td>17,269,665 (24%)</td><td>14,121</td></tr><tr><td>1807</td><td>53,773,174</td><td>44,524,188 (83%)</td><td>9,248,985 (17%)</td><td>14,251</td></tr><tr><td rowspan="4">LG</td><td>1890</td><td>51,157,100</td><td>42,460,393 (83%)</td><td>8,696,707 (17%)</td><td>14,241</td></tr><tr><td>1923</td><td>71,021,405</td><td>58,450,616 (82%)</td><td>12,570,788 (18%)</td><td>14,449</td></tr><tr><td>5629</td><td>75,046,371</td><td>62,063,348 (83%)</td><td>12,983,022 (17%)</td><td>14,465</td></tr><tr><td>5678</td><td>69,207,601</td><td>57,027063 (82%)</td><td>12,180,537 (18%)</td><td>14,362</td></tr></table> |
aea433216b2c8841e13c90a0d012ce8fefe1c1d9911cbf07132c4004ec468378.png | complex | <table><tr><td>Category</td><td>AML</td><td>ALL</td><td>CML</td><td>MDS</td><td>MM</td><td>LD</td><td>SAA</td><td>Total</td></tr><tr><td colspan="9">Sex</td></tr><tr><td>Male</td><td>33 (55.9%)</td><td>30 (62.5%)</td><td>45 (59.2%)</td><td>6 (37.5%)</td><td>1 (100%)</td><td>12 (44.4%)</td><td>29 (56.9%)</td><td>156 (56.1%)</td></tr><tr><td>Female</td><td>26 (44.1%)</td><td>18 (37.5%)</td><td>31 (40.8%)</td><td>10 (62.5%)</td><td>0</td><td>15 (55.6%)</td><td>22 (43.1%)</td><td>122 (43.9%)</td></tr><tr><td colspan="9">Source</td></tr><tr><td>BM</td><td>49 (83.1%)</td><td>41 (85.4%)</td><td>63 (82.9%)</td><td>11 (68.8%)</td><td>0</td><td>7 (25.9%)</td><td>49 (96.1%)</td><td>220 (79.1%)</td></tr><tr><td>PBSC</td><td>10 (16.9%)</td><td>3 (6.3%)</td><td>13 (17.1%)</td><td>4 (25%)</td><td>1 (100%)</td><td>20 (74.1%)</td><td>1 (2%)</td><td>52 (18.7%)</td></tr><tr><td>CB </td><td>0</td><td>4 (8.3%)</td><td>0</td><td>1 (6.3%)</td><td>0</td><td>0</td><td>1 (2%)</td><td>6 (2.2%)</td></tr><tr><td colspan="9">Regimen</td></tr><tr><td>Myeloablative</td><td>58 (98.3%)</td><td>48 (100%)</td><td>76 (100%)</td><td>12 (75%)</td><td>0</td><td>0</td><td>46 (90.2%)</td><td>241 (86.7%)</td></tr><tr><td>RIC</td><td>1 (1.7%)</td><td>0</td><td>0</td><td>4 (25%)</td><td>1 (100%)</td><td>27 (100%)</td><td>5 (9.8%)</td><td>37 (13.3%)</td></tr><tr><td colspan="9">Patient age</td></tr><tr><td>Median</td><td>35</td><td>15</td><td>36.5</td><td>35</td><td>31</td><td>43</td><td>20</td><td>32</td></tr><tr><td>Range</td><td>1–55</td><td>1–47</td><td>7–57</td><td>2–55</td><td>31</td><td>18–56</td><td>5–51</td><td>1–57</td></tr><tr><td colspan="9">Age</td></tr><tr><td><20</td><td>14 (23.7%)</td><td>27 (56.3%)</td><td>6 (7.9%)</td><td>4 (25%)</td><td>0</td><td>2 (7.4%)</td><td>26 (51%)</td><td>79 (28.4%)</td></tr><tr><td>20–40</td><td>27 (45.8%)</td><td>16 (33.3%)</td><td>40 (52.6%)</td><td>6 (37.5%)</td><td>1 (100%)</td><td>10 (37%)</td><td>19 (37.3%)</td><td>119 (42.8%)</td></tr><tr><td>>40</td><td>18 (30.5%)</td><td>5 (10.4%)</td><td>30 (39.5%)</td><td>6 (37.5%)</td><td>0</td><td>15 (55.6%)</td><td>6 (11.8%)</td><td>80 (28.8%)</td></tr><tr><td colspan="9">Disease stage</td></tr><tr><td>Early</td><td>28 (47.5%)</td><td>18 (37.5%)</td><td>60 (78.9%)</td><td>16 (100%)</td><td>0</td><td>2 (7.4%)</td><td>51 (100%)</td><td>175 (62.9%)</td></tr><tr><td>Intermediate</td><td>17 (28.8%)</td><td>23 (47.9%)</td><td>12 (15.8%)</td><td>0</td><td>1 (100%)</td><td>7 (25.9%)</td><td>—</td><td>60 (21.6%)</td></tr><tr><td>Advanced</td><td>14 (23.7%)</td><td>7 (14.6%)</td><td>4 (5.3%)</td><td>0</td><td>0</td><td>18 (66.7%)</td><td>—</td><td>43 (15.5%)</td></tr><tr><td colspan="9">Time interval</td></tr><tr><td><12 months</td><td>24 (40.7%)</td><td>13 (27.1%)</td><td>13 (17.1%)</td><td>5 (31.3%)</td><td>0</td><td>1 (3.7%)</td><td>36 (70.6%)</td><td>92 (33.1%)</td></tr><tr><td>>12 months</td><td>35 (59.3%)</td><td>35 (72.9%)</td><td>63 (82.9%)</td><td>11 (68.7%)</td><td>1 (100%)</td><td>26 (96.3%)</td><td>15 (29.45)</td><td>186 (66.9%)</td></tr><tr><td colspan="9">HLA</td></tr><tr><td>HLA IS</td><td>50 (84.7%)</td><td>33 (68.8%)</td><td>69 (90.8%)</td><td>14 (87.5%)</td><td>1 (100%)</td><td>27 (100%)</td><td>44 (86.3%)</td><td>238 (85.6%)</td></tr><tr><td>Unrelated</td><td>9 (15.35)</td><td>15 (31.3%)</td><td>7 (9.2%)</td><td>2 (12.5%)</td><td>0</td><td>0</td><td>7 (13.7%)</td><td>40 (14.4%)</td></tr><tr><td colspan="9">Gender com</td></tr><tr><td>Other</td><td>42 (71.2%)</td><td>34 (70.8%)</td><td>58 (76.3%)</td><td>16 (100%)</td><td>0</td><td>21 (77.8%)</td><td>38 (74.5%)</td><td>209 (75.2%)</td></tr><tr><td>DF/RM</td><td>17 (28.8%)</td><td>14 (29.2%)</td><td>18 (23.7%)</td><td>0</td><td>1 (100%)</td><td>6 (22.2%)</td><td>13 (25.5%)</td><td>69 (24.8%)</td></tr><tr><td colspan="9">Score</td></tr><tr><td>0</td><td>2 (3.4%)</td><td>4 (8.3%)</td><td>1 (1.3%)</td><td>2 (12.5%)</td><td>0</td><td>0</td><td>13 (25.5%)</td><td>22 (7.9%)</td></tr><tr><td>1</td><td>10 (16.9%)</td><td>6 (12.5%)</td><td>7 (9.2%)</td><td>4 (25%)</td><td>0</td><td>0</td><td>18 (35.3%)</td><td>45 (16.2%)</td></tr><tr><td>2</td><td>17 (28.8%)</td><td>12 (25%)</td><td>20 (26.3%)</td><td>3 (18.8%)</td><td>0</td><td>1 (3.7%)</td><td>13 (25.5%)</td><td>66 (23.7%)</td></tr><tr><td>3</td><td>9 (15.3%)</td><td>12 (25%)</td><td>35 (46.1%)</td><td>7 (15.3%)</td><td>0</td><td>3 (11.1%)</td><td>6 (11.8%)</td><td>72 (25.9%)</td></tr><tr><td>4</td><td>10 (16.9%)</td><td>11 (22.9%)</td><td>9 (11.8%)</td><td>0</td><td>1 (100%)</td><td>11 (40.7%)</td><td>1 (2.0%)</td><td>43 (15.5%)</td></tr><tr><td>5</td><td>8 (13.6%)</td><td>2 (4.2%)</td><td>4 (5.3%)</td><td>0</td><td>0</td><td>11 (40.7%)</td><td>0</td><td>25 (9.0%)</td></tr><tr><td>6</td><td>3 (5.1%)</td><td>1 (2.1%)</td><td>0</td><td>0</td><td>0</td><td>1 (3.7%)</td><td>0</td><td>5 (1.8%)</td></tr><tr><td colspan="9">CMV </td></tr><tr><td>Recipient pos</td><td>52 (91.2%)</td><td>37 (77.1%)</td><td>65 (85.5%)</td><td>14 (87.5%)</td><td>1 (100%)</td><td>23 (88.5%)</td><td>46 (90.2%)</td><td>238 (86.5%)</td></tr><tr><td>Recipient neg</td><td>5 (8.8%)</td><td>11 (22.9%)</td><td>11 (14.5%)</td><td>2 (12.5%)</td><td>0</td><td>3 (11.5%)</td><td>5 (9.8%)</td><td>37 (13.5%)</td></tr></table> |
be43d87c456e8317174a329f394649512f2d51b66d133e9e5283ef0b92244cfb.png | complex | <table><tr><td></td><td colspan="2">IQ</td><td colspan="2">TMT interference</td><td colspan="2">Stroop interference</td><td colspan="2">ZOO MAP</td></tr><tr><td></td><td>B</td><td>95%CI</td><td>B</td><td>95%CI</td><td>B</td><td>95%CI</td><td>B</td><td>95%CI</td></tr><tr><td>Distress experience</td><td>- 0.04</td><td>-0.06 - -0.12*</td><td>-0.05</td><td>-0.16 – 0.05</td><td>0.79</td><td>-0.23 – 1.82</td><td>0.75</td><td>-0.08 – 0.23</td></tr><tr><td>Perceived control</td><td>0.03</td><td>-0.00 – 0.05</td><td>-0.01</td><td>-0.09 – 0.11</td><td>-0.17</td><td>-1.20 – 0.85</td><td>0.03</td><td>-0.14 – 0.19</td></tr></table> |
06e053209eb0b5e01885a82f6470ed43eaa1da0a332c78b57efe4808f1361f37.png | complex | <table><tr><td></td><td>Control group</td><td>Pancreatic cancer patients</td></tr><tr><td>Age (years)</td><td>58 ± 11</td><td>61 ± 7</td></tr><tr><td>Gender (M-men/W-women)</td><td>(10-M/9-W)</td><td>(19-M/10-W)</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>25.12 ± 3.43</td><td>26.18 ± 4.56</td></tr><tr><td>RBC (×10<sup>12</sup> cells/l)</td><td>4.67 ± 0.73</td><td>4.38 ± 0.84</td></tr><tr><td>Hb (g/dl)</td><td>14.26 ± 1.57</td><td>12.56 ± 2.63</td></tr><tr><td>Platelets count (×10<sup>9</sup> cells/l)</td><td>209 ± 47</td><td>253 ± 102</td></tr><tr><td>WBC count (×10<sup>9</sup> cells/l)</td><td>8.01 ± 1.91</td><td>9.16 ± 4.09</td></tr><tr><td>CRP (mg/l)</td><td>3.07 ± 2.88</td><td>8.57 ± 2.14*</td></tr><tr><td>CA19.9 (U/ml)</td><td>17.81 ± 4.15</td><td>194.11 ± 73.01*</td></tr><tr><td colspan="3">Subjective pain intensity (n [%])</td></tr><tr><td> None</td><td>17 [89.5]</td><td>15 [51.7]</td></tr><tr><td> Delicate</td><td>2 [10.5]</td><td>6 [20.7]</td></tr><tr><td> Moderate</td><td>0 [0]</td><td>4 [13.8]</td></tr><tr><td> Intensive</td><td>0 [0]</td><td>4 [13.8]</td></tr><tr><td colspan="3">General feeling (n [%])</td></tr><tr><td> Good</td><td>19 [100]</td><td>15 [51.7]</td></tr><tr><td> Poor</td><td>0 [0]</td><td>10 [34.5]</td></tr><tr><td> Terrible/very weak</td><td>0 [0]</td><td>4 [13.8]</td></tr></table> |
f4679c7c2aa45df58db93d4ddd4cb9725a1b6c32bd471426bfea26d579e7f6b8.png | simple | <table><tr><td>Patients</td><td><i>n</i> = 13</td></tr><tr><td>Mean age years (min – max)</td><td>53 (28–77)</td></tr><tr><td>Male/female</td><td>7/6</td></tr><tr><td>Mean height cm (min-max)</td><td>166 (146–177)</td></tr><tr><td>Mean weight kg (min-max)</td><td>72 (44–105)</td></tr><tr><td>Mean BMI (min-max)</td><td>27 (19–38)</td></tr><tr><td>ASA I/II/III/IV</td><td>2/4/2/5</td></tr><tr><td>Mallampati class I/II/III/IV</td><td>6/2/2/3</td></tr><tr><td>Orally/nasally awake fiberoptic intubation</td><td>6/7</td></tr><tr><td>Reasons for awake fiberoptic intubation</td><td></td></tr><tr><td> o Cervical spine disease, i.e. rheumatoid arthritis</td><td>5</td></tr><tr><td> o Head and neck abnormality, i.e. supraglottic cancer, oral abscess</td><td>2</td></tr><tr><td> o Thyroidea abnormality</td><td>3</td></tr><tr><td> o Upper airway trauma, i.e. acute pharyngeal bleeding, mandible fracture</td><td>3</td></tr><tr><td>Previous experience with anaesthesia, yes/no</td><td>10/3</td></tr></table> |
2806acd4c29eeec5bbfd6aadac2d1cc5cf0d1a626f51c8d67bb611671dc498e0.png | simple | <table><tr><td>Genome</td><td>Proteome size</td><td>Clustered proteins</td><td>Core proteome</td></tr><tr><td><i>Halobacterium </i>sp. NRC-1</td><td>2626</td><td>2174 (82.8%)</td><td>857 (32.6%)</td></tr><tr><td><i>Haloarcula marismortui </i></td><td>4240</td><td>3464 (81.7%)</td><td>893 (23.1%)</td></tr><tr><td><i>Natronomonas pharaonis </i></td><td>2822</td><td>2285 (81.0%)</td><td>847 (30.0%)</td></tr><tr><td><i>Haloquadratum walsbyi </i></td><td>2626</td><td>2108 (80.3%)</td><td>835 (31.8%)</td></tr><tr><td><i>Halorubrum lacusprofundi </i></td><td>3913</td><td>3166 (80.9%)</td><td>870 (22.2%)</td></tr><tr><td><i>Halogeometricum borinquense </i></td><td>4303</td><td>3209 (74.6%)</td><td>891 (20.7%)</td></tr><tr><td><i>Halomicrobium mukohataei </i></td><td>3548</td><td>2902 (81.8%)</td><td>858 (24.2%)</td></tr><tr><td><i>Halorhabdus utahensis </i></td><td>3160</td><td>2334 (73.9%)</td><td>856 (27.1%)</td></tr><tr><td><i>Haloferax volcanii </i></td><td>4074</td><td>3240 (79.5%)</td><td>870 (21.4%)</td></tr></table> |
b39dac85c49dae1d41b2656c56a4137fdc10c27d9764f82c5edf146ca9e72e77.png | simple | <table><tr><td>Strains</td><td>Characteristics</td><td>Source/origin</td></tr><tr><td>J940047</td><td>Wild-type isolate</td><td>Clinical, Portugal</td></tr><tr><td>J940557</td><td>Wild-type isolate</td><td>Clinical, Portugal</td></tr><tr><td>J940915</td><td>Wild-type isolate</td><td>Clinical, Portugal</td></tr><tr><td>06L3FF02</td><td>Wild-type isolate</td><td>Wine cellar; Bairrada Wine Region, Portugal</td></tr><tr><td>06L1FF11</td><td>Wild-type isolate</td><td>Wine cellar; Bairrada Wine Region, Portugal</td></tr><tr><td>06L3FF15</td><td>Wild-type isolate</td><td>Wine cellar; Bairrada Wine Region, Portugal</td></tr><tr><td>06L6FF20</td><td>Wild-type isolate</td><td>Wine cellar; Bairrada Wine Region, Portugal</td></tr><tr><td>UM218</td><td>Wild-type isolate</td><td>Vineyard; Vinho Verde Wine Region, Portugal</td></tr><tr><td>UM237</td><td>Wild-type isolate</td><td>Vineyard; Vinho Verde Wine Region, Portugal</td></tr><tr><td>BB1235</td><td>Wild-type isolate</td><td>Vineyard; Bairrada Wine Region, Portugal</td></tr><tr><td>BB2453</td><td>Wild-type isolate</td><td>Vineyard; Bairrada Wine Region, Portugal</td></tr><tr><td>Lalvin EC-1118</td><td>Commercial; used in the Vinho Verde Wine Region</td><td>Champagne, France</td></tr><tr><td>Lalvin ICV D254</td><td>Commercial; used in the Bairrada Wine Region</td><td>Rhône Valley, France</td></tr><tr><td>IOC 18–2007</td><td>Commercial; used in the Bairrada Wine Region</td><td>Institut Oenologique de Champagne, France</td></tr><tr><td>AEB Fermol Rouge</td><td>Commercial; used in the Bairrada Wine Region</td><td>Montpellier University, France</td></tr><tr><td>Davis Lalvin 522</td><td>Commercial; used in the Bairrada Wine Region</td><td>University of California, Davis, USA</td></tr><tr><td>S288C</td><td>MATα SUC2 <i>mal mel gal2 CUP1 flo1 flo8-1</i></td><td>Mortimer & Johnston, 1986 [87]</td></tr></table> |
f4e1d7deaaac314419e6faead6ffa3badcc2e61f3cd43165b2e1ecdbd26782a7.png | simple | <table><tr><td>Gene</td><td>Accession number</td><td>Forward Primer (5'-3')</td><td>Reverse Primer (5'-3')</td><td>qPCR primer combination (product length)</td><td>Sequencing primer combination (product length)</td></tr><tr><td>GST mu 1</td><td>AF462190</td><td>F1: GCTATTGGGATCTTCGTGGA</td><td>R1:TGCCCAAATACCGGAGAATA</td><td>F1/R1 (228 bp)</td><td>F1/R2 (628 bp)</td></tr><tr><td></td><td></td><td></td><td>R2: TGTATTCCATTTCGCCATTG</td><td></td><td></td></tr><tr><td>GST mu 2</td><td>AY825933</td><td>F1: GCCCATCAGAATGATGCTTT</td><td>R1: TTCTCAAGATAATCTGGCTTTA</td><td>F1/R1 (344 bp)</td><td>F1/R2 (519 bp)</td></tr><tr><td></td><td></td><td></td><td>R2: GAATCGATTAACATAGTTGCC</td><td></td><td></td></tr><tr><td>GST mu 3</td><td>AY825934</td><td>F1: ATCTGGCGTGCAGATAAAC</td><td>R1: CTCGAGCCTTCTCGAAATTG</td><td>F1/R1 (241 bp)</td><td>F2/R2 (929 bp)</td></tr><tr><td></td><td></td><td>F2: ACGCAGTTTTGTTTCGTTGG</td><td>R2: GTCTGGATTTGTTCCGTGGT</td><td></td><td></td></tr><tr><td>GST delta 1</td><td>AY825935</td><td>F1: TGGACCAACATTAGCCGATA</td><td>R1: TTGCATTTGTTGAGCGAATC</td><td>F1/R1 (193 bp)</td><td>F2/R1 (631 bp)</td></tr><tr><td></td><td></td><td>F2: CAGAAAGTGCACCATGTCGT</td><td></td><td></td><td></td></tr><tr><td>GST delta 2</td><td>AY825936</td><td>F1: AGCTCAAACCGATGAGCCTA</td><td>R1:GCGAATGCAATGATGTTAGC</td><td>F1/R1 (192 bp)</td><td>F2/R1 (652 bp)</td></tr><tr><td></td><td></td><td>F2:TGGGTTCTATTCGACCGATAA</td><td></td><td></td><td></td></tr><tr><td>GST delta 3</td><td>AY825937</td><td>F1: ATGGAGGTGGTTTGAACGAG</td><td>R1: TCGTGATCGACAGCATTCAT</td><td>F1/R1 (244 bp)</td><td>F2/R1 (580 bp)</td></tr><tr><td></td><td></td><td>F2: AGAGAGCCCACCATGTCGTA</td><td></td><td></td><td></td></tr><tr><td>P-glycoprotein</td><td>DQ146410</td><td>AGGCAACTTCAGCACTCGAT</td><td>ACATTCTGACCGCCATCAAT</td><td>155 bp</td><td></td></tr><tr><td>SsCl</td><td>EF611372</td><td>TGATTTCTATATGTCGGGCCATTTG</td><td>CAGGGAACCAAAGATCAACA</td><td>329 bp</td><td></td></tr><tr><td>β-actin</td><td>EU624346</td><td>CAACCATCCTTCTTGGGTATG</td><td>CCAGCTTCGTCGTATTCTTGT</td><td>311 bp</td><td></td></tr></table> |
891b3ab202757b9da9bd4696cd45aa08a3948bac24699f63ca9e0de480e700ad.png | complex | <table><tr><td>Characteristics</td><td>HR</td><td>95% CI</td><td><i>P</i>-value</td></tr><tr><td colspan="4">Health knowledge<sup>a</sup></td></tr><tr><td> Low (0)</td><td>1</td><td></td><td></td></tr><tr><td> Moderate (1–3)</td><td>0.63</td><td>0.33–1.19</td><td>0.15</td></tr><tr><td> High (4–15)</td><td>0.43</td><td>0.22–0.86</td><td>0.02</td></tr><tr><td>Age</td><td>1.04</td><td>1.00–1.07</td><td>0.04</td></tr><tr><td>Sex</td><td>0.81</td><td>0.42–1.58</td><td>0.54</td></tr><tr><td colspan="4">Smoking status</td></tr><tr><td> Never</td><td>1</td><td></td><td></td></tr><tr><td> Current</td><td>2.24</td><td>1.13–4.44</td><td>0.02</td></tr><tr><td> Former</td><td>0.92</td><td>0.25–3.34</td><td>0.90</td></tr><tr><td colspan="4">Comorbidities</td></tr><tr><td colspan="4"> Hypertension</td></tr><tr><td>No</td><td>1</td><td></td><td></td></tr><tr><td>Yes</td><td>0.96</td><td>0.50–1.85</td><td>0.91</td></tr><tr><td colspan="4"> Hyperlipidemia</td></tr><tr><td>No</td><td>1</td><td></td><td></td></tr><tr><td>Yes</td><td>1.88</td><td>1.00–3.55</td><td>0.05</td></tr><tr><td colspan="4"> Atrial fibrillation</td></tr><tr><td>No</td><td>1</td><td></td><td></td></tr><tr><td>Yes</td><td>3.61</td><td>1.28–10.20</td><td>0.02</td></tr><tr><td colspan="4"> Coronary artery disease</td></tr><tr><td>No</td><td>1</td><td></td><td></td></tr><tr><td>Yes</td><td>1.16</td><td>0.67–2.01</td><td>0.60</td></tr><tr><td colspan="4"> Congestive heart failure</td></tr><tr><td>No</td><td>1</td><td></td><td></td></tr><tr><td>Yes</td><td>1.61</td><td>0.75–3.45</td><td>0.22</td></tr></table> |
6b736ff69deee157caac1f67df964cde9cb66958842dd7a48235fd7e7e1ebd9c.png | complex | <table><tr><td></td><td>Different scales</td><td>Mean</td><td>SD</td><td>Score ≥ 3,5 (total)</td></tr><tr><td rowspan="3">Images of God (5 point scale)</td><td>Personal God</td><td>2,75</td><td>1,42</td><td>18 (50)</td></tr><tr><td>Non-personal God</td><td>2,70</td><td>0,75</td><td>24 (49)</td></tr><tr><td>Unknowable God</td><td>3,23</td><td>1,18</td><td>19 (46)</td></tr><tr><td rowspan="5">Attitudes towards death (5 point scale)</td><td>Explicitly religious</td><td>2,53</td><td>1,34</td><td></td></tr><tr><td>Agnostic/Atheistic</td><td>3,35</td><td>0,96</td><td></td></tr><tr><td>Reincarnation</td><td>2,17</td><td>1,08</td><td></td></tr><tr><td>Community</td><td>2,43</td><td>1,24</td><td></td></tr><tr><td>Continuation</td><td>2,70</td><td>1,27</td><td></td></tr><tr><td rowspan="5">Spiritual wellbeing scales (4 point scale)</td><td>Existential wellbeing</td><td>2,96</td><td>,59</td><td></td></tr><tr><td>Relation to Self</td><td>3,05</td><td>,54</td><td></td></tr><tr><td>Relation to Others</td><td>3,30</td><td>,50</td><td></td></tr><tr><td>Relation to Something Greater</td><td>2,40</td><td>,73</td><td></td></tr><tr><td>Relation to God (1-item scale for ‘believers’ <i>n</i> = 29 completed this scale)</td><td>2,38</td><td>1,02</td><td></td></tr></table> |
d10e286588512894399f0b8f4ab2f7fead15f440412406c04c9ba0fee882880d.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">Frequencies of graft cell subsets, (%), mean ± SD</td><td></td><td colspan="2">Doses of graft cell subsets infused, 10<sup>6</sup> cells/kg of body weight, median (min–max)</td><td></td></tr><tr><td>G-BM (<i>n</i> = 49)</td><td>G-PBSC (<i>n</i> = 52)</td><td><i>P</i></td><td>G-BM (<i>n</i> = 49)</td><td>G-PBSC (<i>n</i> = 52)</td><td><i>P</i></td></tr><tr><td>CD3<sup>+</sup></td><td>60 ± 10</td><td>68.0 ± 14.0</td><td>0.007</td><td>69.6(22–156)</td><td>285.8(68–467)</td><td><0.001</td></tr><tr><td>CD3<sup>+</sup>CD4<sup>+</sup></td><td>29 ± 8.7</td><td>35.0 ± 10.7</td><td>0.065</td><td>33(10–56)</td><td>139.3(45–257)</td><td><0.001</td></tr><tr><td>CD4<sup>+</sup>CD45RA<sup>+</sup></td><td>9.5 ± 5.7</td><td>13.1 ± 8.1</td><td>0.220</td><td>11(3–30)</td><td>51.3(16–121)</td><td><0.001</td></tr><tr><td>CD4<sup>+</sup>CD45RO<sup>+</sup></td><td>13.8 ± 7.7</td><td>16.2 ± 8.0</td><td>0.647</td><td>16(5–39)</td><td>63.6(16–150)</td><td><0.001</td></tr><tr><td>CD3<sup>+</sup>CD8<sup>+</sup></td><td>26.6 ± 7.4</td><td>27.9 ± 9.2</td><td>0.297</td><td>30(25–59)</td><td>111.8(28–265)</td><td><0.001</td></tr><tr><td>CD8<sup>+</sup>CD45RA<sup>+</sup></td><td>19.6 ± 6.6</td><td>20.5 ± 7.6</td><td>0.625</td><td>22(11–60)</td><td>79.0(20–189)</td><td><0.001</td></tr><tr><td>CD4<sup>+</sup>/CD8<sup>+</sup></td><td>1.04 ± 0.5</td><td>1.12 ± 0.5</td><td>0.967</td><td></td><td></td><td></td></tr><tr><td>CD19<sup>+</sup></td><td>12.3 ± 5.0</td><td>12.7 ± 6.0</td><td>0.659</td><td>14(5–42)</td><td>48.5(12–90)</td><td><0.001</td></tr><tr><td>CD3<sup>−</sup>CD56<sup>+</sup></td><td>10.0 ± 7.0</td><td>7.0 ± 8.9</td><td>0.144</td><td>12(6–38)</td><td>27.9(3–76)</td><td><0.010</td></tr><tr><td>Treg</td><td>3.1 ± 3.2</td><td>2.3 ± 2.0</td><td>0.192</td><td>3.0(1.5–6.7)</td><td>8.6(3.6–12.6)</td><td><0.010</td></tr><tr><td>MDSCs</td><td>0.66 ± 0.23</td><td>0.40 ± 0.19</td><td><0.01</td><td>3.9(1.4–7.3)</td><td>3.5(1.7–6.0)</td><td>0.045</td></tr></table> |
68d15063b19ca77ea3c6954b107336df26d83d7030b7675236d3560fb9eab70e.png | simple | <table><tr><td>Characteristics</td><td>No. (%)</td></tr><tr><td><i>Sex</i></td><td> </td></tr><tr><td>M</td><td>65 (67%)</td></tr><tr><td>F</td><td>32 (33%)</td></tr><tr><td><i>Age (years)</i></td><td> </td></tr><tr><td>0-14</td><td>3 (3%)</td></tr><tr><td>15-24</td><td>23 (24%)</td></tr><tr><td>25-34</td><td>43 (44%)</td></tr><tr><td>35-44</td><td>24 (25%)</td></tr><tr><td>≥45</td><td>4 (4%)</td></tr><tr><td><i>Hospitalization</i></td><td> </td></tr><tr><td>Yes</td><td>90 (93%)</td></tr><tr><td>No</td><td>7 (7%)</td></tr></table> |
23367f7eb9c69bdbea3d279a6a661ac4747f41dc3e0ee53c320fe48274c87664.png | complex | <table><tr><td rowspan="2">Calendar year</td><td rowspan="2">Participation</td><td colspan="2">RP & dependents</td><td colspan="2">Office worker</td><td colspan="2">Non-office worker</td><td colspan="2">Public officers</td></tr><tr><td>N</td><td>%</td><td>N</td><td>%</td><td>N</td><td>%</td><td>N</td><td>%</td></tr><tr><td rowspan="3">2006</td><td>No</td><td>5,110,899</td><td>64.0</td><td>437,274</td><td>28.9</td><td>945,129</td><td>20.4</td><td>152,241</td><td>16.5</td></tr><tr><td>Yes</td><td>2,880,225</td><td>36.0</td><td>1,078,249</td><td>71.1</td><td>3,677,914</td><td>79.6</td><td>771,830</td><td>83.5</td></tr><tr><td>Total</td><td>7,991,124</td><td></td><td>1,515,523</td><td></td><td>4,623,043</td><td></td><td>924,071</td><td></td></tr><tr><td rowspan="3">2007</td><td>No</td><td>4,717,810</td><td>59.7</td><td>232,925</td><td>21.7</td><td>923,421</td><td>18.1</td><td>65,021</td><td>23.3</td></tr><tr><td>Yes</td><td>3,189,796</td><td>40.3</td><td>839,517</td><td>78.3</td><td>4,176,693</td><td>81.9</td><td>213,526</td><td>76.7</td></tr><tr><td>Total</td><td>7,907,606</td><td></td><td>1,072,442</td><td></td><td>5,100,114</td><td></td><td>278,547</td><td></td></tr><tr><td rowspan="3">2008</td><td>No</td><td>4,651,095</td><td>56.8</td><td>738,024</td><td>26.5</td><td>720,013</td><td>15.6</td><td>120,249</td><td>13.4</td></tr><tr><td>Yes</td><td>3,531,109</td><td>43.2</td><td>2,044,152</td><td>73.5</td><td>3,909,321</td><td>84.4</td><td>779,838</td><td>86.6</td></tr><tr><td>Total</td><td>8,182,204</td><td></td><td>2,782,176</td><td></td><td>4,629,334</td><td></td><td>900,087</td><td></td></tr><tr><td rowspan="3">2009</td><td>No</td><td>4,360,434</td><td>51.8</td><td>682,419</td><td>25.0</td><td>652,252</td><td>13.3</td><td>44,268</td><td>18.4</td></tr><tr><td>Yes</td><td>4,051,519</td><td>48.2</td><td>2,049,755</td><td>75.0</td><td>4,240,682</td><td>86.7</td><td>195,910</td><td>81.6</td></tr><tr><td>Total</td><td>8,411,953</td><td></td><td>2,732,174</td><td></td><td>4,892,934</td><td></td><td>240,178</td><td></td></tr><tr><td rowspan="3">2010</td><td>No</td><td>4,172,755</td><td>48.3</td><td>728,312</td><td>25.9</td><td>563,799</td><td>11.5</td><td>83,178</td><td>12.1</td></tr><tr><td>Yes</td><td>4,470,443</td><td>51.7</td><td>2,088,031</td><td>74.1</td><td>4,326,907</td><td>88.5</td><td>606,349</td><td>87.9</td></tr><tr><td>Total</td><td>8,643,198</td><td></td><td>2,816,343</td><td></td><td>4,890,706</td><td></td><td>689,527</td><td></td></tr><tr><td rowspan="3">2011</td><td>No</td><td>3,303,175</td><td>41.0</td><td>758,846</td><td>24.8</td><td>485,263</td><td>9.8</td><td>46,406</td><td>15.6</td></tr><tr><td>Yes</td><td>4,743,687</td><td>59.0</td><td>2,302,668</td><td>75.2</td><td>4,442,913</td><td>90.2</td><td>250,506</td><td>84.4</td></tr><tr><td>Total</td><td>8,046,862</td><td></td><td>3,061,514</td><td></td><td>4,928,176</td><td></td><td>296,912</td><td></td></tr><tr><td rowspan="3">2012</td><td>No</td><td>3,138,510</td><td>38.9</td><td>855,579</td><td>28.8</td><td>584,841</td><td>11.6</td><td>68,834</td><td>10.8</td></tr><tr><td>Yes</td><td>4,935,574</td><td>61.1</td><td>2,120,013</td><td>71.2</td><td>4,458,500</td><td>88.4</td><td>569,189</td><td>89.2</td></tr><tr><td>Total</td><td>8,074,084</td><td></td><td>2,975,592</td><td></td><td>5,043,341</td><td></td><td>638,023</td><td></td></tr><tr><td rowspan="3">2013</td><td>No</td><td>3,302,678</td><td>40.4</td><td>950,361</td><td>31.2</td><td>505,778</td><td>9.4</td><td>43,762</td><td>13.5</td></tr><tr><td>Yes</td><td>4,875,356</td><td>59.6</td><td>2,091,641</td><td>68.8</td><td>4,860,568</td><td>90.6</td><td>281,320</td><td>86.5</td></tr><tr><td>Total</td><td>8,178,034</td><td></td><td>3,042,002</td><td></td><td>5,366,346</td><td></td><td>325,082</td><td></td></tr></table> |
20026742540e47b26e4ea35e9063dd225fc40904a5a41679d50dea98c0109368.png | complex | <table><tr><td rowspan="2">Degradation Time (Week)</td><td colspan="4">Tg (°C)</td></tr><tr><td>nHA 0%</td><td>nHA 10%</td><td>nHA 30%</td><td>nHA 50%</td></tr><tr><td>0</td><td>51.5</td><td>50.4</td><td>52.9</td><td>51.0</td></tr><tr><td>1</td><td>52.2</td><td>52.8</td><td>51.9</td><td>51.8</td></tr><tr><td>2</td><td>51.8</td><td>52.1</td><td>51.5</td><td>53.1</td></tr><tr><td>3</td><td>52.6</td><td>52.2</td><td>51.9</td><td>52.5</td></tr><tr><td>4</td><td>52.1</td><td>52.4</td><td>51.8</td><td>52.8</td></tr><tr><td>6</td><td>52.1</td><td>52.1</td><td>51.9</td><td>52.9</td></tr><tr><td>8</td><td>51.0</td><td>51.9</td><td>52.1</td><td>52.5</td></tr></table> |
3bbcd111321819a69724bd6a073c23f13246490c04f76802f9f50f3f47f4d899.png | complex | <table><tr><td rowspan="2">Pt.</td><td rowspan="2">Indication for tons.</td><td rowspan="2">CP type</td><td rowspan="2">Initial cleft repair</td><td rowspan="2">Protons. endoscopy</td><td rowspan="2">Posttons. endoscopy</td><td colspan="3">Speech intelligibility</td><td colspan="3">VPI Severity</td></tr><tr><td>Preop.</td><td>postop.</td><td>Diff.</td><td>Preop.</td><td>Postop.</td><td>Diff.</td></tr><tr><td>4</td><td>VPI</td><td>SM</td><td>Unk.</td><td>Palate 9 lat 4</td><td>Palate 9 lat 4</td><td>2</td><td>2</td><td>0</td><td>2</td><td>2</td><td>0</td></tr><tr><td>5</td><td>VPI</td><td>None</td><td>None</td><td>Palate 7 lat 2</td><td>Palate 9 lat 4</td><td>2</td><td>2</td><td>0</td><td>3</td><td>2</td><td>−1</td></tr><tr><td>6</td><td>VPI</td><td>UC</td><td>2 flap</td><td>Palate 0 lat 0</td><td>Palate 0 lat 1</td><td>3</td><td>2</td><td>−1</td><td>2</td><td>2</td><td>0</td></tr><tr><td>7</td><td>VPI</td><td>UC</td><td>2 flap</td><td>Palate 9 lat 2</td><td>Palate 9 lat 1</td><td>3</td><td>2</td><td>−1</td><td>1</td><td>2</td><td>1</td></tr><tr><td>9</td><td>VPI</td><td>UC</td><td>2 flap</td><td>Palate 1 lat 1</td><td>Palate 2 lat 1</td><td>3</td><td>4</td><td>1</td><td>4</td><td>4</td><td>0</td></tr><tr><td>12</td><td>VPI</td><td>UC</td><td>2 flap</td><td>Palate 5 lat 1</td><td>Palate 5 lat 3</td><td>4</td><td>4</td><td>0</td><td>4</td><td>4</td><td>0</td></tr><tr><td>15</td><td>Recurrent strep + VPI</td><td>I</td><td>2 flap</td><td>Palate 8 lat 4</td><td>Palate 9 lat 4</td><td>2</td><td>1</td><td>−1</td><td>1</td><td>2</td><td>1</td></tr><tr><td>16</td><td>VPI</td><td>None</td><td>None</td><td>Palate 9 lat 4</td><td>Palate 7/8, lat 1</td><td>3</td><td>3</td><td>0</td><td>3</td><td>3</td><td>0</td></tr><tr><td>17</td><td>OSA</td><td>UC</td><td>2 flap</td><td>Palate 8 lat 0</td><td>Palate 8 lat 1</td><td>2</td><td>2</td><td>0</td><td>2</td><td>2</td><td>0</td></tr><tr><td>22</td><td>VPI</td><td>SM</td><td>furlow</td><td>Palate 4 lat 0</td><td>Palate 3.5 lat 1</td><td>4</td><td>4</td><td>0</td><td>3</td><td>3</td><td>0</td></tr></table> |
1b1edbf980a6881a44e5292ae99c42f4eadcc8759d27dc6401f4355093ed2333.png | complex | <table><tr><td>Genes</td><td colspan="2">Primer Sequences (5'-3')</td><td>Cycles</td><td>Size (bp)</td><td>Annealing Temperature (°C)</td></tr><tr><td colspan="6">Pluripotency-associated markers</td></tr><tr><td><i>Oct4</i></td><td>F</td><td>TCTCGCCCCCTCCAGGT</td><td>30</td><td>218</td><td>53</td></tr><tr><td></td><td>R</td><td>GCCCCACTCCAACCTGG</td><td></td><td></td><td></td></tr><tr><td><i>Sox2</i></td><td>F</td><td>GGCAGCTACAGCATGATGCAGGACC</td><td>34</td><td>130</td><td>60</td></tr><tr><td></td><td>R</td><td>CTGGTCATGGAGTTGTACTGCAGG</td><td></td><td></td><td></td></tr><tr><td colspan="6">Endodermal-associated markers</td></tr><tr><td><i>FoxA2</i></td><td>F</td><td>GGGAGCGGTGAAGATGGA</td><td>38</td><td>89</td><td>55</td></tr><tr><td></td><td>R</td><td>TCATGTTGCTCACGGAGGAGTA</td><td></td><td></td><td></td></tr><tr><td><i>Gata6</i></td><td>F</td><td>GAGTGAGAGAAGATGGAAGGG</td><td>38</td><td>250</td><td>55</td></tr><tr><td></td><td>R</td><td>CGCACATGAAATCTGGATGTGG</td><td></td><td></td><td></td></tr><tr><td colspan="6">Ectodermal-associated markers</td></tr><tr><td><i>Nestin</i></td><td>F</td><td>CAGCTGGCGCACCTCAAGATG</td><td>30</td><td>209</td><td>55</td></tr><tr><td></td><td>R</td><td>AGGGAAGTTGGGCTCAGGACTGG</td><td></td><td></td><td></td></tr><tr><td><i>Pax6</i></td><td>F</td><td>AACAGACACAGCCCTCACAAACA</td><td>30</td><td>275</td><td>55</td></tr><tr><td></td><td>R</td><td>CGGGAACTTGAACTGGAACTGAC</td><td></td><td></td><td></td></tr><tr><td colspan="6">Mesodermal-associated markers</td></tr><tr><td><i>Brachyury</i></td><td>F</td><td>GAACCAGCACCCTGTGTCCAC</td><td>38</td><td>608</td><td>57</td></tr><tr><td></td><td>R</td><td>GCCACGACAAAAAGTCACTGC</td><td></td><td></td><td></td></tr><tr><td><i>Goosecoid</i></td><td>F</td><td>CTCAACCAGCTGCACTGTC</td><td>38</td><td>322</td><td>55</td></tr><tr><td></td><td>R</td><td>GTCAGCTGTCCGAGTCCAAATC</td><td></td><td></td><td></td></tr><tr><td colspan="6">Control-associated markers</td></tr><tr><td><i>GAPDH</i></td><td>F</td><td>ATGGAGAAGGCTGGGGCTC</td><td>28</td><td>196</td><td>55</td></tr><tr><td></td><td>R</td><td>AAGTTGTCATGGATGACCTTG</td><td></td><td></td><td></td></tr></table> |
9427c36e017966c0671c77df978d5b843d3d73b6a47e965b8ab16f67b7ed022f.png | complex | <table><tr><td>Referrals & Services</td><td colspan="2">Team 1</td><td colspan="2">Team 2</td><td colspan="2">Team 3</td><td colspan="2">Team 4</td><td colspan="2">Team 5</td></tr><tr><td></td><td>T<sup>1</sup></td><td>A<sup>2</sup></td><td>T</td><td>A</td><td>T</td><td>A</td><td>T</td><td>A</td><td>T</td><td>A</td></tr><tr><td># of referrals</td><td>1104</td><td>61</td><td>0</td><td>0</td><td>172</td><td>10</td><td>2742</td><td>152</td><td>250</td><td>14</td></tr><tr><td># of new registration</td><td>418</td><td>23</td><td>1163</td><td>65</td><td>81</td><td>5</td><td>488</td><td>27</td><td>71</td><td>4</td></tr><tr><td># of consultation</td><td>1889</td><td>105</td><td>7207</td><td>400</td><td>107</td><td>6</td><td>2682</td><td>149</td><td>110</td><td>6</td></tr><tr><td># of telephone contact with Patient</td><td>328</td><td>18</td><td>2296</td><td>128</td><td>76</td><td>4</td><td>585</td><td>33</td><td>50</td><td>3</td></tr><tr><td># of telephone contact with family members</td><td>0</td><td>-</td><td>0</td><td>-</td><td>33</td><td>2</td><td>43</td><td>2</td><td>15</td><td>1</td></tr></table> |
18cca2f5653bd84077ae041380f36cf77626ab148a9c29bc24c4a557b3f6ad8a.png | complex | <table><tr><td>WAT</td><td colspan="2">Continuous grazing</td><td colspan="3">Rotational grazing</td><td colspan="3">Rotational grazing + parasiticide fungi</td></tr><tr><td></td><td colspan="2">G-1 (<i>n</i> = 6)<sup>a</sup></td><td colspan="3">G-2 (<i>n</i> = 8)<sup>b</sup></td><td colspan="3">G-3 (<i>n</i> = 8)<sup>c</sup></td></tr><tr><td></td><td>FECR (95% CI)</td><td>PHR (95% CI)</td><td>Pasture</td><td>FECR (95% CI)</td><td>PHR (95% CI)</td><td>Pasture</td><td>FECR (95% CI)</td><td>PHR (95% CI)</td></tr><tr><td>2</td><td>100</td><td>100</td><td rowspan="5">A</td><td>96 (94–98)</td><td>75 (50–100)</td><td rowspan="5">1</td><td>99 (98–100)</td><td>88 (65–100)</td></tr><tr><td>3</td><td>99 (97–99)</td><td>83 (46–100)</td><td>96 (94–98)</td><td>75 (50–100)</td><td>98 (97–99)</td><td>88 (65–100)</td></tr><tr><td>4</td><td>91 (87–93)</td><td>50 (10–90)</td><td>93 (91–96)</td><td>63 (29–96)</td><td>98 (96–99)</td><td>75 (45–100)</td></tr><tr><td>5</td><td>90 (87–93 )</td><td>50 (10–90)</td><td>92 (90–95)</td><td>63 (29–96)</td><td>96 (95–98)</td><td>75 (45–100)</td></tr><tr><td>6</td><td>80 (76–84)</td><td>0</td><td>92 (89–95)</td><td>50 (15–85)</td><td>96 (94–98)</td><td>75 (45–100)</td></tr><tr><td>7</td><td>72 (68–77)</td><td>0</td><td rowspan="5">B</td><td>92 (89–95)</td><td>50 (15–85)</td><td rowspan="5">2</td><td>95 (94–97)</td><td>75 (45–100)</td></tr><tr><td>8</td><td>54 (49–59)</td><td>0</td><td>90 (87–93)</td><td>38 (4–71)</td><td>95 (93–97)</td><td>63 (29–96)</td></tr><tr><td>9</td><td>52 (47–57)</td><td>0</td><td>91 (88–93)</td><td>38 (4–71)</td><td>94 (93–96)</td><td>63 (29–96)</td></tr><tr><td>10</td><td>51 (46–56)</td><td>0</td><td>77 (72–81)</td><td>38 (4–71)</td><td>93 (9195)</td><td>63 (29–96)</td></tr><tr><td>12</td><td>17 (13–20)</td><td>0</td><td>69 (65–74)</td><td>38 (4–71)</td><td>93 (9195)</td><td>50 (15–85)</td></tr><tr><td>14</td><td>15 (12–19)</td><td>0</td><td rowspan="2">C</td><td>58 (53–63)</td><td>0</td><td rowspan="2">3</td><td>91 (8893)</td><td>50 (15–85)</td></tr><tr><td>16</td><td>14 (11–18)</td><td>0</td><td>39 (34–44)</td><td>0</td><td>83 (79–86)</td><td>38 (4–71)</td></tr><tr><td>20</td><td>3 (1–4)</td><td>0</td><td rowspan="2">D</td><td>24 (20–28)</td><td>0</td><td rowspan="2">4</td><td>74 (70–77)</td><td>38 (4–71)</td></tr><tr><td>24</td><td>0</td><td>0</td><td>22 (18–26)</td><td>0</td><td>63 (59–67)</td><td>25 (0–55)</td></tr><tr><td>26</td><td>0</td><td>0</td><td rowspan="2">A</td><td>0</td><td>0</td><td rowspan="2">1</td><td>60 (56–65)</td><td>0</td></tr><tr><td>30</td><td>0</td><td>0</td><td>0</td><td>0</td><td>60 (56–65)</td><td>0</td></tr><tr><td>32</td><td>0</td><td>0</td><td rowspan="2">B</td><td>0</td><td>0</td><td rowspan="2">2</td><td>64 (60–68)</td><td>0</td></tr><tr><td>36</td><td>0</td><td>0</td><td>0</td><td>0</td><td>61 (57–66)</td><td>0</td></tr><tr><td>38</td><td>0</td><td>0</td><td rowspan="2">C</td><td>0</td><td>0</td><td rowspan="2">3</td><td>54 (50–59)</td><td>0</td></tr><tr><td>42</td><td>0</td><td>0</td><td>0</td><td>0</td><td>60 (56–65)</td><td>0</td></tr><tr><td>44</td><td>0</td><td>0</td><td rowspan="2">D</td><td>0</td><td>0</td><td rowspan="2">4</td><td>59 (55–63)</td><td>0</td></tr><tr><td>48</td><td>0</td><td>0</td><td>0</td><td>0</td><td>54 (50–58)</td><td>0</td></tr></table> |
7c8de629c59f0a2bcd62702b4b12f551c9c2b37e44a1b09c72f872b054eaf15d.png | complex | <table><tr><td rowspan="2">Points censoring (days)</td><td rowspan="2">All patients (%)</td><td colspan="3"><i>IL</i>-<i>6</i> rs1800795 polymorphism</td></tr><tr><td>rs1800795GG/CG (%)</td><td>rs1800795CC (%)</td><td><i>p</i> value (log-rank test)</td></tr><tr><td>7</td><td>86.6</td><td>88.5</td><td>68.4</td><td>0.005</td></tr><tr><td>28</td><td>60.7</td><td>63.2</td><td>32.9</td><td>0.009</td></tr><tr><td>90</td><td>14.3</td><td>15.5</td><td>0.0</td><td>0.006</td></tr></table> |
f2384178258b5ef3a24be92839bb406e4e12011b871ab508cadb58f56626ac73.png | complex | <table><tr><td colspan="2"> Screening options</td></tr><tr><td>Fecal screening tests</td><td>These tests search for occult blood in stool, which is nonspecific but can be detected especially in larger polyps and CRC. It is important to collect samples from consecutive bowel movements [39, 40].Guaiac fecal occult blood test (gFOBT) detects qualitatively heme in the stool, using a guaiac material to which hydroperoxidase is added. Heme promotes a process that leads to the guaiac's oxygenation and to a blue discoloration [41, 42]. It has a low sensitivity for the detection of CRC, but when performed every year or two, mortality is reduced [39, 43, 44].Fecal immunochemical tests (FITs) use monoclonal or polyclonal antibodies to detect human haemoglobin. They can give qualitative or quantitative results. FIT is more accurate than gFOBT, because it does not react with nonhuman heme and is less sensitive to upper gastrointestinal tract's bleeding [41, 45].</td></tr><tr><td>Endoscopic screening</td><td>Flexible Sigmoidoscopy is a screening option that allows examining the rectum and the lower part of the colon. It is an invasive technique that requires simple bowel preparation but cannot detect lesion in the whole colon [41, 45].Colonoscopy is esteemed as the gold standard for CRC screening; it allows exploring the whole colon and removing the suspicious lesions [46, 47]. It is an invasive and expensive exam that must be performed if any other test has a positive result [39]. The most common side effect is postpolypectomy bleeding, but also tearing and perforation may be possible [45]. It is recommended that colonoscopy be practiced every 10 years in average-risk patients that underwent to a complete, negative exam [39, 48, 49].</td></tr><tr><td>CT-colonography (CTC)</td><td>CTC is a noninvasive test that has become a common method for CRC screening. It requires a bowel preparation, but sedation is not needed. The estimated sensitivity and sensibility in detecting polyps > 1 cm are high, above 90%. Limitation of this technique includes low sensitivity for small lesion and serrated polyps, the exposure to radiation, and the need of follow-up for extra colic incidental findings [39, 49–51].</td></tr></table> |
6772f49f4d4a152d1ca62eb1e7eed74b587ea0961fcd50e94fd1610183844a96.png | complex | <table><tr><td colspan="2">Effect:</td><td colspan="5">Relevance<sup>a</sup></td><td>Points<sup>b</sup></td><td>Class<sup>c</sup></td></tr><tr><td> </td><td> </td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td> </td><td> </td></tr><tr><td>1</td><td>Temperature: Heat-related mortality</td><td>6</td><td>2</td><td>1</td><td> </td><td> </td><td>41</td><td>IV</td></tr><tr><td>2</td><td>Temperature: Heat-related cardiovascular problems</td><td>1</td><td> </td><td>2</td><td> </td><td> </td><td>11</td><td>III</td></tr><tr><td>3</td><td>Temperature: Heat-related respiratory problems</td><td>1</td><td>1</td><td> </td><td>1</td><td> </td><td>11</td><td>III</td></tr><tr><td>4</td><td>Temperature: Heat-related stress and sleep disturbance</td><td>1</td><td> </td><td> </td><td> </td><td> </td><td>5</td><td>II</td></tr><tr><td>5</td><td>Temperature: Cold-related mortality</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>I</td></tr><tr><td>6</td><td>Temperature: Cold-related diseases</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>I</td></tr><tr><td>7</td><td>Temperature: Drought-related exposure to contaminants</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>I</td></tr><tr><td>8</td><td>Temperature: Shortages of drinking water</td><td> </td><td> </td><td> </td><td> </td><td>1</td><td>1</td><td>II</td></tr><tr><td>9</td><td>Temperature: Dehydration</td><td> </td><td>2</td><td> </td><td> </td><td> </td><td>8</td><td>II</td></tr><tr><td>10</td><td>Allergies: Asthma</td><td> </td><td> </td><td>1</td><td> </td><td>1</td><td>4</td><td>II</td></tr><tr><td>11</td><td>Allergies: Allergic eczema</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>I</td></tr><tr><td>12</td><td>Allergies: Hay fever: duration of pollen season</td><td> </td><td>2</td><td> </td><td>1</td><td>2</td><td>12</td><td>III</td></tr><tr><td>13</td><td>Allergies: Hay fever: pollen types, abundance and allergenicity</td><td> </td><td>2</td><td>1</td><td> </td><td> </td><td>11</td><td>III</td></tr><tr><td>14</td><td>Pests: Wasps</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>I</td></tr><tr><td>15</td><td>Pests: Oak processionary caterpillar</td><td> </td><td>1</td><td> </td><td> </td><td> </td><td>4</td><td>II</td></tr><tr><td>16</td><td>Vector-borne: Native vector-borne diseases</td><td>1</td><td>1</td><td> </td><td> </td><td>1</td><td>10</td><td>II</td></tr><tr><td>17</td><td>Vector-borne: Incidents of non-native vector-borne diseases</td><td>1</td><td>2</td><td>2</td><td>1</td><td> </td><td>21</td><td>IV</td></tr><tr><td>18</td><td>Vector-borne: Epidemics of non-native vector-borne diseases</td><td>2</td><td> </td><td> </td><td>2</td><td> </td><td>14</td><td>III</td></tr><tr><td>19</td><td>Food/water-borne: Food poisoning</td><td> </td><td> </td><td> </td><td>1</td><td> </td><td>2</td><td>II</td></tr><tr><td>20</td><td>Food/water-borne: Legionnaires Disease</td><td> </td><td> </td><td> </td><td> </td><td>1</td><td>1</td><td>II</td></tr><tr><td>21</td><td>Food/water-borne: Contamination of swimming/recreation water</td><td> </td><td> </td><td> </td><td>1</td><td>2</td><td>4</td><td>II</td></tr><tr><td>22</td><td>Air quality: Respiratory problems due to ground-level ozone</td><td> </td><td> </td><td>1</td><td>2</td><td> </td><td>7</td><td>II</td></tr><tr><td>23</td><td>Air quality: Respiratory problems due to particulate matter</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>I</td></tr><tr><td>24</td><td>Air quality: Air quality-related cardiovascular problems</td><td> </td><td> </td><td> </td><td>1</td><td>1</td><td>3</td><td>II</td></tr><tr><td>25</td><td>Flood/storm: Flood-related mortality</td><td>1</td><td> </td><td>1</td><td>1</td><td> </td><td>10</td><td>II</td></tr><tr><td>26</td><td>Flood/storm: Flood-related infectious diseases</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>I</td></tr><tr><td>27</td><td>Flood/storm: Flood-related exposure to dangerous substances and contaminants</td><td> </td><td> </td><td>1</td><td> </td><td> </td><td>3</td><td>II</td></tr><tr><td>28</td><td>Flood/storm: Flood-related respiratory problems</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>I</td></tr><tr><td>29</td><td>Flood/storm: Flood-related mental health problems</td><td> </td><td>1</td><td> </td><td> </td><td>2</td><td>6</td><td>II</td></tr><tr><td>30</td><td>Flood/storm: Storm-related mortality and injury</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>I</td></tr><tr><td>31</td><td>UV: Cataract</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>I</td></tr><tr><td>32</td><td>UV: Skin cancer</td><td> </td><td> </td><td>2</td><td> </td><td> </td><td>6</td><td>II</td></tr><tr><td>33</td><td>UV: Weakening of the immune system</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>I</td></tr><tr><td>34</td><td>OTHER: societal disruption elsewhere</td><td>1</td><td> </td><td> </td><td> </td><td> </td><td>5</td><td>II</td></tr></table> |
17b025524f4d1e155c69004c42745342cacc47ce43d89c328fd5575aa0383db8.png | complex | <table><tr><td rowspan="2">Catchment Area</td><td rowspan="2">Size of catchment area population</td><td colspan="2">Public Corporation</td><td colspan="2">Third Sector</td><td colspan="2">Private Company</td><td rowspan="2">Different MTC</td></tr><tr><td>BSIC</td><td>Different MTC</td><td>BSIC</td><td>Different MTC</td><td>BSIC</td><td>Different MTC</td></tr><tr><td>Länsi-Uusimaa (1)</td><td>35296</td><td>13</td><td>11</td><td>6</td><td>4</td><td>4</td><td>2</td><td>16</td></tr><tr><td>Lohja (2)</td><td>70379</td><td>17</td><td>8</td><td>14</td><td>7</td><td>9</td><td>3</td><td>16</td></tr><tr><td>Hyvinkää (3)</td><td>139734</td><td>41</td><td>13</td><td>37</td><td>15</td><td>16</td><td>2</td><td>26</td></tr><tr><td>Porvoo (4)</td><td>74611</td><td>17</td><td>8</td><td>20</td><td>7</td><td>6</td><td>2</td><td>13</td></tr><tr><td>Helsinki (5)</td><td>501929</td><td>94</td><td>16</td><td>93</td><td>26</td><td>5</td><td>3</td><td>38</td></tr><tr><td>Jorvi (6)</td><td>230005</td><td>29</td><td>16</td><td>29</td><td>13</td><td>11</td><td>5</td><td>27</td></tr><tr><td>Peijas (7)</td><td>187332</td><td>34</td><td>15</td><td>32</td><td>11</td><td>11</td><td>3</td><td>23</td></tr><tr><td>Carea (8)</td><td>143265</td><td>38</td><td>13</td><td>66</td><td>18</td><td>12</td><td>4</td><td>24</td></tr><tr><td>Eksote (9)</td><td>109379</td><td>34</td><td>16</td><td>30</td><td>8</td><td>9</td><td>4</td><td>23</td></tr><tr><td>Turku (10)</td><td>151616</td><td>34</td><td>12</td><td>44</td><td>19</td><td>15</td><td>6</td><td>32</td></tr><tr><td>Turku (10)</td><td>128039</td><td>52</td><td>17</td><td>42</td><td>15</td><td>11</td><td>7</td><td>21</td></tr><tr><td>Vakka-Suomi (12)</td><td>81392</td><td>25</td><td>8</td><td>14</td><td>5</td><td>9</td><td>6</td><td>19</td></tr><tr><td>Turunmaa (13)</td><td>18200</td><td>8</td><td>3</td><td>3</td><td>1</td><td>2</td><td>2</td><td>6</td></tr><tr><td>Total BSICs<sup>c</sup></td><td>1871178</td><td>436</td><td></td><td>430</td><td></td><td>120</td><td></td><td></td></tr><tr><td>%</td><td></td><td>44 %</td><td></td><td>44 %</td><td></td><td>12 %</td><td></td><td></td></tr><tr><td>Different MTC</td><td></td><td></td><td>41</td><td></td><td>52</td><td></td><td>14</td><td>65</td></tr><tr><td>%</td><td></td><td></td><td>63 %</td><td></td><td>80 %</td><td></td><td>22 %</td><td>100 %</td></tr></table> |
6e8c77651de3286df3d51d385d3e5c6c98e137552e55bc3bdd5b3ce9bf816052.png | simple | <table><tr><td>Parameters</td><td>Supplemented group (<i>n =</i> 9)</td><td>Control group (<i>n =</i> 7)</td></tr><tr><td>Age (years)</td><td>21.3 ± 0.82</td><td>21.3 ± 0.71</td></tr><tr><td>Body mass (kg)</td><td>93.6 ± 6.02</td><td>81.6 ± 9.44</td></tr><tr><td>Body height (cm)</td><td>192.6 ± 6.53</td><td>189.0 ± 4.62</td></tr><tr><td>Duration of training (years)</td><td>7.5 ± 1.5</td><td>6.9 ± 1.2</td></tr></table> |
61b50c12888cc6c837dcebf2f14033bab9fc2eaa235edb4383187db5cf1823e8.png | simple | <table><tr><td>Species</td><td>Age (M)</td><td>DiseaseStage*</td><td>Gene</td><td>Expression, HD/Control</td><td>SEM</td><td>t-value</td><td>p-value</td></tr><tr><td>Mouse</td><td>3</td><td></td><td>Casp2</td><td>.704</td><td>.063</td><td>1.78</td><td>> 0.05</td></tr><tr><td>Mouse</td><td>6</td><td></td><td>Casp2</td><td>1.15</td><td>.11</td><td>0.56</td><td>> 0.05</td></tr><tr><td>Mouse</td><td>9</td><td></td><td>Casp2</td><td>1.20</td><td>.12</td><td>0.71</td><td>> 0.05</td></tr><tr><td>Mouse</td><td>12</td><td></td><td>Casp2</td><td>1.01</td><td>.12</td><td>0.08</td><td>> 0.05</td></tr><tr><td>Human**</td><td></td><td>0-2</td><td>Casp2</td><td>0.996</td><td></td><td>-0.14</td><td>> 0.05</td></tr><tr><td>Human**</td><td></td><td>0-2</td><td>HMGCR</td><td>0.739</td><td></td><td>-5.04</td><td>< 0.001</td></tr></table> |
89d45545a93907fa7f21a89371beb28b4c5daf857650d3a89827b7687334532d.png | complex | <table><tr><td rowspan="3">Strain</td><td colspan="2">Phenotype<sup><i>b</i></sup></td><td colspan="10">Vancomycin MIC (μg/ml) by Etest after various periods of incubation</td></tr><tr><td rowspan="2">CLSI classification (48 h)</td><td rowspan="2">New classification</td><td colspan="5">Without antibiotics</td><td colspan="5">With mupirocin at 0.032 μg/ml</td></tr><tr><td>48 h</td><td>72 h</td><td>96 h</td><td>120 h</td><td>144 h</td><td>48 h</td><td>72 h</td><td>96 h</td><td>120 h</td><td>144 h</td></tr><tr><td>209P</td><td>VSSA (MSSA)</td><td>VSSA (MSSA)</td><td>1.5</td><td>1.5</td><td>1.5</td><td>1.5</td><td>1.5</td><td>1.5</td><td>1.5</td><td>1.5</td><td>1.5</td><td>1.5</td></tr><tr><td>N315ΔIP</td><td>VSSA (MRSA)</td><td>VSSA (MRSA)</td><td>2</td><td>2</td><td>2</td><td>2</td><td>2</td><td>2</td><td>2</td><td>2</td><td>2</td><td>2</td></tr><tr><td>Mu3</td><td>hVISA</td><td>hVISA</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td></tr><tr><td>Mu50</td><td>VISA</td><td>VISA</td><td>12</td><td>12</td><td>12</td><td>12</td><td>12</td><td>12</td><td>12</td><td>12</td><td>12</td><td>12</td></tr><tr><td>MI (HIP5827)</td><td>VISA</td><td>VISA</td><td>12</td><td>12</td><td>12</td><td>12</td><td>12</td><td>12</td><td>12</td><td>12</td><td>12</td><td>12</td></tr><tr><td>Mu3-6R</td><td>VISA</td><td>Slow VISA</td><td>8</td><td>8</td><td>12</td><td>12</td><td>16</td><td>16</td><td>16</td><td>16</td><td>16</td><td>16</td></tr><tr><td>Clinical blood culture isolates from 9 hospitals</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>MRSA212</td><td>VSSA</td><td>VSSA</td><td>1.5</td><td>2</td><td>2</td><td>2</td><td>2</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td></tr><tr><td>MRSA84</td><td>VSSA</td><td>hVISA</td><td>2</td><td>2</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td></tr><tr><td>MRSA220</td><td>VSSA</td><td>hVISA</td><td>1.5</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td></tr><tr><td>MRSA192</td><td>VSSA</td><td>hVISA</td><td>2</td><td>2</td><td>2</td><td>2</td><td>2</td><td>2</td><td>2</td><td>2</td><td>2</td><td>2</td></tr><tr><td>MRSA190</td><td>VISA</td><td>Slow VISA</td><td>4</td><td>8</td><td>8</td><td>8</td><td>8</td><td>12</td><td>12</td><td>12</td><td>12</td><td>12</td></tr><tr><td>MRSA194</td><td>VISA</td><td>Slow VISA</td><td>4</td><td>6</td><td>8</td><td>12</td><td>12</td><td>8</td><td>12</td><td>12</td><td>12</td><td>12</td></tr><tr><td>T series clinical blood culture isolates<sup><i>a</i></sup></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>T12</td><td>VISA</td><td>Slow VISA</td><td>4</td><td>4</td><td>8</td><td>8</td><td>8</td><td>8</td><td>8</td><td>8</td><td>8</td><td>8</td></tr><tr><td>T15</td><td>VISA</td><td>Slow VISA</td><td>4</td><td>6</td><td>8</td><td>8</td><td>8</td><td>8</td><td>8</td><td>8</td><td>8</td><td>8</td></tr><tr><td>T61</td><td>VISA</td><td>Slow VISA</td><td>4</td><td>6</td><td>8</td><td>8</td><td>8</td><td>8</td><td>8</td><td>8</td><td>8</td><td>8</td></tr><tr><td>T89</td><td>VISA</td><td>Slow VISA</td><td>4</td><td>8</td><td>16</td><td>16</td><td>16</td><td>16</td><td>16</td><td>16</td><td>16</td><td>16</td></tr><tr><td>T122</td><td>VISA</td><td>Slow VISA</td><td>4</td><td>8</td><td>8</td><td>8</td><td>8</td><td>6</td><td>6</td><td>8</td><td>8</td><td>8</td></tr><tr><td>T123</td><td>VISA</td><td>Slow VISA</td><td>4</td><td>6</td><td>8</td><td>8</td><td>8</td><td>6</td><td>8</td><td>8</td><td>8</td><td>8</td></tr><tr><td>T12-L</td><td>hVISA</td><td>hVISA</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td></tr><tr><td>T15-L</td><td>hVISA</td><td>hVISA</td><td>3</td><td>3</td><td>3</td><td>3</td><td>4</td><td>4</td><td>4</td><td>4</td><td>4</td><td>4</td></tr><tr><td>T61-L</td><td>hVISA</td><td>hVISA</td><td>3</td><td>3</td><td>3</td><td>3</td><td>4</td><td>6</td><td>6</td><td>6</td><td>6</td><td>6</td></tr><tr><td>T89-L</td><td>hVISA</td><td>hVISA</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td></tr><tr><td>T122-L</td><td>VSSA</td><td>VSSA</td><td>2</td><td>2</td><td>2</td><td>2</td><td>2</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td></tr><tr><td>T123-L</td><td>VSSA</td><td>VSSA</td><td>2</td><td>2</td><td>2</td><td>2</td><td>2</td><td>3</td><td>3</td><td>3</td><td>3</td><td>3</td></tr></table> |
End of preview. Expand
in Data Studio
OCRFlux-pubtabnet-single
OCRFlux-pubtabnet-single is a benchmark of 9064 table images and their corresponding ground-truth HTML, which are derived from the public PubTabNet benchmark with some format transformations.
This dataset can be used to measure the performance of OCR systems in single-page table parsing.
Quick links:
Data Mix
Table 1: Tables breakdown by complexity (whether they contain rowspan or colspan cells)
| Complexity | Number |
|---|---|
| Simple | 4623 |
| Complex | 4441 |
| Total | 9064 |
Data Format
Each row in the dataset corresponds to a table image and its corresponding ground-truth HTML.
Different from the original PubTabNet dataset, we do not distinguish cells in the table headers and table bodies, which means there are no <thead> and <tbody> tags, and all <th> tags are replaced by <td> tags.
Features:
{
'image_name': string, # Name of the table image
'type': string, # "simple" or "complex"
'gt_table': string, # Ground-truth HTML of the table
}
License
This dataset is licensed under Apache-2.0.
- Downloads last month
- 1